Cover
Cover | 12 Months Ended |
Dec. 31, 2022 shares | |
Entity Addresses [Line Items] | |
Document Type | 20-F |
Document Registration Statement | false |
Document Annual Report | true |
Document Period End Date | Dec. 31, 2022 |
Current Fiscal Year End Date | --12-31 |
Document Transition Report | false |
Document Shell Company Report | false |
Entity File Number | 001-39084 |
Entity Registrant Name | Innate Pharma SA |
Entity Incorporation, State or Country Code | I0 |
Entity Address, Address Line One | 117, Avenue de Luminy |
Entity Address, Postal Zip Code | 13009 |
Entity Address, City or Town | Marseille |
Entity Address, Country | FR |
Title of 12(b) Security | Ordinary shares, nominal value €0.05 per share |
Trading Symbol | IPHA |
Security Exchange Name | NASDAQ |
Entity Common Stock, Shares Outstanding | 79,542,627 |
Entity Well-known Seasoned Issuer | No |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
ICFR Auditor Attestation Flag | false |
Document Accounting Standard | International Financial Reporting Standards |
Entity Shell Company | false |
Entity Central Index Key | 0001598599 |
Amendment Flag | false |
Document Fiscal Period Focus | FY |
Document Fiscal Year Focus | 2022 |
American Depository Shares, NASDAQ Stock Market | |
Entity Addresses [Line Items] | |
Title of 12(b) Security | American Depositary Shares, each representing one ordinary share, nominal value €0.05 per share |
Trading Symbol | IPHA |
Security Exchange Name | NASDAQ |
Business Contact | |
Entity Addresses [Line Items] | |
Entity Address, Address Line One | 117 Avenue de Luminy |
Entity Address, Postal Zip Code | 13009 |
Entity Address, City or Town | Marseille |
Entity Address, Country | FR |
Contact Personnel Name | Mondher Mahjoubi, M.D. |
City Area Code | +33 |
Local Phone Number | 4 30 30 30 30 |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2022 | |
Auditor Information [Abstract] | |
Auditor Firm ID | 1756 |
Auditor Name | Deloitte & Associés |
Auditor Location | Paris La Défense, France |
Consolidated Statements of Fina
Consolidated Statements of Financial Position - EUR (€) | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Non-current assets | |||
Intangible assets | € 1,556,000 | € 44,192,000 | € 46,289,000 |
Property and equipment | 8,542,000 | 10,174,000 | 11,694,000 |
Non-current financial assets | 35,119,000 | 39,878,000 | 38,934,000 |
Other non-current assets | 149,000 | 148,000 | 147,000 |
Trade receivables and others - non-current | 14,099,000 | 29,821,000 | 29,821,000 |
Deferred tax assets | 8,568,000 | 5,028,000 | 7,087,000 |
Total non-current assets | 68,033,000 | 129,241,000 | 133,972,000 |
Current assets | |||
Cash and cash equivalents | 84,225,000 | 103,756,000 | 136,792,000 |
Short-term investments | 17,260,000 | 16,080,000 | 14,845,000 |
Trade receivables and others - current | 38,346,000 | 18,420,000 | 21,814,000 |
Total current assets | 139,831,000 | 138,256,000 | 173,451,000 |
TOTAL ASSETS | 207,863,000 | 267,496,000 | 307,423,000 |
Shareholders' equity | |||
Share capital | 4,011,308 | 3,978,000 | 3,950,000 |
Share premium | 379,637,000 | 375,220,000 | 372,131,000 |
Retained earnings | (272,213,000) | (219,404,000) | (156,476,000) |
Other reserves | 819,000 | 456,000 | 355,000 |
Net income (loss) | (58,103,000) | (52,809,000) | (63,984,000) |
Total shareholders’ equity | 54,151,000 | 107,440,000 | 155,976,000 |
Non-current liabilities | |||
Collaboration liabilities – non-current portion | 52,988,000 | 32,997,000 | 44,854,000 |
Financial liabilities – non-current portion | 40,149,000 | 13,503,000 | 16,945,000 |
Defined benefit obligations | 2,550,000 | 2,975,000 | 4,177,000 |
Deferred revenue – non-current portion | 7,921,000 | 25,413,000 | 32,674,000 |
Provisions – non-current portion | 198,000 | 253,000 | 221,000 |
Deferred tax liabilities | 8,568,000 | 5,028,000 | 7,087,000 |
Total non-current liabilities | 112,374,000 | 80,169,000 | 105,959,000 |
Current liabilities | |||
Trade payables and others | 20,911,000 | 28,573,000 | 29,539,000 |
Collaboration liabilities – current portion | 10,223,000 | 7,418,000 | 1,832,000 |
Financial liabilities – current portion | 2,102,000 | 30,748,000 | 2,142,000 |
Deferred revenue – current portion | 6,560,000 | 12,500,000 | 11,299,000 |
Provisions – current portion | 1,542,000 | 647,000 | 676,000 |
Total current liabilities | 41,338,000 | 79,886,000 | 45,488,000 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | € 207,863,000 | € 267,496,000 | € 307,423,000 |
Consolidated Statements of Inco
Consolidated Statements of Income (Loss) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | [1] | |
Revenue and other income | ||||
Revenue from collaboration and licensing agreements | € 49,580 | € 12,112 | € 56,155 | |
Government financing for research expenditures | 8,035 | 12,591 | 13,618 | |
Other income | 59 | 0 | 0 | |
Total revenue and other income | 57,674 | 24,703 | 69,773 | |
Operating expenses | ||||
Research and development expenses | (51,663) | (47,004) | (49,708) | |
General and administrative expenses | (22,436) | (25,524) | (18,986) | |
Impairment of intangible assets | (41,000) | 0 | 0 | |
Total operating expenses | (115,099) | (72,528) | (68,694) | |
Net income (loss) from distribution agreements | 0 | 0 | 0 | |
Operating income (loss) | (57,425) | (47,825) | 1,079 | |
Financial income | 4,775 | 6,344 | 4,855 | |
Financial expenses | (5,321) | (3,997) | (6,763) | |
Net financial income (loss) | (546) | 2,347 | (1,908) | |
Net income (loss) before tax | (57,972) | (45,478) | (829) | |
Income tax expense | 0 | 0 | 0 | |
Net income (loss) from continuing operations | (57,972) | (45,478) | (829) | |
Net income (loss) from discontinued operations | (131) | (7,331) | (63,155) | |
Net income (loss) | € (58,103) | € (52,809) | € (63,984) | |
Basic income (loss) per share (in EUR per share) | € (0.73) | € (0.66) | € (0.81) | |
Diluted income (loss) per share (in EUR per share) | (0.73) | (0.66) | (0.81) | |
Basic income (loss) per share from continuing operations (in EUR per share) | (0.73) | (0.57) | (0.01) | |
Diluted income (loss) per share from continuing operations (in EUR per share) | (0.73) | (0.57) | (0.01) | |
Basic income (loss) per share from discontinued operations (in EUR per share) | 0 | (0.09) | (0.80) | |
Diluted income (loss) per share from discontinued operations (in EUR per share) | € 0 | € (0.09) | € (0.80) | |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income (Loss) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Statement of comprehensive income [abstract] | ||||
Net income (loss) for the period | € (58,103) | € (52,809) | € (63,984) | [1] |
Elements which will be reclassified in the consolidated statement of income (loss): | ||||
Change in fair value of short-term investments and non-current financial assets | 0 | 0 | 0 | |
Foreign currency translation gain (loss) | (428) | (483) | 222 | |
Items which will not be reclassified in the consolidated statement of income (loss): | ||||
Actuarial gains and (losses) related to defined benefit obligations | 790 | 584 | (200) | |
Other comprehensive income (loss) | 362 | 101 | 22 | |
Total comprehensive income (loss) | € (57,741) | € (52,708) | € (63,962) | |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Cash flows from (used in) operating activities [abstract] | ||||
Net income (loss) | € (58,103) | € (52,809) | € (63,984) | [1] |
Reconciliation of the net income (loss) and the cash generated from (used for) the operating activities | ||||
Depreciation and amortization, net | 45,405 | 4,596 | 56,797 | |
Employee benefits costs | 365 | 437 | 216 | |
Provisions for charges | 839 | 4 | 604 | |
Share-based compensation expense | 4,249 | 2,617 | 2,475 | |
Change in fair value of financial assets | 1,372 | (987) | 577 | |
Foreign exchange (gains) losses on financial assets | (912) | (1,136) | 1,256 | |
Change in accrued interests on financial assets | 118 | (55) | 372 | |
Gains (losses) on assets and other financial assets | 0 | (367) | (962) | |
Interest paid | 0 | 312 | 341 | |
Other profit or loss items with no cash effect | 15 | (1,185) | (254) | |
Operating cash flow before change in working capital | (6,652) | (48,573) | (2,562) | |
Change in working capital | (12,502) | (9,884) | (49,206) | |
Net cash generated from / (used in) operating activities | (19,154) | (58,457) | (51,767) | |
Cash flows from (used in) investing activities [abstract] | ||||
Acquisition of intangible assets | (587) | (401) | (10,375) | |
Acquisition of property and equipment, net | (535) | (929) | (907) | |
Purchase of non-current financial instruments | 0 | 0 | (3,000) | |
Disposal of property and equipment | 0 | 7 | 9 | |
Disposal of other assets | 0 | 40 | 0 | |
Acquisition of other assets | (1) | (1) | (59) | |
Disposal of non-current financial instruments | 3,000 | 0 | 0 | |
Interest received on financial assets | 0 | 367 | 962 | |
Net cash generated from / (used in) investing activities | 1,877 | (917) | (13,370) | |
Cash flows from (used in) financing activities [abstract] | ||||
Proceeds from the exercise / subscription of equity instruments | 198 | 499 | 48 | |
Proceeds from borrowings | 0 | 28,700 | 1,360 | |
Repayment of borrowings | (2,026) | (2,069) | (2,245) | |
Net interest paid | 0 | (312) | (341) | |
Net cash generated from / (used in) financing activities | (1,828) | 26,818 | (1,177) | |
Effect of the exchange rate changes | (428) | (483) | 219 | |
Net increase / (decrease) in cash and cash equivalents | (19,531) | (33,037) | (66,096) | |
Cash and cash equivalents at the beginning of the year | 103,756 | 136,792 | 202,887 | |
Cash and cash equivalents at the end of the year | 84,225 | 103,756 | 136,792 | |
Summary of changes in working capital [abstract] | ||||
Trade receivables and others (excluding rebates related to capital expenditures) | 52,445 | 48,241 | 51,635 | |
Trade receivables and others (excluding rebates related to capital expenditures), variance | (4,204) | 3,394 | ||
Trade payables and others (excluding payables related to capital expenditures) | (20,911) | (28,573) | (29,519) | |
Trade payables and others (excluding payables related to capital expenditures), variance | (7,662) | (946) | ||
Collaboration liabilities - current and non-current portion | (63,211) | (40,415) | (46,686) | |
Collaboration liabilities - current and non-current portion, variance | 22,796 | (6,271) | ||
Deferred revenue - current and non-current portion | (14,481) | (37,913) | (43,973) | |
Deferred revenue - current and non-current portion, variance | (23,432) | (6,060) | ||
Change in working capital | (46,158) | (58,660) | (68,543) | |
Change in working capital, variance | € (12,502) | € (9,884) | € (49,206) | |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Consolidated Statement of Chang
Consolidated Statement of Changes in Shareholders' Equity - EUR (€) | Total | Share capital | Share premium | Retained earnings | Other reserves | Net income (loss) | Increase (decrease) due to changes in accounting policy required by IFRSs | [2] | Increase (decrease) due to changes in accounting policy required by IFRSs Retained earnings | [2] | |
Balance at beginning of period (in shares) at Dec. 31, 2019 | 78,825,621 | ||||||||||
Balance at beginning of period at Dec. 31, 2019 | € 217,416,000 | € 3,941,281 | € 369,617,017 | € (134,912,000) | € (472,000) | € (20,759,000) | |||||
Net loss | (63,984,000) | [1] | (63,984,000) | ||||||||
Actuarial losses (gains) on defined benefit obligations | (200,000) | (200,000) | |||||||||
Foreign currency translation gain (loss) | 222,000 | (805,000) | 1,027,000 | ||||||||
Total comprehensive income (loss) | (63,962,000) | (805,000) | 827,000 | (63,984,000) | |||||||
Allocation of prior period income (loss) | € 0 | (20,759,000) | 20,759,000 | ||||||||
Exercise and subscription of equity instruments (in shares) | 175,331 | ||||||||||
Exercise and subscription of equity instruments | € 47,000 | 9,000 | 38,000 | ||||||||
Increase capital, net | 0 | ||||||||||
Share-based payment | € 2,476,000 | 2,476,000 | |||||||||
Balance at end of period (in shares) at Dec. 31, 2020 | 79,000,952 | ||||||||||
Balance at end of period at Dec. 31, 2020 | € 155,976,000 | 3,950,048 | 372,130,982 | (156,476,000) | 355,000 | (63,984,000) | € 1,054,000 | € 1,054,000 | |||
Net loss | (52,809,000) | (52,809,000) | |||||||||
Actuarial losses (gains) on defined benefit obligations | 584,000 | 584,000 | |||||||||
Foreign currency translation gain (loss) | (483,000) | (483,000) | |||||||||
Total comprehensive income (loss) | (52,708,000) | 101,000 | (52,809,000) | ||||||||
Allocation of prior period income (loss) | € 0 | (63,984,000) | 63,984,000 | ||||||||
Exercise and subscription of equity instruments (in shares) | 555,770 | ||||||||||
Exercise and subscription of equity instruments | € 499,000 | 28,000 | 471,000 | ||||||||
Increase capital, net | 0 | ||||||||||
Share-based payment | € 2,617,000 | 2,617,000 | |||||||||
Balance at end of period (in shares) at Dec. 31, 2021 | 79,556,722 | ||||||||||
Balance at end of period at Dec. 31, 2021 | € 107,440,000 | 3,977,836 | 375,219,667 | (219,404,000) | 456,000 | (52,809,000) | |||||
Net loss | (58,103,000) | (58,103,000) | |||||||||
Actuarial losses (gains) on defined benefit obligations | 790,000 | 790,000 | |||||||||
Foreign currency translation gain (loss) | (428,000) | (428,000) | |||||||||
Total comprehensive income (loss) | (57,741,000) | 362,000 | (58,103,000) | ||||||||
Allocation of prior period income (loss) | € 0 | (52,809,000) | 52,809,000 | ||||||||
Exercise and subscription of equity instruments (in shares) | 669,442 | ||||||||||
Exercise and subscription of equity instruments | € 202,000 | 34,000 | 168,000 | ||||||||
Increase capital, net | 0 | ||||||||||
Share-based payment | € 4,249,000 | 4,249,000 | |||||||||
Balance at end of period (in shares) at Dec. 31, 2022 | 80,226,164 | ||||||||||
Balance at end of period at Dec. 31, 2022 | € 54,151,000 | € 4,011,308 | € 379,636,744 | € (272,213,000) | € 819,000 | € (58,103,000) | |||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report.[2]This restatement represents the impact of the change in accounting method following the IFRIC (International Financial Reporting Interpretations Committee) opinion validated by the IAS Board in June 2021, according to which the method for measuring the obligations of certain retirement benefit plans must be modified. The details of this change in method are presented in note 10. |
The company
The company | 12 Months Ended |
Dec. 31, 2022 | |
Company Information [Abstract] | |
The company | The company Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) proprietary platform. Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non small cell lung cancer, as well as ANKET ® multi-specific NK cell engagers to address multiple tumor types. The Company has developed, internally and through its business development strategy, a broad and diversified portfolio including five clinical product candidates and a robust preclinical pipeline. Innate has entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi. Innate Pharma believes its product candidates and clinical development approach are differentiated from current immuno-oncology therapies and have the potential to significantly improve the clinical outcome for patients with cancer. From its inception, the Company has incurred losses due to its research and development (“R&D”) activity. The financial year ended December 31, 2022 generated a €58,103 thousand net loss. As of December 31, 2022, the shareholders’ equity amounted to €54,151 thousand. Subject to potential new milestone payments related to its collaboration agreements, the Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates in development. The Company’s future operations are highly dependent on a combination of factors, including: (i) the success of its R&D; (ii) regulatory approval and market acceptance of the Company’s future product candidates; (iii) the timely and successful completion of additional financing; and (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments. The Company’s activity is not subject to seasonal fluctuations. As of December 31, 2022, the Company had one wholly owned subsidiary: Innate Pharma, Inc., incorporated under the laws of Delaware in 2009. This subsidiary is fully consolidated. 1.1. Significant contracts The following paragraphs describe the key provisions of significant contracts. a) Agreements related to monalizumab with Novo Nordisk A/S and with AstraZeneca 2014 Novo Nordisk A/S monalizumab agreement On February 5, 2014, the Company acquired from Novo Nordisk A/S full development and commercialization rights to monalizumab. Novo Nordisk A/S received €2.0 million in cash and 600,000 ordinary shares at a price of €8.33 per share (€5.0 million). Novo Nordisk A/S is eligible to receive up to €20.0 million in potential regulatory milestones and single-digit tiered royalties on sales of monalizumab products. The agreement with Novo Nordisk A/S included a right to additional consideration in the event of an out-licensing agreement. Consequently, following the agreement signed with AstraZeneca in April 2015 (as described below), the Company paid to Novo Nordisk A/S additional consideration of €6.5 million (paid in April 2016). Following the exercise of the option by AstraZeneca in October 2018 (as described below), Novo Nordisk A/S became entitled to a second and final additional payment amounting to $15.0 million (€13.1 million) which was recognized as a liability as of December 31, 2018 and was paid in February 2019. There are no other potential additional milestones payments due to Novo Nordisk A/S. These amounts were added to the net book value of the intangible asset and are amortized according to the same amortization plan as the initial €7.0 million recognized in 2014. The net book value of the license amounted to €1.6 million as of December 31, 2022. Refer to Notes 2.h, 2.i and 6 for accounting description. 2015 AstraZeneca monalizumab agreements Under co-development and option agreements signed with AstraZeneca in 2015, the Company granted to AstraZeneca an exclusive license, subject to certain exclusions, to certain of its patents and know-how to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology diseases and conditions. The Company further granted to AstraZeneca a worldwide, non-exclusive license to certain of its other patents to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology diseases and conditions. The Company received an initial payment of $250 million under these agreements in June 2015, of which $100 million was paid to the Company as an initial payment for the co-development agreement and $150 million was paid to the Company as consideration for the option agreement. On October 22, 2018, AstraZeneca exercised this option, triggering the payment of $100.0 million, which was received by the Company in January 2019. Following the option exercise, AstraZeneca became the lead party in developing the licensed products and must use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize each licensed product in certain major markets. In July 31, 2019, the Company notified AstraZeneca of its decision to co-fund a future monalizumab Phase 3 clinical development program. In September 2020, the Company signed an amendment to the collaboration and license agreement concluded with AstraZeneca in 2015. Following the analysis of a longer patient follow-up as well as the maturation of the survival data of the Cohort 2, and after discussion with AstraZeneca, the Company agreed to amend the original agreement. This amendment changed the financial terms relating to the milestone payment expected following the treatment of the first patient with AstraZeneca in the first Phase 3 trial evaluating monalizumab. The original agreement signed in 2015 provided for a milestone payment of $100 million. Following the inclusion by AstraZeneca of the first patient in the first Phase 3 trial evaluating monalizumab (INTERLINK-1) in October 2020, and in accordance with the amendment signed in September 2020, the Company received a payment of $50 million . An additional payment of $50 million was subject to an interim analysis. On August 1, 2022, the Company announced that the combination of monalizumab and cetuximab did not reach the pre-specified efficacy threshold in the protocol-planned interim futility analysis of the Phase 3 INTERLINK-1 clinical study conducted by AstraZeneca. AstraZaneca has thus informed the Company that the study will be discontinued. Consequently, the Company is not eligible for the additional payment of $50.0 million as provided for in the amendment signed in September 2020. On June 2022, the Company received an additionnal payment of $50.0 million from AstraZeneca following the inclusion of the first patient in the second trial evaluating monalizumab, on April 2022 ("PACIFIC-9"). In addition to the initial payment, the option exercise payment and the payment received for the inclusion of the first patient in the first Phase 3 trial, AstraZeneca is obligated to pay the Company up to $775 million in the aggregate upon the achievement of certain development and regulatory milestones ($350 million) and commercialization milestones ($425 million). The Company is eligible to receive tiered royalties ranging from a low double-digit to mid-teen percentage on net sales of licensed products outside of Europe. The Company is required for a defined period of time to co-fund 30% of the Phase 3 clinical trials of licensed products, subject to an aggregate cap, in order to receive 50% of the profits in Europe. Refer to Notes 2.a, 2.p and 13.a for accounting description. b) Agreement related to Lumoxiti with AstraZeneca In October 2018, the Company obtained an exclusive license from AstraZeneca under certain patents and know-how to develop, manufacture and commercialize Lumoxiti for all uses in humans and animals in the United States, the European Union and Switzerland. Under this Agreement, AstraZeneca was obligated to provide support for the continued development and commercialization of Lumoxiti in the European Union and Switzerland prior to regulatory submission and approval as well as support for the continued commercialization of Lumoxiti in the United States for a specified period running until September 30, 2020. Following this transition period, the company took charge of all marketing of Lumoxiti in the United States. Under the agreement signed in 2018, the Company was obligated to pay a $50.0 million initial payment (€43.8 million), which it paid in January 2019, and a $15.0 million regulatory milestone (€13.4 million), which was paid in January 2020. The Company has reimbursed reimburse AstraZeneca for the development, production and commercialization costs it incurs during the transition period, ended in September 30, 2020. Further to the decision to terminate the Lumoxiti Agreement and termination notice sent in December 2020, a Termination and Transition Agreement was discussed and executed, effective as of June 30, 2021 terminating the Lumoxiti Agreement as well as Lumoxiti related agreements (including the supply agreement, the quality agreement and other related agreements) and transferring of the U.S. marketing authorization and distribution rights of Lumoxiti back to AstraZeneca. The FDA has effectively transferred the BLA to AstraZeneca on February 8, 2022. AstraZeneca has reimbursed Innate Pharma for all Lumoxiti related costs, expenses and benefited net sales. In the year ended December 31, 2020 results announcement, the Company reported a contingent liability of up to $12.8 million in its consolidated financial statements, which was related to the splitting of certain manufacturing costs. As part of the Termination and Transition Agreement, Innate and AstraZeneca agreed to split these manufacturing costs, and Innate has paid $6.2 million to AstraZeneca (€5.9 million) on April 2022. Following the termination and transition agreement signed in 2021, Lumoxiti activities are presented as discontinued operations as of December 31, 2021 and 2022, respectively. Refer to Notes 2.v and 17 for accounting description. c) Agreement related to IPH5201 with AstraZeneca In October 2018, the Company signed a collaboration and option agreement with AstraZeneca for co-development and co-commercialization of IPH5201. Under the agreement, AstraZeneca paid the Company a $50.0 million upfront payment ($26.0 million paid in October 2018 and $24.0 million paid in January 2019), and a milestone payment of $5.0 million paid in June 2020 following the assay of the first patient in the first Phase 1 trial evaluating IPH5201, in March 2020. AstraZeneca is obligated to pay the Company up to an aggregate of $5.0 million upon the achievement of certain development milestones. On June 1, 2022, the Company signed an amendment to the collaboration and license option agreement IPH5201 concluded with AstraZeneca in October 2018. Subsequently, the Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancers for which the Company will be the sponsor. In accordance with the amendment signed on June 1, 2022, the Company is eligible for a milestone payment of $5.0 million by AstraZeneca. This milestone payment was received on August 2, 2022 by the Company. Upon exercise of its option under the agreement, AstraZeneca is committed to pay an option exercise fee of $25.0 million and up to $800.0 million in the aggregate upon the achievement of certain development and regulatory milestones ($300 million) and commercialization milestones ($500 million). The arrangement also provides for a 50% profit share in Europe if the Company opts into certain co-promoting and late stage co-funding obligations. In addition, the Company would be eligible to receive tiered royalties ranging from a high-single digit to mid-teen percentage on net sales of IPH5201, or from a mid-single digit to low-double digit percentage on net sales of other types of licensed products, outside of Europe. The royalties payable to the Company under the agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent protection. As of December 31, 2020, since the Company had fulfilled all of its commitments on preclinical work related to the start of Phase 1 of the IPH5201 program, the initial payment of $50.0 million and the milestone payment of $5.0 million were fully recognized in revenue. The Company was reimbursed by AstraZeneca for certain research and development expenses related to IPH5201 for the year ended December 31, 2022. The Company has the option to co-fund 30% of the shared development expenses related to the Phase 3 clinical trials in order to acquire co-promotion rights and to share in 50% of the profits and losses of licensed products in Europe. If the Company does not opt into the co-funding obligations, among other things, its right to share in 50% of the profits and losses in Europe and right to co-promote in certain European countries will terminate and will be replaced by rights to receive royalties on net sales at the rates applicable to outside of Europe. Additionally, certain milestone payments that may be payable to the Company would be materially reduced. Refer to Notes 2.p and 13.b for accounting description. d) Agreement related to additional preclinical molecules with AstraZeneca In October 2018, the Company granted to AstraZeneca four exclusive options that are exercisable until IND approval to obtain a worldwide, royalty-bearing, exclusive license to certain of the Company’s patents and know-how relating to certain specified pipeline candidates to develop and commercialize optioned products in all fields of use. Pursuant to the agreement, AstraZeneca paid the Company a $20.0 million upfront payment (€17.4 million) in October 2018. The Company recognized this upfront payment in the consolidated statement of financial position as deferred revenue as of December 31, 2018, until the exercise or the termination of each option at the earliest. During 2022 first semester, the Company received from AstraZeneca a notice that it will not exercise its option to license the four preclinical programs covered in the " Future Programs Option Agreement ". Innate has now regained full rights to further develop the four preclinical molecules. Consequently, the entire initial payment of $20.0 million, or €17.4 million was recognized as revenue as of June 30, 2022 Refer to Notes 2.q and 13.c for accounting description. e) Agreements related to avdoralimab with Novo Nordisk and with AstraZeneca 2017 avdoralimab in-licensing agreement with Novo Nordisk A/S In July 2017, the Company signed an exclusive license agreement with Novo Nordisk A/S relating to avdoralimab. Under the agreement, Novo Nordisk A/S granted the Company a worldwide, exclusive license to develop, manufacture and commercialize pharmaceutical products that contain or comprise an anti-C5aR antibody, including avdoralimab. The Company made an upfront payment of €40.0 million, €37.2 million of which was contributed in new shares and €2.8 million of which in cash. In 2020, the Company made an additional payment of €1.0 million to Novo Nordisk A/S following the launch of the first Phase 2 trial of avdoralimab. The Company is obligated to pay up to an aggregate of €369.0 million upon the achievement of development, regulatory and sales milestones and tiered royalties ranging from a low double-digit to low-teen percentage of net sales. Refer to Notes 2.h, 2.j and 6 for accounting description. 2018 avdoralimab AstraZeneca agreement On January 1, 2021, the Company entered into a clinical trial collaboration agreement with AstraZeneca to sponsor a Phase 1/2 clinical trial (STELLAR-001) to evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with avdoralimab, as a treatment for patients with select solid tumors. The Company is the sponsor of the trial and the costs are equally shared between the two partners. This collaboration is a non-exclusive agreement and does not include any licensing rights on avdoralimab to AstraZeneca. In the first half of 2020, and based on data from cohort extensions in the first two cohorts, the Company decided to stop recruiting in the STELLAR-001 trial. Refer to Notes 2.p and 13 for accounting description. f) Collaboration and license agreements concluded with Sanofi for the development of "NK Cell engages" in oncology License and collaboration agreement with Sanofi signed in 2016 On January 2016, the Company entered into a research collaboration and licensing agreement with Sanofi to apply its proprietary technology to the development of multi-specific antibody formats engaging NK cells to kill tumor cells through the activating receptor NKp46. The Company granted to Sanofi under certain of its intellectual property a non-exclusive, worldwide, royalty-free research license, as well as an exclusive, worldwide license to research, develop and commercialize products directed against two specified targets, for all therapeutic, prophylactic and diagnostic indications and uses. The Company had work together with Sanofi on the generation and evaluation to two mulspecific NK cell engagers (IPH6101/SAR443579 and IPH6401/SAR'514), using its technology and Sanofi’s tumor targets and technology. Under the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. The Company will be eligible for up to €400.0 million in payments, primarily upon the achievement of development and commercial milestones, as well as royalties ranging from a mid to high single-digit percentage on net sales. On January 5, 2021, the Company announced that Sanofi has made the decision to progress IPH6101/SAR443579 into investigational new drug (IND) enabling studies. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate’s proprietary multi-specific antibody format. The decision triggered a €7.0m milestone payment from Sanofi to Innate. Sanofi will be responsible for all future development, manufacturing and commercialization of IPH6101/SAR443579. In December 2021, the Company announced that the first patient was dosed in a Phase 1/2 clinical trial, evaluating IPH6101/SAR443579, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplastic syndrome (HR-MDS). Following the initiation of the trial, the Company received a €3.0m milestone from Sanofi. During 2022 first semester, th e Company was informed of Sanofi's decision to advance IPH6401/SAR’514 towards regulatory preclinical studies aimed at studying an investigational new drug. As such, Sanofi has selected a second multi-specific antibody that engages NK cells as a drug candidate. This selection triggered a €3.0 million milestone payment from Sanofi to the Company. Collaboration and research license agreement with Sanofi signed in 2022 On December 19, 2022, the Company announced that it had entered into a research collaboration and license agreement with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (“Sanofi”) pursuant to which the Company granted Sanofi an exclusive license on the Innate Pharma's B7H3 ANKET® program and options on two additional targets. Once selected, Sanofi will be responsible for all development, manufacturing and marketing. Under the terms of the research collaboration and license agreement, the Company was eligible for an initial payment of €25.0 million, received in March 2023. Under the agreement, the Company is eligible for the duration of the research and collaboration agreement, to milestone payments of up to €1.35 billion in total, mainly linked to the achievement of preclinical, clinical, regulatory and commercial milestones (plus royalties on potential net sales). Refer to Notes 2.p and 13 for accounting description 1.2. Key events a) Key events for the year ended December 31, 2022 On February 14, 2022, the Executive Board carried out a capital increase of €9,301.50 and a net increase in share premium of €182,141 following (i) the exercise of 750 "BSAAR 2012", and (ii) the creation of 185,280 ordinary shares benefiting the employees of the company, including 138,960 ordinary shares issued free of charge (subscription). The capital increase carried out can be broken as follow : (i) a creation of 750 ordinary shares, with a nominal value of €0.05 and an issue price of €2.04 per share (i.e an increase in share premium of €1,492.50), and (ii) a creation of 138,960 free shares with a nominal value of €0.05 issued free of charge by deduction from the share premium, with a creation of 46,320 ordinary shares with a nominal value of €0.05 and an issue price of €4.10 (i.e an increase in share premium of €180,648.00). On March 16, 2022, the Company received a tax inspection opinion from the French tax authorities relating to the 2019 and 2020 financial years as well as to the research tax credit and the accuracy of its calculation for the 2018 to 2020 financial years. Following the review of the elements for calculating the research tax credit on 2018 expenses, the administration considered that the company had included expenses not eligible for the research tax credit. The expenses not included in the calculation of the research tax credit by the tax authorities mainly relates to depreciation on fixed assets and personnel costs. As of December 31,2022, and in the absence of a notice of adjustment received, the Company has assessed the impact on research tax credit claims relating to expenses for the years under review. A €1,270 thousand provision was recognized based on estimated amounts and adjustments not disputed by the Company. On April 22, 2022, the Executive Board carried out a capital increase of €1,250 thousand following the definitive acquisition of 25,000 free shares granted on April 29, 2019, under the “AGA New Members 2017 plan. Thus, 25,000 ordinary shares were created with a nominal value of €0.05 issued free of charge by deduction from the issue premium. On April 29, 2022, the Company announced the inclusion of the first patient in the “PACIFIC-9” Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclumab in patients with lung cancer. Under the monalizumab collaboration and license agreement entered into with AstraZeneca in 2015, AstraZeneca paid on June 17, 2022 a payment of $50.0 million (€47.7 million). On June 1, 2022, the Company signed an amendment to the collaboration and license option agreement IPH5201 concluded with AstraZeneca in October 2018. Subsequently, the Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancers for which the Company will be the sponsor. In accordance with the amendment signed on June 1, 2022, the Company is eligible for a milestone payment of $5.0 million by AstraZeneca. This milestone payment was received on August 2, 2022 by the Company for an amount of €4.9 million. During the first half of 2022, the Company received from AstraZeneca a notice that it will not exercise its option to license the four preclinical programs covered in the "Future Programs Option Agreement". This option agreement was part of the 2018 multi-term agreement between AstraZeneca and the Company under which the Company received an upfront payment of $20.0 million ( €17.4 million). Innate has now regained full rights to further develop the four preclinical molecules. Consequently, the entire initial payment of $20.0 million, or €17.4 million was recognized as revenue during 2022 fiscal year. During the first half of 2022, the Company was informed of Sanofi's decision to advance IPH6401/SAR’514 towards regulatory preclinical studies aimed at studying an investigational new drug. As such, Sanofi has selected a second multi-specific antibody that engages NK cells as a drug candidate. This selection triggered a €3.0 million milestone payment from Sanofi to the Company. This amount was received by the Company on September 9, 2022. On July 13, 2022, the Executive Board carried out a capital increase of 680.70 following the definitive acquisition of 13,614 free shares granted on July 13, 2020, under the “AGA Bonus 2020-2" plan. Thus, 13,614 ordinary shares were created with a nominal value of €0.05 issued free of charge by deduction from the issue premium. On July 27, 2022, the Executive Board carried out a capital increase of €6,287.70 following the definitive acquisition of 125,748 free shares granted on July 22, 2021, under the “AGA Bonus 2021-1" plan. Thus, 125,748 ordinary shares were created with a nominal value of €0.05 issued free of charge by deduction from the issue premium. On August 2022, the Company requested the extension repayment of the non-dilutive financing of €28.7 million obtained in December 2021 in the form of two State Guaranteed Loans ( “PGE”), respectively for 20.0 and 8.7 million euros for an additional period of five years starting in 2022 and including a one period, the Company will only be liable for the payment of interest and the guarantee fees, with amortization of the two loans starting in 2024 over a period of four years. Consequently, financial liabilities linked to the PGEs loans are presented as "financial liabilities - current" and "financial liabilities - non-current" in view of the new amortization plan of extended loans. On November 7, 2022 the Executive Board approved the final performance relating to the "AGA Perf Employees 2019-1" and "AGA Perf Management 2019-1" free performances shares plans, granted on November 4, 2019. The definitive performance was 50%. Consequently, the Executive Board carried out a capital increase of €15,952.50 following (i) the definitive acquisition of 147,500 free performance shares under the "AGA Perf Employee 2019-1" plan and (ii) the definitive acquisition of 171,550 free performance shares under the "AGA Perf Management 2019-1" plan. Thus, 319,050 ordinary shares were created with a nominal value of €0.05 issued free of charge by deduction from the issue premium. On December 2022, the Executive Board granted 1,371,500 free performances shares to employees of the Company (“AGA Perf Employees 2022-1”), and 550,000 free performances shares to members of the management (“AGA Perf Management 2022-1”). |
Accounting policies and stateme
Accounting policies and statement of compliance | 12 Months Ended |
Dec. 31, 2022 | |
Significant Accounting Policies [Abstract] | |
Accounting policies and statement of compliance | Accounting policies and statement of compliance a) Basis of preparation Consolidated financial statements of the Company for the years ended December 31, 2020, 2021 and 2022 (the “Consolidated Financial Statements”) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development Phase. The general accounting conventions were applied in compliance with the principle of prudence, in accordance with the underlying assumptions namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with IFRS, as defined below. Except for share data and per share amounts, the Consolidated Financial Statements are presented in thousands of euro. Amounts are rounded up or down to the nearest whole number for the calculation of certain financial data and other information contained in these accounts. Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures b) Statement of compliance The Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standard Board (“IASB”) and were approved and authorized for issuance by the Board of Directors of the Company on March 22, 2023. They will be approved by the General Meeting of the Company on May 12, 2023, which has the right to modify them. Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the Consolidated Financial Statements of the Company for the years ended December 31, 2020, 2021 and 2022 are also prepared in accordance with IFRS, as adopted by the European Union (EU). For the years ended December 31, 2020, 2021 and 2022, all IFRS that the IASB had published and that are mandatory are the same as those endorsed by the EU and mandatory in the EU. As a result, the Consolidated Financial Statements comply with International Financial Reporting Standards as published by the IASB and as adopted by the EU. IFRS include International Financial Reporting Standards (IFRS), International Accounting Standards (“ IAS ”), as well as the interpretations issued by the Standing Interpretations Committee (“SIC”), and the International Financial Reporting Interpretations Committee (“ IFRIC ”). The main accounting methods used to prepare the Consolidated Financial Statements are described below. These methods were used for all periods presented. c) Recently issued accounting standards and interpretations Application of the following new and amended standards is mandatory for the first time for the financial period beginning on January 1, 2020 and, as such, they have been adopted by the Company: • Amendments to IFRS 3 "Definition of a company", published on October 22, 2018. • Amendment to IFRS 16: "Covid-19-Adjustments to tenants' rents". The entry into force of this amendment had no impact on the Company's financial statements. • Amendments to IAS 1 and IAS 8 relating to the modification of the definition of the term “significant”, published on October 31, 2018. • Amendments to IAS 39, IFRS 7 and IFRS 9 relating to the reform of benchmark interest rates. • Conceptual framework for financial reporting and modification of references to Conceptual Framework in IFRS. Application of the following new and amended standards is mandatory for the first time for the financial period beginning on January 1, 2021 and, as such, they have been adopted by the Company: • Amendments to IFRS 16 : Covid-19-Related Rent Concessions, published on May 22, 2020. • Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 : Interest Rate Benchmark Reform — Phase 2, published on September 26, 2019. • IFRS IC opinion (IFRS / IAS Standards Interpretation Committee) addressed to the IASB in May 2021 and validated in June 2021 proposing to modify the way in which the commitments relating to certain defined benefit plans including an obligation of attendance at the retirement, a ceiling on rights from a certain number of years of seniority and depending on the seniority of the employee on the date of retirement. The changes in the calculation method presented in this opinion have been adopted by the Company from the financial year ended beginning on January 1, 2021 in the assessment of its commitments relating to retirement benefits. The details relating to this change in calculation method are presented in note 10) "Employee benefits" Those standards and interpretations have no impact on the Consolidated Financial statements, except as noted below following IFRS IC opinion addressed to IASB and validated in June 2021. The following new standards, amendments to existing standards and interpretations have been published but are not applicable in 2021 or have not yet been adopted by the European Union, and have not been applied early: • Amendment to IFRS 3 "Update of a reference to the conceptual framework" • Amendment to IAS16 "Products generated before their intended use" • Amendment to IAS37 "Onerous contracts - Costs of performing a contract" • Amendment to IAS1 "Classification of current or non-current liabilities" The accounting rules and valuation principles used for the financial statements at December 31, 2022 are identical to those used for the previous comparative year. Application of the following new and amended standards is mandatory for the first time for the financial period beginning on January 1, 2022 and, as such, they have been adopted by the Company: • Amendment to IFRS 3 "Update of a reference to the conceptual framework" • Amendment to IAS16 "Products generated before their intended use" • Amendment to IAS37 "Onerous contracts - Costs of performing a contract" The following new standards, amendments to existing standards and interpretations have been published but are not applicable in 2022 or have not yet been adopted by the European Union, and have not been applied early: • Amendment to IAS1 "Classification of current or non-current liabilities" d) Change in accounting policies Except for the adoption of IFRS 16 as of IFRS IC opinion on certain defined benefit plans validated by the IASB as of January, 2021 (see details in note 10), there has been no change in accounting policies for any of the years presented. e) Translation of transactions denominated in foreign currency Pursuant to IAS 21 The effects of changes in foreign exchange rates, transactions performed by consolidated entities in currencies other than their functional currency are translated at the prevailing exchange rate on the transaction date. Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the period-end exchange rate. Unrealized gains and losses arising from translation are recognized in net operating income. Foreign exchange gains and losses arising from the translation of inter-Group transactions or receivables or payables denominated in currencies other than the functional currency of the entity are recognized in the line “net financial income (loss)” of the consolidated statements of income (loss). Foreign currency transactions are translated into the presentation currency using the following exchange rates: December 31, 2020 December 31, 2021 December 31, 2022 €1 EQUALS TO AVERAGE RATE CLOSING RATE AVERAGE RATE CLOSING RATE AVERAGE RATE CLOSING RATE USD 1.1422 1.2271 1.1827 1.1326 1.0530 1.0666 f) Consolidation method The Group applies IFRS 10 Consolidated financial statements. IFRS 10 presents a single consolidation model identifying control as the criteria for consolidating an entity. An investor controls an investee if it has the power over the entity, is exposed or has rights to variable returns from its involvement with the entity and has the ability to use its power over the entity to affect the amount of the investor’s returns. Subsidiaries are entities over which the Company exercises control. They are fully consolidated from the date the Group obtains control and are deconsolidated from the date the Group ceases to exercise control. Intercompany balances and transactions are eliminated. g) Financial instruments Financial assets Financial assets are initially measured at fair value plus directly attributable transaction costs in the case of instruments not measured at fair value through profit or loss. Directly attributable transaction costs of financial assets measured at fair value through profit or loss are recorded in the consolidated statement of income (loss). Under IFRS 9, financial assets are classified in the following three categories: • Financial assets at amortized cost; • Financial assets at fair value through other comprehensive income (“FVOCI”); and • Financial assets at fair value through profit or loss. The classification of financial assets depends on: • The characteristics of the contractual cash flows of the financial assets; and • The business model that the entity follows for the management of the financial asset. Financial assets at amortized cost Financial assets are measured at amortized cost when (i) they are not designated as financial assets at fair value through profit or loss, (ii) they are held within a business model whose objective is to hold assets in order to collect contractual cash flows and (iii) they give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding (“SPPI” criterion). They are subsequently measured at amortized cost, determined using the effective interest method (“EIR”), less any expected impairment losses in relation to the credit risk. Interest income, exchange gains and losses, impairment losses and gains and losses arising on derecognition are all recorded in the consolidated statement of income (loss). This category primarily includes trade receivables, as well as other loans and receivables. Long-term loans and receivables that are not interest-bearing or that bear interest at a below-market rate are discounted when the amounts involved are material. Financial assets at fair value through other comprehensive income Financial assets at fair value through other comprehensive income is mainly comprised is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses. The Company did not hold this type of instrument as of January 1, 2022 or as of December 31, 2022. Financial assets at fair value through profit or loss Financial assets at fair value through profit or loss is comprised of: • financial assets that are not part of the above categories; and • instruments that management has designated as “fair value through profit or loss” on initial recognition. Gains and losses arising from changes in fair value are recognized in profit or loss within the line items financial income or financial expenses. Impairment of financial assets measured at amortized cost The main assets involved are trade receivables and others. Trade receivables are recognized when the Company has an unconditional right to payment by the customer. Impairment losses on trade receivables and others are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within Operating expenses in the consolidated statement of income (loss). Financial liabilities Financial liabilities comprise deferred revenue, collaboration liabilities, loans and trade and other payables. Financial liabilities are initially recognized on the transaction date, which is the date that the Company becomes a party to the contractual provisions of the instrument. They are derecognized when the Company’s contractual obligations are discharged, cancelled or expire. Loans are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they are measured at amortized cost using the EIR method. All costs related to the issuance of loans, and all differences between the issuance proceeds net of transaction costs and the value on redemption, are recognized within financial expenses in the consolidated statement of income (loss) over the term of the debt using the EIR method. Other financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost. Cash and cash equivalents Cash equivalents are short-term, highly liquid investments, that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Cash and cash equivalents comprise the cash that is held at the bank and petty cash as well as the short-term fixed deposits for which the maturity is less than three months. For the purpose of establishing the statement of cash flows, cash and cash equivalents include cash in hand, demand deposits and short fixed-term deposits with banks and short-term highly liquid investments with original maturities of three months or less, net of bank overdrafts. Cash and cash equivalents are initially recognized at their purchase costs on the transaction date, and are subsequently measured at fair value. Changes in fair value are recognized in profit or loss. Fair value of financial instruments Under IFRS 13 Fair value measurement and IFRS 7 Financial instruments: disclosures, or IFRS 7, fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; • level 2: fair value calculated using valuation techniques based on observable market data such as prices of similar assets and liabilities or parameters quoted in an active market; and • level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as prices in an inactive market or a valuation based on multiples for unlisted securities. h) Intangible assets Research and development (R&D) expenses In accordance with IAS 38 Intangible assets, or IAS 38, expenses on research activities are recognized as an expense in the period in which it is incurred. An internally generated intangible asset arising from the Company’s development activities is recognized only if all of the following conditions are met: • Technically feasible to complete the intangible asset so that it will be available for use or sale; • The Company has the intention to complete the intangible assets and use or sell it; • The Company has the ability to use or sell the intangible assets; • The intangible asset will generate probable future economic benefits, or indicate the existence of a market; • Adequate technical, financial and other resources to complete the development are available; and • The Company is able to measure reliably the expenditure attributable to the intangible asset during its development. Because of the risks and uncertainties related to regulatory approval, the R&D process and the availability of technical, financial and human resources necessary to complete the development Phases of the product candidates, the six criteria for capitalization are usually considered not to have been met until the product candidate has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within Research and development expenses. However, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an intangible asset. These related costs are capitalized when they are incurred and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained. Licenses Payments for separately acquired research and development are capitalized within “Other intangible assets” provided that they meet the definition of an intangible asset: a resource that is (i) controlled by the Group, (ii) expected to provide future economic benefits for the Group and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of IAS 38 standard, the first recognition criterion, relating to the likelihood of future economic benefits generated by the intangible asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts paid to third parties in the form of initial payments or milestone payments relating to product candidates that have not yet obtained a regulatory approval are recognized as intangible assets. These rights are amortized on a straight-line basis: (i) after obtaining the regulatory approval, over their useful life; or (ii) after entering in an out-license collaboration agreement with a third-party partner, over their estimated useful life. This estimated useful life takes into consideration the period of protection of the out-licensed exclusivity rights and the anticipated period over which the Company will receive the economic benefits of the asset. Unamortized rights (before marketing authorization) are subject to impairment tests in accordance with the method defined in Note 6. When intangible assets acquired separately are acquired through variable or conditional payments, these payments are recognized as an increase of the carrying amount of the intangible asset when they become due. Royalties due by the Company related to acquired licenses are recognized as operating expenses when the Company recognizes sales subject to royalties. Estimate of the useful life of the acquired licenses: intangible assets are amortized on a straight line basis over their anticipated useful life. The estimated useful life is the period over which the asset provides future economic benefits. It is estimated by management and is regularly revised by taking into consideration the period of development over which it expects to receive economic benefits such as collaboration revenues, royalties, product of sales, etc. However, given the uncertainty surrounding the duration of the R&D activities for the programs in development and their likelihood to generate future economic benefits to the Company, the estimated useful life of the rights related to these programs is rarely longer than the actual development Phase of the product candidate. When a program is in commercialization Phases, the useful life takes into account the protection of the exclusivity rights and the anticipated period of commercialization without taking into account any extension or additional patents. The prospective amendment of the amortization plan of the monalizumab intangible asset, which is modified according to the estimate ending date of the Phase 2 clinical trial is described in Note 6. Other intangible assets Other intangible assets consist of acquired software. Costs related to the acquisition of software licenses are recognized as assets based on the costs incurred to acquire and set up the related software. Software is amortized using the straight-line method over a period of one i) Property and equipment Property and equipment are carried at acquisition cost. Major renewals and improvements are capitalized while repairs and maintenance are expensed as incurred. Property and equipment are depreciated over their estimated useful lives using the straight-line depreciation method. Leasehold improvements are depreciated over the life of the improvement or the remaining lease term, whichever is shorter. The headquarters of the Company was split into several components (e.g., foundations, structure, electricity, heating and ventilation systems) which are depreciated over different useful lives according to the anticipated useful life of these elements. Depreciation periods are as follows: Buildings and improvements on buildings 20 to 40 years Installations 5 to 20 years Technical installations and equipment 8 years Equipment and office furniture 5 years Computers and IT equipment 3 years j) Impairment of intangible assets, property, and equipment The Group assesses at the end of each reporting period whether there is an indication that intangible assets, property and equipment may be impaired. If any indication exists, the Group estimates the recoverable amount of the related asset. Whether or not there is any indication of impairment, intangible assets not yet available for use are tested for impairment annually by comparing their carrying amount with their recoverable amount. Pursuant to IAS 36— Impairment of Assets, criteria for assessing indication of loss in value may notably include performance levels lower than forecast, a significant change in market data and/or the regulatory environment, the asset development strategy approved by management, or obsolescence or physical damage of the asset not included in the amortization/depreciation schedule. The recognition of an impairment loss alters the amortizable/depreciable amount and potentially, the amortization/depreciation schedule of the relevant asset. Impairment losses on intangible assets, property and equipment shall be reversed subsequently if the impairment loss no longer exists or has decreased. In such case, the recoverable amount of the asset is to be determined again so that the reversal can be quantified. The asset value after reversal of the impairment loss may not exceed the carrying amount net of depreciation/amortization that would have been recognized if no impairment loss had been recognized in prior periods. The Group does not have any intangible assets with an indefinite useful life. However, as explained in Note 2.h, the Group recognized intangible assets in progress, which will be amortized once marketing authorization is received. k) Employee benefits Long-term pension benefits Company employees are entitled to pension benefits required by French law: • Pension benefit, paid by the Company upon retirement (i.e. defined benefit plan); and • Pension payments from social security entities, financed by contributions from businesses and employees (i.e. defined contribution plan”). In addition, the Company has implemented an additional, non-mandatory, pension plan (“Article 83”), initially for the benefit of executives only. This plan was extended to the non-executive employees starting on January 1, 2014. This plan meets the definition of defined contribution plan and is financed through a contribution that corresponds to 2.2% of the employee’s annual wage, with the Company paying 1.4% and the employee paying 0.8%. For the defined benefit plan, the costs of the pension benefit are estimated using the “projected unit credit” method. According to this method, the pension cost is accounted for in the consolidated statement of income (loss), so that it is distributed uniformly over the term of the services of the employees. The pension benefit commitments are valued using the actual present value of estimated future payments, adopting the rate of interest of long-term bonds in the private sector (i.e. Euro zone AA or higher rated corporate bonds + 10 years). The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized in the consolidated statement of income (loss) for the portion representing the costs of services rendered and the net interest costs, and through other comprehensive income for the portion representing the actuarial gains and losses. The Company’s commitments under the defined benefit plan are not covered by any plan assets. Payments made by the Company for defined contribution plans are accounted for as expenses in the consolidated statement of income (loss) in the period in which they are incurred. Other long-term benefits The Company pays seniority bonuses to employees reaching 10, 15 and 20 years of seniority. These bonuses represent long-term employee benefits. Under IAS 19R “Employee benefits”, they are recording as a defined benefit obligation in the consolidated statement of financial position, but their remeasurements is not recognized in the consolidated statement of other comprehensive income (loss). Other short-term benefits An accrued expense is recorded for the amount the Company expects to pay its eligible employees in relation to services rendered during the reporting period (actual legal or implicit obligation to make to these payments on a short-term basis). l) Leases The Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise: • fixed lease payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date; • the amount expected to be payable by the lessee under residual value guarantees; • the exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and • payment of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease. The lease liability is included in the financial liabilities in the consolidated statement of financial position and is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Whenever the Company incurs an obligation for costs to dismantle and remove a leased asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease, a provision is recognized and measured under IAS 37. To the extent that the costs relate to a right-of-use asset, the costs are included in the related right-of-use asset, unless those costs are incurred to produce inventories. Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease. The right-of-use assets are included in the property and equipment line item in the consolidated statement of financial position. The Company applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss. m) Provisions and contingent liabilities In the course of its business, the Company could be exposed to certain risks and litigations, notably in relation to contractual arrangements. Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that the Company is subject to a release of outflow representatives of economic benefits to settle the obligation and a reliable estimate of the amount of the obligation can be made. Management of the Company estimates the probability and the expected amount of a cash outflow associated with risks, together with the other information to be provided on possible liabilities. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is certain. In addition, the Company may assess a potential obligation towards a third party resulting from events the existence of which will only be confirmed by the occurrence, or not, of one or more events. uncertain futures which are not totally under the control of the Company; or an obligation to a third party for which it is not probable or certain that it will result in an outflow of resources without at least equivalent consideration expected from the latter. These elements are mentioned in note 18 of the group's consolidated financial statements as contingent liabilities. n) Capital Ordinary shares are classified in shareholders’ equity. Costs associated with the issuance of new shares are directly accounted for in shareholders’ equity in diminution of issuance premium. The Company’s own shares bought in the context of a brokering/liquidity agreement are presented as a reduction in shareholders’ equity until their cancellation, their reissuance or their disposal. o) Share-based compensation Since its inception, the Company has established several plans for compensation paid in equity instruments in the form of free shares (“ Attributions gratuites d’actions,” or “AGA” ), free preferred shares convertible into ordinary shares (“ Attributions gratuites d’actions de préférence convertibles en actions ordinaires,” or “AGAP” ), free performance shares (“ Attributions gratuites d’actions de performance,” or “AGA Perf ”), share subscription warrants (“ Bons de souscription d’actions,” or “BSA ”), redeemable share subscription warrants (“ Bons de Souscription et/ou d’Acquisition d’Actions Remboursables,” or “BSAAR”), granted to its employees, executives, members of the Executive Board and scientific consultants. Pursuant to IFRS 2— Share-based Payment, these awards are measured at their fair value on the date of grant. The fair value is calculated with the most relevant formula regarding the conditions and the settlement of each plan. For share-based compensation granted to employees, executives, members of |
Management of financial risks a
Management of financial risks and fair value | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of nature and extent of risks arising from financial instruments [abstract] | |
Management of financial risks and fair value | Management of financial risks and fair valueThe principal financial instruments held by the Company are cash, cash equivalents and marketable securities. The purpose of holding these instruments is to finance the ongoing business activities of the Company. It is not the Company’s policy to invest in financial instruments for speculative purposes. The Company does not utilize derivatives. The principal risks to which the Company is exposed are liquidity risk, foreign currency exchange risk, interest rate risk and credit risk. Liquidity risk The Company’s cash management is performed by the Finance department, in charge of monitoring the day-to-day financing and the short-term forecast and enabling the Company to face its financial commitments by maintaining an amount of available cash consistent with the maturities of its liabilities. As of December 31, 2022, cash, cash equivalents and short-term investments were €101,485 thousand, which represents more than a year of cash consumption. The company's assets are fairly split between top-rated banks (S&P A+ rating). The main characteristics of the financial instruments owned by the Company (including liquidity) are presented in Note 4. Foreign currency exchange risk The Company is exposed to foreign exchange risk inherent in certain subcontracting activities relating to its operations in the United States, which have been invoiced in U.S. dollars. The Company does not currently have recurring revenues in euros, dollars or in any other currency. The revenue denominated in U.S. dollars has represented approximately 88%, 78% and 92% of revenue in the years ended December 31, 2020, 2021 and 2022, respectively. Payments in U.S dollars represented approximately 48%, 50%, and 50% of the payments in the years ended December 31, 2020, 2021 and 2022, respectively. In order to cover this risk, the Company kept in U.S. dollars a part of the consideration received from AstraZeneca in June 2015, January 2019 and December 2020. The Company entirely kept the U.S dollars portion of the proceeds received from our Global Offering in October 2019. The Company’s foreign exchange policy does not include the use of hedging instruments in its current operations. Interest rate risk The Company has very low exposure to interest rate risk. Such exposure primarily involves money market funds and time deposit accounts. Changes in interest rates have a direct impact on the rate of return on these investments and the cash flows generated. The Company has no credit facilities. The repayment flows of the advances from Banque Publique d’Investissement (“BPI France”), the borrowings subscribed in 2017 and the two State Guaranteed Loans obtained in 2021 and extended in 2022, are not subject to interest rate risk. Credit risk The credit risk related to the Company’s cash equivalents, short-term investments and non-current financial assets is not significant in light of the quality of the issuers. The Company deemed that none of the instruments in its portfolio are exposed to credit risk. Fair value The fair value of financial instruments traded on an active market is based on the market rate as of December 31, 2022. The market prices used for the financial assets owned by the Company are the bid prices in effect on the market as of the valuation date. |
Cash, cash equivalents and fina
Cash, cash equivalents and financial assets | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Cash, cash equivalents and financial assets | Cash, cash equivalents and financial assets December 31 (in thousands of euro) 2020 2021 2022 Cash and cash equivalents 136,792 103,756 84,225 Short-term investments 14,845 16,080 17,260 Cash and cash equivalents and short-term investments 151,637 119,836 101,485 Non-current financial assets 38,934 39,878 35,119 Total cash, cash equivalents and financial assets 190,570 159,714 136,604 Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts. Other non-current financial assets generally include a guarantee of capital at the maturity date (which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as non-current due to their maturity. As of December 31, 2020, 2021 and 2022 the amount of cash, cash equivalents and financials assets denominated in U.S. dollars amounted respectively to €64,654 thousand , €47,164 thousand and €34,735 thousand The variation of short-term investments and non-current financial assets for the periods presented, are the following: (in thousands of euro) December 31, 2020 Additions(1) Deductions (2) Variance of fair value through the consolidated statement of income (loss) Variance of accrued interests Foreign currency effect December 31, 2021 Short-term investments 14,845 — — 99 — 1,136 16,080 Non-current financial assets 38,934 — — 888 55 — 39,878 Total 53,779 — — 987 55 1,136 55,958 (in thousands of euro) December 31, 2021 Additions(1) Deductions (2) Variance of fair value through the consolidated statement of income (loss) Variance of accrued interests Foreign currency effect December 31, 2022 Short-term investments 16,080 — — 268 — 912 17,260 Non-current financial assets 39,878 — (3,000) (1,640) (118) — 35,119 Total 55,958 — (3,000) (1,372) (118) 912 52,379 |
Trade receivables and others
Trade receivables and others | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Trade receivables and others | Trade receivables and others Trade receivables and others are analyzed as follows: Year ended December 31, (in thousands of euro) 2020 2021 2022 Other receivables 741 814 61 Research tax credit (1) — 10,310 25,904 Other tax credits 333 333 361 Prepaid expenses (2) 6,833 2,582 4,672 VAT refund 2,208 1,170 1,614 Trade account receivables (3) 10,585 846 3,080 Prepayments made to suppliers 1,114 2,364 2,652 Receivables and others - current 21,815 18,420 38,345 Research tax credit (1) 29,821 29,821 13,018 Prepaid expenses (2) — — 1,081 Receivables and others - non-current 29,821 29,821 14,099 Trade receivables and others - excluding rebate related to capital expenditures 51,635 48,241 52,445 (1) In accordance with the principles described in Note 2.q, the research tax credit (Crédit d’Impôt Recherche or “CIR”) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of €13,018 thousand recognized in non-current receivables corresponds to the CIR for the 2020 tax year following the fact that the Company no longer met the eligibility criteria for the SME status as of December 31, 2019. Thus, the CIR for the 2020 represented a non-current receivable which will in principle be offset against the French corporate income tax due by the Company with respect to the three following years, or refunded if necessary upon expiry of such a period. Since December 2020, the Company has ensured that the eligibility criteria for the SME status are met again. As a result, the CIR related to the 2021 tax year which amounted €10,302 thousand has been refunded in advance by the French Treasury to the Company. This amount was received by the Company on November 16, 2022. The Company is also eligible for the early repayment by the French treasury of the 2022 Research Tax Credit during the fiscal year 2023 for an amount of €9,167 thousand and also the CIR related to the 2019 tax year for an amount of €16,737 thousand given the expiry of the three-year period (see note 2.q). (2) As of December 31, 2022, the prepaid expenses include an amount of €1,256 thousand relating to the guarantee fees in line with the two State Guaranteed Loans from Société Générale and BNP Paribas. Following the extension of these two loans repayment for an additional period, the full amount of the guarantee fee over the additional five-year period has been recognized as an operating expense in 2022. As of December 31, 2022, an adjustment is made through the prepaid accounts to reflect the fact that the expenses are related to the fiscal year (see note 9). (3) As of December 31, 2022, the amount is entirely comprised of the receivables from AstraZeneca for an amount of €1,775 thousand and €1,303 thousand in line with the performance of research and development services under the monalizumab and IPH5201 collaboration agreements, respectively. As a reminder, as of December 31, 2020, the amount included a receivable of €8,400 thousands (including €1,400 thousand of value added tax) linked to the collaboration and licensing agreement signed with Sanofi in January 2016. This receivable resulted from the decision taken by Sanofi to advance IPF6101/SAR443579 towards regulatory preclinical studies for the study of a new investigational drug. This payment was received by the Company in January 2021. Trade receivables and others have payment terms of less than one year. No valuation allowance was recognized on trade receivables and others as the credit risk of each of debtors was considered as not significant. |
Intangible assets
Intangible assets | 12 Months Ended |
Dec. 31, 2022 | |
Intangible assets other than goodwill [abstract] | |
Intangible assets | Intangible assets Intangible assets can be broken down as follows: (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2020 56,851 116 40,000 96,968 Acquisitions — 264 — 264 Additional considerations 2,685 (1) — 1,000 (2) 3,685 Disposals — — — — Depreciation (10,904) (3) (195) — (11,099) Impairment (43,529) (4) — — (43,529) Transfers — — — — December 31, 2020 5,103 185 41,000 46,289 (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2021 5,103 185 41,000 46,289 Acquisitions — 13 — 13 Additional considerations 368 (5) — — 368 Disposals — (39) — (39) Depreciation (2,310) (3) (130) — (2,440) Transfers — — — — December 31, 2021 3,161 29 41,000 44,192 (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2022 3,161 29 41,000 44,192 Acquisitions — — — Additional considerations 587 (6) — — 587 Disposals — — — Depreciation (2,195) (3) (29) — (2,224) Impairment — — (41,000) (7) (41,000) Transfers — — — — December 31, 2022 1,553 — — 1,556 (1) This amount of 2,685 thousand euros included two additional payments made to Orega Biotech in April 2020 (2,500 thousand euros) and June 2020 (185 thousand euros) relating to IPH5201 rights following the first patient dosed in Phase 1 clinical trial in Mars 2020. (2) This amount of €1,000 thousand was paid in October 2020 to Novo Nordisk A / S following the launch of the first Phase 2 trial regarding avdoralimab. (3) As of December 31, 2020, this amount included the amortization of rights relating to monalizumab (€2,844 thousand), IPH5201 (€4,314 thousand) and Lumoxiti (€3,746 thousand). The amortization relating to Lumoxiti rights related to the period prior to the decision to return the commercial rights to AstraZeneca. Impact of the decision on the book value of said rights is presented in note 6 below. As of December 31, 2021, the amount includes the amortization of rights relating to monalizumab (€1,942 thousand) and IPH5201 (€368 thousand). As of December 31, 2022, this amount includes the amortization of rights relating to monalizumab (€1,604 thousand) and IPH5201 (€587 thousand). (4) Following the Company's decision to return the commercial rights to Lumoxiti in the United States and in Europe at the end of November 2020, the rights relating to the intangible asset were fully impaired for the carrying amount of the intangible asset to the date of the decision, amounting to €43,529 thousand. (5) This amount relates to an additional consideration paid to Orega Biotech in January 2022 following the arbitration decision rendered in December 2021 relating to the joint ownership of certain patents relating to IPH5201. This additional payment is fully amortized as of December 31, 2021. (6) This amount corresponds to the additional payment made to Orega Biotech in October 2022 for the rights relating to IPH5201, following the amendment to the collaboration and license option agreement IPH5201 concluded with AstraZeneca in October 2018 and the announcement by the Company on June 3, 2022, of the progression of IPH5201 towards a Phase 2 study in lung cancers of which the Company will be a sponsor. (7) Following the Company's decision in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well that as of June 30, 2022), the rights relating to the intangible asset have been fully impaired for their net book value on the date of the decision, i.e. €41,000 thousand (see below "Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S') Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement At the agreement inception, acquired rights were recorded as intangible asset for an amount of €7,000 thousand. The Company recorded an additional consideration of €6,325 thousand in 2015 and a final consideration of $15,000 thousand (€13,050 thousand) due in 2018 (see Note 1.1.a). Since their acquisition by the Company, monalizumab rights are amortized on a straight-line basis over the anticipated residual duration of the Phase 2 trials. The Company has reassessed the anticipated residual duration of the Phase 2 trials as of December 31, 2022 and estimated that it would be fully amortized by 2023, which is the same estimation as of December 31, 2021, as a result of the completion of some trials and by modifying the estimated end dates relating to certain cohorts. The net book values of the monalizumab rights were €1,551 thousand and €3,155 thousand as of December 31, 2022 and December 31, 2021, respectively. IPH5201 (Anti-CD39) rights acquired from Orega Biotech On January 4, 2016, the Company and Orega Biotech entered into an exclusive licensing agreement by which Orega Biotech granted the Company full worldwide rights to its program of first-in-class anti-CD39 checkpoint inhibitors. The undisclosed upfront payment paid by the Company to Orega Biotech has been recognized as an intangible asset in the consolidated financial statements for the year ended December 31, 2016. Criteria relating to the first development milestone were reached in December 2016. Consequently, the amount of this milestone was recognized as an intangible asset in addition to the initial payment, for a total of €1.8 million as of December 31, 2021. In June 2019, the Company also paid Orega Biotech €7.0 million in relation to the anti-CD39 program as consideration following the collaboration and option agreement signed on October 22, 2018 with AstraZeneca regarding IPH5201. Under this agreement, the Company also paid in April and June 2020, respectively €2.5 and €0.2 million to Orega Biotech following the first Phase 1 dosing relating to IPH5201. This asset was amortized on a straight-line basis since November 1, 2018 (corresponding to the effective beginning date of the collaboration) until the date the Company expected to fulfill its commitment (end of fiscal year 2020). As a reminder, these collaboration commitments have all been fulfilled. Thus, the rights relating to IPH5201 are fully amortized since December 31, 2020. Orega Biotech claimed joint ownership of certain patents relating to IPH5201. the Company and Orega Biotech have resolved these claims in an arbitration proceeding, which decision was rendered in December 2021. As a result of this decision, the Company will be required to pay a low-teen percentage of sub-licensing revenues received by the Company pursuant to its agreement with AstraZeneca regarding IPH5201 Following this arbitration decision, the Company paid in January 2022 an additional amount of 0.4 million euros to Orega Biotech. The Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancer, of which the Company will be a sponsor. In accordance with the amendment signed on June 1, 2022, the Company was eligible for a milestone payment of $5 million by AstraZeneca, received in August 2022 by the Company. In October 2022, the Company therefore paid an additional €0.6 million to Orega Biotech. The Company may also be obligated to pay Orega Biotech up to €48.2 million upon the achievement of development and regulatory milestones. Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S At the agreement inception, an upfront payment of €40 million for acquired rights were recorded as intangible asset. As part of this agreement, an additional amount of €1.0 million was paid in October 2020 to Novo Nordisk A / S following the launch of the first avdoralimab Phase 2 trial. As avdoralimab is still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. No impairment were recorded since inception. According to the agreement, the Company will pay additional payments according to the reach of specific steps. As of December 31, 2022, according to the uncertainty of these potential future payments, no liability was recognized. Development costs incurred by the Company are recognized as research and development expenses. During 2022 fourth quarter, the Company was informed by the sponsor of the Phase 2 clinical trial evaluating avdoralimab in inflammation in bullous pemphigoid ("BP") indication of its decision to discontinue said trial. Consequently, the Company decided in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well that as of June 30, 2022). Following that decision, the Company applied IAS 36 "Impairment of assets" and assessed that there was an indication of impairment sufficiently significant to result in the full impairment of the intangible asset. This depreciation was recognized with regard to the estimate of the recoverable value of avdoralimab's intangible assets, based on expected future cash flows, as of December 2022, date of the decision. Thus, on decision date to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, avdoralimab rights were fully written down to their net book value, i.e €41,000 thousand. Lumoxiti rights acquired from AstraZeneca under the 2018 AstraZeneca multi-term agreement The license by which the Company acquired Lumoxiti rights was initially amortized on a straight-line basis through July 31, 2031, which corresponds to the expiration of the current composition of matter patent, not including any additional patent extensions or patents. The net book value of the Lumoxiti rights was €47,276 thousand as of December 31, 2019. End of November 2020, the Company decided to return the marketing rights of Lumoxiti in the United States and in Europe. Following this decision, the Company applied IAS 36 "Impairment of assets" and assessed that there was an indication of impairment sufficiently significant to result in the full impairment of the intangible asset. This depreciation was recognized with regard to the estimate of the recoverable value of Lumoxiti's intangible assets, based on expected future cash flows, determined using the marketing plan and budget approved by management, and future expenses to be exposed in particular as part of the transition plan, which was under negotiation as of December 31, 2020. Thus, on the date of the decision to return the rights, the Lumoxiti rights were fully written down to their net book value as of October 31, 2020, i.e. €43,529 thousand. |
Property and equipment
Property and equipment | 12 Months Ended |
Dec. 31, 2022 | |
Property, plant and equipment [abstract] | |
Property and equipment | Property and equipment (in thousands of euro) Land and buildings Laboratory equipment and other In progress Total Of which finance leases January 1, 2020 5,356 5,947 369 11,672 6,270 Acquisitions 1,152 944 132 2,228 1,195 Disposals — (9) — (9) — Transfers — 134 (134) — (1,042) Depreciation (757) (1,440) — (2,197) — December 31, 2020 5,751 5,576 367 11,694 6,423 (in thousands of euro) Land and buildings Laboratory equipment and other In progress Total Of which right of use assets January 1, 2021 5,751 5,576 367 11,694 6,423 Acquisitions 11 987 — 998 — Disposals (7) — (7) — Depreciation (781) (1,373) — (2,154) — Transfers 4 (361) (357) — December 31, 2021 4,981 5,187 6 10,174 6,423 (in thousands of euro) Land and buildings Laboratory equipment and other In progress Total Of which right of use assets January 1, 2022 4,981 5,187 6 10,174 6,423 Acquisitions 20 535 556 — Disposals (11) (6) (17) — Depreciation (759) (1,413) (2,171) — Transfers — — — — — December 31, 2022 4,242 4,298 — 8,542 6,423 |
Trade payables and others
Trade payables and others | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Trade payables and others | Trade payables and others This line item is analyzed as follows: December 31, (in thousands of euro) 2020 2021 2022 Suppliers (excluding payables related to capital expenditures) 20,730 14,729 13,656 Tax and employee-related payables 8,325 7,463 5,978 Other payables (1) 463 6,380 1,260 Trade payables and others excluding payables related to capital expenditures 29,519 28,573 20,894 Payables related to capital expenditures 20 — 17 Payables and others 29,539 28,573 20,911 (1) As of December 31, 2022, this amount mainly includes the liability related to the payment of the guarantee fees on the two State Guaranteed Loans obtained from Société Générale and BNP Paribas in 2021 (see note 9). As a reminder, this amount included, as of December 31, 2021, the liability of $6,200 thousand (€5,474 thousand as of December 31, 2021) to be paid to AstraZeneca on April 30, 2022 under the Lumoxiti termination and transition agreement effective June 30, 2021 (see note 17). The book value of trade payables and others is considered to be a reasonable approximation of their fair value. |
Financial liabilities
Financial liabilities | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Financial liabilities | Financial liabilities This line item was broken down per maturity and is analyzed as follows: In thousand euros December 31, 2019 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings and lease liabilities December 31, 2020 BPI PTZI IPH41 (1) 450 — — (300) 150 BPI Refundable advance - FORCE (2) — 1,360 94 — 1,454 Lease liabilities – Real estate property 418 — — (418) — Property transaction (down-payment) (74) — — 74 — Lease liabilities – Building "Le Virage" 1,437 — 1,114 (164) 2,387 Lease liabilities – Premises Innate Inc 496 — — (49) 447 Lease liabilities – Laboratory equipment 815 — — (176) 639 Lease liabilities – Vehicles 37 — — (16) 21 Lease liabilities - Printers — 41 — 41 Loans – Equipment 319 — — (57) 262 Loans – Building (4) 14,826 — (1,139) 13,687 Total 18,723 1,360 1,249 (2,245) 19,087 In thousand euros December 31, 2020 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings and lease liabilities December 31, 2021 BPI PTZI IPH41 (1) 150 — (150) — BPI Refundable advance - FORCE (2) 1,454 — (1,454) — — State guaranteed loan Société Générale (3) — 20,000 — — 20,000 State guaranteed loan BNP Paribas (3) — 8,700 — — 8,700 Lease liabilities – Building "Le Virage" 2,387 — — (512) 1,875 Lease liabilities – Premises Innate Inc 447 — (16) (40) 391 Lease liabilities – Laboratory equipment 639 — — (175) 464 Lease liabilities – Vehicles 21 — 62 (30) 53 Lease liabilities - Printers 41 — — (6) 35 Loans – Equipment 262 — — (53) 209 Loans – Building (4) 13,687 — — (1,162) 12,525 Total 19,087 28,700 (1,408) (2,128) 44,251 In thousand euros December 31, 2021 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings and lease liabilities December 31, 2022 State guaranteed loan Société Générale (3) 20,000 — — — 20,000 State guaranteed loan BNP Paribas (3) 8,700 — — — 8,700 State guaranteed loans - accrued interest — — 15 — 15 Lease liabilities – Building "Le Virage" 1,875 — — (522) 1,353 Lease liabilities – Premises Innate Inc 391 — 15 (61) 345 Lease liabilities – Laboratory equipment 464 — — (177) 287 Lease liabilities – Vehicles 53 — 12 (32) 33 Lease liabilities - Printers 35 — — (8) 27 Loans – Equipment 209 — — (55) 154 Loans – Building (4) 12,525 — — (1,187) 11,338 Total 44,251 — 42 (2,042) 42,251 (1) In 2013, the Company was granted an interest- free loan for innovation (“PTZI”) by BPI France relating to the program lacutamab IPH4102 for an amount of €1,500 thousand. (2) As a reminder, on August 11, 2020, the Company signed a financing contract with Bpifrance Financement as part of the program set up by the French government to help develop a therapeutic solution with a preventive or curative aim against COVID-19. This funding, for a maximum amount of € 6.8m, consisted of (i) an advance repayable only in the event of technical and commercial success and (ii) a non-repayable grant. This funding should have been received in four successive installments. The first tranche of 1.7 million euros was paid at signing, and the other three tranches should be received after successful completion of certain clinical milestones, particularly around Phase 2 of the FORCE trial. The portion relating to the repayable advance included in this first tranche amounted to €1,454 thousand as of December 31, 2020 (including actualization). As of December 31, 2021, this financing is considered by the Company to be non-refundable, in accordance with the terms of the agreement, in light of the technical and commercial failure of the project based on the results of the Phase 2 "Force" trial evaluating avdoralimab in COVID-19, published on July 6, 2021 (see note 13.2). (3) On January 5, 2022, the Company announced that it had obtained €28.7 million in non-dilutive financing in the form of two State Guaranteed Loans from Société Générale (€20.0 million) and BNP Paribas (€8.7 million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years from August 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtained agreements from Société Générale and BNP Paribas. The effective interest rates applied to these contracts during the additional period are 1.56% and 0.95% for Société Générale and BNP Paribas loans, respectively, excluding insurance and guarantee fees, with an amortization exemption for the entire year 2023. During this grace period, the Company will only be liable for the payment of interest and the guarantee fees, with amortization of the two loans starting in 2024 over a period of four years. The state guarantee fees amounts to €877 thousand and €379 thousand for Société Générale and BNP Paribas loans respectively. (4) On July 3, 2017, the Company borrowed from the Bank “Société Générale” in order to finance the construction of its future headquarters. This loan amounting to a maximum of €15,200 thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of €1,300 thousand. The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the €15,200 thousand loan granted, for an amount of €13,900 thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (12 years). Given the development of its portfolio and in particular the refocusing of its activities on research and development, the Company has for the time being suspended the project to build its new head office on the land acquired in Luminy. In the meantime, the loan will be used to finance several structuring projects (improvement of the information system, development of a commercial platform, development of additional premises rented, etc.). As of December 31, 2022, the remaining capital of the loan amounted to €11,338 thousand. The Company authorized collateral over financial “Société Générale” instruments amounting to €15,200 thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: €4,200 thousand in July 2024, €5,000 thousand in August 2027 and €6,000 thousand in August 2031. This loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end. The table below shows the schedule for the contractual flows (principal only) as of December 31, 2020, 2021 and 2022 respectively : In thousand euros Year ended December 31, Current financial liabilities 2020 2021 2022 BPI PTZI IPH41 150 — — BPI Refundable advance - FORCE — — — State guaranteed loan Société Générale — 20,000 — State guaranteed loan BNP Paribas — 8,700 — State guaranteed loans - accrued interest — — 15 Lease finance obligations – Rent Le Virage 511 522 532 Lease liabilities – Premises Innate Inc 72 74 90 Lease finance obligations – Laboratory equipment 175 177 177 Lease liabilities – Vehicles 13 23 16 Lease liabilities - Printers 6 8 9 Loans - Equipment 55 55 55 Loans - Building 1,161 1,187 1,210 Total – Current financial liabilities 2,142 30,748 2,102 In thousand euros Year ended December 31, Non-Current financial liabilities 2020 2021 2022 BPI PTZI IPH41(1) — — — BPI Refundable advance - FORCE 1,454 — — State guaranteed loan Société Générale — — 20,000 State guaranteed loan BNP Paribas — — 8,700 State guaranteed loans - accrued interest — — — Lease finance obligations – Building Le Virage 1,876 1,352 820 Lease liabilities – Premises Innate Inc 375 317 255 Lease finance obligations – Laboratory equipment 463 287 110 Lease finance obligations – Vehicles 8 30 17 Lease liabilities - Printers 35 26 18 Loans - Equipment 208 154 99 Loans - Building 12,526 11,338 10,128 Total – Non-Current financial liabilities 16,945 13,503 40,149 The table below shows the schedule for the contractual flows (being principal and interest payments): (in thousands of euro) ≤ 1 year 2 to 5 years included ≥ 5 years Total State guaranteed loan Société Générale 312 20,670 — 20,982 State guaranteed loan BNP Paribas 86 8,884 — 8,970 State guaranteed loans - accrued interest 15 — — 15 Lease finance obligations – Rent Le Virage 558 838 — 1,396 Lease liabilities – Premises Innate Inc. 96 312 — 408 Lease liabilities – Laboratory equipment 179 110 — 289 Lease liabilities – Vehicles 19 20 — 39 Lease liabilities - Printers 9 18 — 27 Loans – Equipment 57 100 — 157 Loan – Building 1,427 5,706 5,112 12,245 Total 2,758 36,658 5,112 44,528 |
Employee benefits
Employee benefits | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of information about defined benefit plans [abstract] | |
Employee benefits | Employee benefits Defined benefit obligations Year ended December 31, (in thousands of euro) 2020 2021 2022 Allowance for retirement defined benefit 3,713 2,544 2,184 Allowance for seniority awards 463 432 366 Total Defined benefit obligations 4,177 2,975 2,550 French law requires payment of a lump sum retirement indemnity to employees based on years of service, the rights guaranteed by the collective agreements and annual compensation at retirement. Benefits do not vest prior to retirement. The Company pays for this defined benefit plan. It is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final. As a reminder, in April 2021, the IFRIC ( or "IFRS Interpretations Committee") sent a proposal to the IAS Board (International Accounting Standards Board) to change the way in which the liabilities for certain defined benefit plans are calculated. The IAS Board endorsed this position in June 2021. The impacts of this change in valuation method are detailed below. On March 24, 2016, the Company entered into an internal labor agreement with the employees representatives whereby the Company is committed to paying a seniority award after 15 years and 20 years of employment. This award is paid on the anniversary date. A similar award existed for employees having a seniority of 10 years but was not booked due to its insignificant amount. As such, in 2016 the Company recorded a provision for seniority awards and a corresponding charge included in “Personnel costs other than share-based payments” (see Note 14) other than payments in shares. These awards meet the definition of other long-term benefits under IAS 19. This provision is determined by an external actuary firm based on the assumptions disclosed hereafter and amounts to €366 thousand as of December 31, 2022 (€432 thousand as of December 31, 2021). The main actuarial assumptions used to evaluate retirement benefits are the following: Year ended December 31, 2020 2021 2022 Economic assumptions Discount rate (iBoxx Corporate AA) for retirement 0.50 % 0.95 % 3.75 % Annual rate of increase in wages 3.00 % 3.00 % 4.00 % Demographical assumptions Type of retirement At the initiative of the employee At the initiative of the employee At the initiative of the employee Annual mobility rate 2.6 % 4.2 % 4.3 % Rate of contributions 45.17 % 48.39 % 47.07 % Rate of wages costs 22.06 % 24.18 % 23.46 % Age at retirement - Executives 64 years 64 years 64 years - Non executives 62 years 62 years 62 years Mortality table TH-TF 00-02 TH-TF 00-02 TH-TF 00-02 Annual turnover by tranche of age All personnel All personnel All personnel 16-24 years 6.0 % 12.0 % 12.0 % 25-29 years 5.0 % 9.0 % 10.0 % 30-34 years 3.7 % 7.0 % 7.0 % 35-39 years 3.0 % 4.5 % 5.0 % 40-44 years 2.0 % 3.0 % 3.0 % 45-49 years 1.0 % 1.5 % 1.5 % +50 years 0 % 0 % 0 % Changes in the projected benefit obligation for the periods presented were as follows (in thousands of euro): As of January 1, 2020 3,760 Service cost 252 Interest costs (35) Actuarial loss 200 As of December 31, 2020 4,177 IAS19 Restatement related to the change in calculation method - IFRIC (1) (1,054) Service cost 484 Interest costs (47) Actuarial gain (584) As of December 31, 2021 2,976 Service cost 427 Interest costs (62) Actuarial loss (790) As of December 31, 2022 2,550 (1) In its April 2021 Update, the IFRS IC published a final agenda decision clarifying how to calculate the obligation relating to certain defined benefit plans under which the retirement benefit is (i) contingent on the employee being employed by the entity at the time of retirement; (ii) capped at a specified number of years of service; and (iii) linked to the employee's length of service at the date of retirement. In that decision, the IFRS IC took the view that the obligation should be recognized only over the years of service preceding the date of retirement in respect of which the employee generates entitlement to the benefit. The application of this decision has led to a change in accounting method, the effects of which should be taken into account retrospectively in accordance with IAS 8. However, as the Company considers the impact of this change of method on defined benefit obligation and the income statement to be insignificant, these impacts have not been restated for years prior to January 1, 2021. The effects of this change of method are therefore taken into account retrospectively as of January 1, 2021 in respect of 2020's and prior years defined benefit obligation. The adjustment at that date corresponds to a reduction in the 2020 commitments in the amount of €1,054 thousand. This reversal has been offset against previous reserves and retained earnings. There is no asset covering the defined benefit obligations. An increase/decrease of +/- 50 basis point of the discount rate would result in a decrease/increase of the total benefit obligation of €174 thousand. The amounts recognized as an expense linked to defined contributions plans amounted to €1,420 thousand, €1,434 thousand and €1,432 thousand in the years ended December 31, 2020, 2021 and 2022, respectively. |
Share capital and share based p
Share capital and share based payments | 12 Months Ended |
Dec. 31, 2022 | |
Share Capital And Share Based Payments [Abstract] | |
Share capital and share based payments | Share capital and share based payments a) Share capital The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. The Company has never declared or paid any dividends on its ordinary shares. The Company does not anticipate paying cash dividends on its equity securities in the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of its business, given our state of development. As of December 31, 2022, the Company’s share capital amounted to €4,011,308 divided into (i) 79,542,627 ordinary shares, each with a nominal value of €0.05, (ii) 6,881 “2016” free preferred shares, each with a nominal value of €0.05 and (iii) 7,581 “2017” free preferred shares, each with a nominal value of €0.05, respectively fully paid up. Share capital does not include BSAs, BSAAR,AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and non-employees of the Company, but not yet exercised. In October 21, 2019 and December 30, 2019, the retention period for the “2016 free preferred shares” has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. Holders of “2016” preferred shares” are entitled to vote at our shareholders’ meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares. In April 3, 2021, the retention period for the "2017 free preferred shares" has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. According to these same performance criteria, the Executive Board of April 7, 2021 noted that the "2017 preferred shares" did not give right to any ordinary shares. The “2017 preferred shares” will not be redeemed by the Company and will remain incorporated into the capital, unless subsequently decided by the Executive Board. As the conversion is void, the "2017 preferred shares" no longer give the right to vote at our general meetings, nor to receive dividends. The table below presents the historical changes in the share capital of the Company as of December 31, 2020, 2021 and 2022, respectively: Number of Date Nature of the Transactions Share Capital Share premium Common shares Preferred shares Nominal value Balance as of January 1, 2020 3,941,281 369,617,017 78,811,114 14,507 €0.05 January 15, 2020 Capital increase by issuance of common shares (exercise of share warrants) 75 2,985 1,500 €0.05 January 27, 2020 Capital increase by issuance of common shares (definitive acquisition of free shares ) 4,283 (4,283) 85,650 €0.05 July 7, 2020 Capital increase by issuance of common shares (exercise of share warrants) 1,250 43,000 25,000 €0.05 July 13, 2020 Capital increase by issuance of common shares (definitive acquisition of free shares ) 2,869 (2,869) 57,376 €0.05 September 11, 2020 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 32 (32) 650 (5) €0.05 September 24, 2020 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 226 (226) 4,550 (35) — December 31, 2020 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 32 (32) 650 (5) €0.05 December 31, 2020 Share based payments — 2,475,422 — €0.05 December 31, 2020 3,950,048 372,130,982 78,986,490 14,462 €0.05 (1) Share issuance costs representing incremental expenses directly attributable to the offering of new shares in the IPO on the Nasdaq and in the European Private Placement (together the “Global Offering”) were recorded through equity for an amount of €621 thousand. They consist mainly of legal, financial, accounting and printing fees associated with drafting and filing the registration statement of Innate Pharma. The other incremental costs incurred in the Global Offering were expensed for an amount of €2,150 thousand. Number of Date Nature of the Transactions Share Capital Share premium Common shares Preferred shares Nominal value Balance as of January 1, 2021 3,950,048 372,130,982 78,986,490 14,462 €0.05 June 4, 2021 Capital increase by issuance of common shares (exercise of share warrants) 1,500 59,700 30,000 — €0.05 July 7, 2021 Capital increase by issuance of common shares (exercise of share warrants) 222 7,637 4,440 — €0.05 July 19, 2021 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 548 (548) 11,050 (85) €0.05 July 22, 2021 Capital increase by issuance of common shares (definitive acquisition of free shares ) 2,418 (2,418) 48,362 — €0.05 July 22, 2021 Capital increase by issuance of common shares (exercise of share warrants) 625 21,500 12,500 — €0.05 August 6, 2021 Capital increase by issuance of common shares (exercise of share warrants) 10,000 398,000 200,000 — €0.05 December 31, 2021 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 1,819 (1,819) 36,660 (282) €0.05 December 31, 2021 Capital increase by issuance of common shares (definitive acquisition of free shares ) 10,656 (10,656) 213,125 — €0.05 December 31, 2021 Share based payments — 2,617,289 — — December 31, 2021 3,977,836 375,219,667 79,542,627 14,095 €0.05 Number of Date Nature of the Transactions Share Capital Share premium Common shares Preferred shares Nominal value Balance as of January 1, 2022 3,977,836 375,219,667 79,542,627 14,095 €0.05 February 14, 2022 Capital increase by issuance of common shares (exercise of share warrants) 38 1,493 750 — €0.05 February 14, 2022 Capital increase by issuance of common shares 2,316 187,596 46,320 — €0.05 February 14, 2022 Capital increase by issuance of common shares (definitive acquisition of free shares ) 6,948 (6,948) 138,960 — €0.05 April 22, 2022 Capital increase by issuance of common shares (definitive acquisition of free shares ) 1,250 (1,250) 25,000 — €0.05 July 13, 2022 Capital increase by issuance of common shares (definitive acquisition of free shares ) 681 (681) 13,614 — €0.05 July 25, 2022 Capital increase by issuance of common shares (exercise of share warrants) 6,287 (6,287) 125,748 — €0.05 December 16, 2022 Subsciption of share warrants — 9,995 — — €— November 7, 2022 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 15,953 (15,953) 319,050 — €0.05 December 31, 2022 Share based payments — 4,249,113 — — — December 31, 2022 4,011,308 379,636,744 80,212,069 14,095 €0.05 Holding by the Company of its own shares The Company held 18,575 of its own shares as of December 31, 2022. b) Share based payments The Company has issued BSAs, BSAARs, stock options, AGAs and AGAPs as follows as of December 31, 2020, 2021 and 2022, respectively: : Date Types Number of warrants issued as of 12/31/2020 Number of warrants void as of 12/31/2020 Number of warrants exercised as of 12/31/2020 Number of warrants outstanding as of 12/31/2020 Maximum number of shares to be issued as of 12/31/2020 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 — 395,000 255,000 255,000 €2.04 May 27, 2013 BSAAR 2012 146,050 — 85,950 60,100 60,100 €2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 €7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 — 1,450 188,500 €— October 21, 2016 AGAP Employees 2016-1 2,486 251 50 2,185 284,050 €— October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — €— December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 €— December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — — April 3, 2018 AGAP Employees 2017-1 5,725 833 — 4,892 489,200 — April 3, 2018 AGAP Management 2017-1 2,400 800 — 1,600 160,000 — April 3, 2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — — November 20, 2018 AGAP Perf Employees 2018-1 327,500 85,000 — 242,500 242,500 — November 20, 2018 AGAP Perf Management 2018-1 260,000 60,000 — 200,000 200,000 — January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — — April 29, 2019 AGA New Members 2017-1 25,000 — — 25,000 25,000 — July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — — November 4, 2019 AGAP 2019 Employees 2019 546,700 86,100 — 460,600 460,600 — November 4, 2019 AGAP 2019 Management 2019 355,000 30,000 — 325,000 325,000 — July 13, 2020 AGA Bonus 2020-1 79,861 — — 79,861 79,861 — August 5, 2020 AGA Perf Employees 2020-1 766,650 70,540 — 696,110 696,110 — August 5, 2020 AGA Perf Management 2020-1 710,000 — — 710,000 710,000 — July 21, 2020 Stock Options 2020-1 102,000 72,000 — 30,000 30,000 — July 29, 2011 BSA 2011-2 225,000 — 183,060 41,940 41,940 €1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 €2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 €8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 €9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 €14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 €11.00 Total as of December 31, 2020 6,398,008 418,263 1,552,225 4,427,520 5,869,143 Date Types Number of warrants issued as of 12/31/2021 Number of warrants void as of 12/31/2021 Number of warrants exercised as of 12/31/2021 Number of warrants outstanding as of 12/31/2021 Maximum number of shares to be issued as of 12/31/2021 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 25,000 625,000 — — €2.04 May 27, 2013 BSAAR 2012 146,050 — 85,950 60,100 60,100 €2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 €7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 250 1,200 156,000 €— October 21, 2016 AGAP Employees 2016-1 2,486 251 167 2,068 268,840 €— October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — €— December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 €— December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — — April 3, 2018 AGAP Employees 2017-1 5,725 5,725 — — — — April 3, 2018 AGAP Management 2017-1 2,400 2,400 — — — — April 3, 2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — — November 20, 2018 AGAP Perf Employees 2018-1 327,500 224,375 103,125 — — — November 20, 2018 AGAP Perf Management 2018-1 260,000 150,000 110,000 — — — January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — — April 29, 2019 AGA New Members 2017-1 25,000 — — 25,000 25,000 — July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — — November 4, 2019 AGAP 2019 Employees 2019 546,700 189,900 — 356,800 356,800 — November 4, 2019 AGAP 2019 Management 2019 355,000 30,000 — 325,000 325,000 — July 13, 2020 AGA Bonus 2020-1 79,861 17,885 48,362 13,614 13,614 — August 5, 2020 AGA Perf Employees 2020-1 766,650 249,826 — 516,824 516,824 — August 5, 2020 AGA Perf Management 2020-1 710,000 30,000 — 680,000 680,000 — July 22, 2021 AGA Bonus 2021-1 125,748 — — 125,748 125,748 — October 1, 2021 AGA Perf Employees 2021-1 1,066,600 17,500 — 1,049,100 1,049,100 — October 1, 2021 AGA Perf Management 2021-1 610,000 30,000 — 580,000 580,000 — July 21, 2020 Stock Options 2020-1 102,000 102,000 — — — — July 29, 2011 BSA 2011-2 225,000 25,000 200,000 — — €1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 €2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 €8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 €9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 €14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 €11.00 Total as of December 31, 2021 8,200,356 1,112,601 2,061,019 5,026,736 5,778,308 Date Types Number of warrants issued as of 12/31/2022 Number of warrants void as of 12/31/2022 Number of warrants exercised as of 12/31/2022 Number of warrants outstanding as of 12/31/2022 Maximum number of shares to be issued as of 12/31/2022 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 25,000 625,000 — — €2.04 May 27, 2013 BSAAR 2012 146,050 — 86,700 59,350 59,350 €2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 €7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 250 1,200 156,000 €— October 21, 2016 AGAP Employees 2016-1 2,486 251 167 2,068 268,840 €— October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — €— December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 €— December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — — April 3, 2018 AGAP Employees 2017-1 5,725 5,725 — — — — April 3, 2018 AGAP Management 2017-1 2,400 2,400 — — — — April 3, 2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — — November 20, 2018 AGAP Perf Employees 2018-1 327,500 224,375 103,125 — — — November 20, 2018 AGAP Perf Management 2018-1 260,000 150,000 110,000 — — — January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — — April 29, 2019 AGA New Members 2017-1 25,000 — 25,000 — — — July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — — November 4, 2019 AGAP 2019 Employees 2019 546,700 375,150 171,550 — — — November 4, 2019 AGAP 2019 Management 2019 355,000 207,500 147,500 — — — July 13, 2020 AGA Bonus 2020-1 & 2 79,861 17,885 61,976 — — — August 5, 2020 AGA Perf Employees 2020-1 766,650 286,306 — 480,344 480,344 — August 5, 2020 AGA Perf Management 2020-1 710,000 60,000 — 650,000 650,000 — July 22, 2021 AGA Bonus 2021-1 125,748 — 125,748 — — — October 1, 2021 AGA Perf Employees 2021-1 1,066,600 95,600 — 971,000 971,000 — October 1, 2021 AGA Perf Management 2021-1 610,000 90,000 — 520,000 520,000 — February 12, 2022 AGA "Plan Epargne Entreprise" 2022 138,960 — 138,960 — — — October 3, 2022 AGA Bonus 2022-1 128,061 — — 128,061 128,061 €— December 12, 2022 AGA Perf Employees 2022-1 1,371,500 — — 1,371,500 1,371,500 €— December 12, 2022 AGA Perf Management 2022-1 550,000 — — 550,000 550,000 €— July 21, 2020 Stock Options 2020-1 102,000 102,000 — — — €— July 29, 2011 BSA 2011-2 225,000 25,000 200,000 — — €1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 €2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 €8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 €9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 €14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 €11.00 December 16, 2022 BSA 2022-1 40,000 31,740 — 8,260 8,260 €2.31 Total as of December 31, 2022 10,428,877 1,711,671 2,684,141 6,033,065 6,784,637 AGA Details of AGA AGAP Management 2016-1 AGAP Employees 2016-1 AGA Management 2016-1 AGA Employees 2016-1 AGAP Management 2016-2 Date of grant (Board of Directors) October 21, 2016 October 21, 2016 October 21, 2016 October 21, 2016 October 21, 2016 Vesting period (years) 1 year 1 year 3 years 1 year 1 year Non transferability period 2 years after the vesting period end 2 years after the vesting period end None 2 years after the vesting period end 2 years after the vesting period end Number of free shares granted 2,000 2,486 50,000 99,932 3,000 Share entitlement per free share 130 (1) 130 (1) 1 1 111 Grant date share fair value €10.87 €10.87 €10.87 €10.87 €12.73 Expected dividends None None None None None Performance conditions Yes Yes None None Yes Expected turnover (yearly basis) 5 % 5 % — 5 % 9 % Volatility 40 % 40 % — — 40 % Fair value per AGA €911 €911 €10.55 €10.55 €956 In October 21, 2019 and December 30, 2019, the retention period for the “2016 free preferred shares” has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfilment of the performance criteria. Holders of “2016” preferred shares” are entitled to vote at our shareholders’ meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares. AGA Management 2016-2 AGA Employees 2016-2 AGA Bonus 2017 AGA Employee 2017 AGAP Employees 2017-1 Date of grant (Board of Directors) December 30, 2016 December 30, 2016 September 20, 2017 April 3, 2018 April 3, 2018 Vesting period (years) 3 years 1 year 1 year 1 year 1 year Non transferability period None 2 years after the vesting period end 1 year after the vesting period end 1 year after the vesting period end 2 years after the vesting period end Number of free shares granted 250,000 149,943 114,500 28,556 5,725 Share entitlement per free share 1 1 1 1 100 Grant date share fair value €12.73 €12.73 €5.52 €10.90 €5.52 Expected dividends None None None None None Performance conditions None None Yes None Yes Expected turnover (yearly basis) — 5 % 4 — % 5 % Volatility — — 55 — % 55 % Fair value per AGA €14.61 €10.55 €5.83 €10.30 €90 AGAP Management 2017 AGA Bonus 2018 AGA Perf Employees 2018 AGA Perf Management 2018 AGA New Members 2017-1 Date of grant (Board of Directors) April 3, 2018 July 3, 2018 November 20, 2018 November 20, 2018 April 29, 2019 Vesting period (years) 1 year 1 year 3 years 3 years 3 years Non transferability period 2 years after the vesting period end 1 year after the vesting period end None None None Number of free shares granted 2,400 67,028 327,500 260,000 25,000 Share entitlement per free share 100 1 1 1 1 Grant date share fair value €5.52 €5.06 €8.00 €8.00 €5.74 Expected dividends None None None None None Performance conditions Yes Yes Yes Yes No Expected turnover (yearly basis) 11 % — 4 % 10 % 10 % Volatility 55 % — 45 % 45 % — Fair value per AGA €90 €4.69 €3.81 €3.81 €5.74 AGA Employees 2018 AGA Bonus 2019-1 AGA Perf Employees 2019 AGA Perf Management 2019 AGA Bonus 2020 Date of grant (Board of Directors) January 14, 2019 July 3, 2019 November 4, 2019 November 4, 2019 July 13, 2020 Vesting period (years) 1 year 1 year 3 years 3 years 1 year Non transferability period 1 year after the vesting period end 1 year after the vesting period end None None 1 year after the vesting period end Number of free shares granted 90,650 57,376 546,700 355,000 79,861 Share entitlement per free share 1 1 1 1 1 Grant date share fair value €7.31 €5.90 €3.13 €3.13 €6.40 Expected dividends None None None None None Performance conditions No No Yes Yes No Expected turnover (yearly basis) 4.03 % — 10 % 10 % — % Volatility N/A — 45 % 45 % — % Fair value per AGA €7.31 €5.72 €3.13 €3.13 €6.40 AGA Perf Employees 2020-1 AGA Perf Management 2020-1 AGA Bonus 2021-1 AGA Perf Employees 2021-1 AGA Perf Management 2021-1 Date of grant (Board of Directors) August 5, 2020 August 5, 2020 July 22, 2021 October 1, 2021 October 1, 2021 Vesting period (years) 3.5 years 3.5 years 1 year 3.5 years 3.5 years Non transferability period None None 1 year None None Number of free shares granted 769,202 710,000 125,748 1,066,600 610,000 Share entitlement per free share 1 1 1 1 1 Grant date share fair value €2.94 €2.94 €3.43 €1.76 €1.76 Expected dividends None None None None None Performance conditions Yes Yes No Yes Yes Expected turnover (yearly basis) 10.00 % 10.00 — 13.32 13.32 Volatility 45.00 % 45.00 — 50.00 50.00 Fair value per AGA €2.94 €2.94 €3.43 €1.76 €1.76 AGA "Plan Epargne Entreprise" 2022 AGA Bonus 2022-1 AGA Perf Employees 2022-1 AGA Perf Management 2022-1 Date of grant (Board of Directors) February 12, 2022 October 3, 2022 December 12, 2022 December 12, 2022 Vesting period (years) None 1 year 3.1 years 3.1 years Non transferability period None None None None Number of free shares granted 138,960 128,061 1,371,500 550,000 Share entitlement per free share 1 1 1 1 Grant date share fair value €4.10 €3.89 €1.39 €1.39 Expected dividends None None None None Performance conditions No No Yes Yes Expected turnover (yearly basis) — % — 10.50 10.50 Volatility — % — 50.00 50.00 Fair value per AGA €4.10 €3.89 €1.39 €1.39 Change in Number of AGAs Outstanding Year ended December 31, Number of AGAs 2020 2021 2022 Balance at beginning of period 1,607,345 2,752,198 3,678,354 Granted during the period 1,556,511 1,802,348 2,188,521 Forfeited during the period (268,587) (614,338) (567,330) Exercised during the period (143,071) (261,854) (622,372) Expired during the period — — — Balance at end of period 2,752,198 3,678,354 4,677,173 Breakdown of the Closing Balance Year ended December 31, 2020 2021 2022 Number of AGAs Outstanding Outstanding Outstanding AGAP Management 2016-1 1,450 1,200 1,200 AGAP Employees 2016-1 2,185 2,068 2,068 AGAP 2016-2 3,000 3,000 3,000 AGAP Management 2017 1,600 — — AGAP Perf Employees 2018 242,500 — — AGAP Perf Management 2018 200,000 — — AGA New Members 2017-1 25,000 25,000 — AGA Perf Employees 2019-1 460,600 356,800 — AGA Perf Management 2019-1 325,000 325,000 — AGA Bonus 2020-1 79,861 13,614 — AGA Perf Employees 2020-1 696,110 516,824 480,344 AGA Perf Management 2020-1 710,000 680,000 650,000 AGA Bonus 2021-1 — 125,748 — AGA Perf Employees 2021-1 — 1,049,100 971,000 AGA Perf Management 2021-1 — 580,000 520,000 AGA Bonus 2022-1 — — 128,061 AGA Perf Employees 2022-1 — — 1,371,500 AGA Perf Management 2022-1 — — 550,000 TOTAL 2,752,198 3,678,354 4,677,173 The fair value of granted free shares is based on the closing price of the Company’s share at grant date, reduced when necessary by an estimated turn-over rate. This estimated fair value is recognized as operating expenses on a straight-line basis over the vesting period. Free performance shares 2018 (AGA Perf Employees 2018-1 and AGA Perf Management 2018-1) Free performance shares granted in 2018 are subject to share price conditions and a vesting kicker triggered by the performance of an internal condition, which is the success of certain clinical trials. The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below: • Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach; • Adjustment of the estimation by applying expected turnover rates. Changes in internal conditions are taken into account in the revision of the estimated number of free performance shares expected to vest during the vesting period. On January 3, 2022, the Executive Board determined the achievement of the performance conditions and the final vesting of the free performance shares 2018 as of November 20, 2021. The underlying performance conditions were thus achieved at 55%, noting on November 20, 2021 the final acquisition of 103,125 “AGA Perf Employees 2018-1” as well as 110,000 “AGA Perf Management 2018-1”. Expenses were €618 thousand, €(232) thousand (income) the financial years ended December 31, 2020, and 2021 respectively. These instruments were definitively acquired during the 2021 financial year. Consequently, no expense relating to these plans was recognized during the financial year ended December 31, 2022. AGA 2018-1 (Employees) Expenses were €23 thousand for the financial year ended December 31, 2020, and respectively. These instruments were definitively acquired during the 2020 financial year. Consequently, no expense relating to these plans was recognized during the financial year ended December 31, 2021 and 2022, respectively. AGA 2017-1 Management (New Members) Expenses were €43 thousand, €71 thousand and nil for the financial years ended December 31, 2020 2021 and 2022, respectively. Free performance shares 2019 (AGA Perf Employees 2019-1 / AGA Perf Management 2019) Free performance shares granted in 2019 are subject to share price conditions and a vesting kicker triggered by the performance of an internal condition, which is Lumoxiti's market penetration rate in the United States. The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below: • Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach; • Adjustment of the estimation by applying expected turnover rates. On November 7, 2022, the Executive Board determined the achievement of the performance conditions and the final vesting of the 2019 free performance shares as of November 4, 2022. The underlying performance conditions were thus achieved at 50%. Consequently, on November 7, 2022, the Executive Board carried out the definitive acquisition of 171,550 free performance shares under the "AGA Perf Management 2019-1" plans. . Expenses were €867 thousand, €649 thousand and €(181) thousand (income) for the financial years ended December 31, 2020, 2021 and 2022, respectively. Income relating to the 2022 financial year is explained by the review of the performance conditions during the 2022 financial year with regard to the definitive achievement of the vesting. Free performance shares 2020 (AGA Perf Employees 2020-1 / AGA Perf Management 2020) Free performance shares granted in 2020 are subject to share price conditions and two vesting kickers triggered by the performance of internal conditions, which are : • A commercial break-even point for Lumoxiti in the U.S. reached at the end of fiscal year 2023 (this criterion will not be met given the return of the commercial rights notified to AstraZeneca in December 2020). • Revenue from collaborative and licensing agreements accrued between the attribution and definitive acquisition date (excluding payment by AstraZeneca for the first patient in Phase 3 for monalizumab), reaching $100 million. The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below: • Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach; • Adjustment of the estimation by applying expected turnover rates. Expenses were €502 thousand, €1,253 thousand and €1,738 thousand for the financial year ended December 31, 2020 2021 and 2022, respectively AGA Bonus 2020-1 AGA Bonus 2020 were granted to the Executive members Committee who opted for these compensation plans. For each recipient, the number of shares definitely acquired is equal to the cash equivalent of 50% of the annual variable compensation increased by a 30% premium. In the event of an over-performance (i.e. achieved target above 100%), the surplus is paid in cash. Expenses were €394 thousand for the financial year ended December 31, 2020. These instruments were definitively acquired during the 2021 financial year. Consequently, no expense relating to these plans were recognized during the financial years ended December 31, 2021 and 2022, respectively. Free performance shares 2021 (AGA Perf Employees 2021-1 / AGA Perf Management 2021-1) Free performance shares granted in 2021 are subject to share price conditions and two vesting kickers triggered by the performance of internal conditions, which are : • An interim analysis demonstrates a predefined threshold of clinical activity in the INTERLINK-1 study (phase 3 study evaluating monalizumab in combination with cetuximab in patients with squamous cell carcinoma of the head and neck and previously treated with chemotherapy). • Obtaining positive Phase 2 results for a product in the Company's portfolio. • The start of a first clinical trial for a product in the Company's portfolio The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below: • Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach; • Adjustment of the estimation by applying expected turnover rates. Expenses were €473 thousand and €1,577 thousand for the financial years ended December 31, 2021 and 2022, respectively. AGA Bonus 2021-1 AGA Bonus 2021 were granted to the Executive members Committee who opted for these compensation plans. For each recipient, the number of shares definitely acquired is equal to the cash equivalent of 50% of the annual variable compensation increased by a 50% premium. In the event of an over-performance (i.e. achieved target above 100%), the surplus is paid in cash. Expenses were €432 thousand for the financial year ended December 31, 2021. Free performance shares 2022 (AGA Perf Employees 2022-1 / AGA Perf Management 2022-1) Free performance shares granted in 2022 are subject to share market capitalization and three vesting kickers triggered by the performance of internal conditions, which are : • The filing and approval of a BLA (Biologic License Application) application filed with the Food and Drug Administration ("FDA") in the United States or the European Medicine Agency ("EMEA") in Europe for one of the Company's products. • The start of a first clinical trial for a product from the Company's portfolio. • The conclusion of a collaboration or license agreement. The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below: • Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach; • Adjustment of the estimation by applying expected turnover rates. Expenses were €46 thousand for the financial year ended December 31, 2022. AGA Bonus 2022-1 AGA Bonus 2022 were granted to the Executive members Committee who opted for these compensation plans. For each recipient, the number of shares definitely acquired is equal to the cash equivalent of 50% of the annual variable compensation increased by a 50% premium. In the event of an over-performance (i.e. achieved target above 100%), the surplus is paid in cash. Expenses were €499 thousand for the financial year ended December 31, 2022. BSA Details of BSA BSA 2013 BSA 2014 BSA 2015-1 BSA 2015-2 BSA 2017 Date of grant (Board of directors) July 17, 2013 July 16, 2014 April 27, 2015 July 1, 2015 September 20, 2017 Vesting period (years) 2 years 2 years 2 years 2 years 2 years Plan expiration date July 17, 2023 July 16, 2024 April 26, 2025 June 30, 2025 September 20, 2027 Number of BSA granted 237,500 150,000 70,000 14,200 37,000 Share entitlement per BSA 1 1 1 1 1 Exercise price €2.36 €8.65 €9.59 €14.05 €11.00 Valuation method used Black & Scholes Black & Scholes Black & Scholes Black & Scholes Black & Scholes Grant date share fair value €2.45 €6.85 €13.65 €13.64 €10.41 Expected volatility 31.83 % 46.72 % 54.08 % 47.83 % 61.74 % Average life of BSA 5.5 years 5.5 years 5.5 years 5.5 years 6 years Risk-free interest rate 2.42 % 1.00 % 0.25 % 0.25 % 0.20 % Expected dividends None None None None None Performance conditions None None None None None Fair value per BSA €0.87 €2.51 €6.59 €4.73 €0.57 BSA 2022-1 Date of grant (Board of directors) December 16, 2022 Vesting period (years) 2 years Plan expiration date October 3, 2032 Number of BSA granted 40,000 Share entitlement per BSA 1 Exercise price €2.31 Valuation method used Black & Scholes Grant date share fair value €1.31 Expected volatility 50.00 % Average life of BSA 5.5 years Risk-free interest rate 2.40 % Expected dividends None Performance conditions None Fair value per BSA €1.21 Change in Number of BSA Outstanding Year ended December 31, Number of BSA 2020 2021 2022 Balance at beginning of period 309,500 284,500 242,560 Granted during the period — — 40,000 Forfeited during the period — — (31,740) Exercised during the period (25,000) (16,940) — Expired during the period — (25,000) — Balance at end of period 284,500 242,560 250,820 Breakdown of the Closing Balance Year ended December 31, 2020 2021 2022 Number of BSA Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BSA 2011-2 41,940 41,940 — — — — BSA 2013 46,360 46,360 46,360 46,360 46,360 46,360 BSA 2014 75,000 75,000 75,000 75,000 75,000 75,000 BSA 2015-1 70,000 70,000 70,000 70,000 70,000 70,000 BSA 2015-2 14,200 14,200 14,200 14,200 14,200 14,200 BSA 2017 37,000 37,000 37,000 37,000 37,000 37,000 BSA 2022-1 — — — — 8,260 8,260 TOTAL 284,500 284,500 242,560 242,560 250,820 250,820 BSAAR BSAAR are securities whose subscription price and exercise price are fixed at their fair value as determined by an expert. The BSAAR subscription therefore represents an invest |
Financial instruments recognize
Financial instruments recognized in the statement of financial position and related effect on the income statement | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of detailed information about financial instruments [abstract] | |
Financial instruments recognized in the statement of financial position and related effect on the income statement | Financial instruments recognized in the statement of financial position and related effect on the income statement The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. As of December 31, 2020 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Receivables Fair value Financial assets Non-current financial assets 38,934 38,934 38,934 Trade receivables and others 51,635 — 51,635 51,635 Short-term investments 14,845 14,845 — 14,845 Cash and cash equivalents 136,792 136,792 — 136,792 Total financial assets 242,206 190,571 51,635 242,206 As of December 31, 2020 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Debt at amortized cost (3) Fair value Financial liabilities Financial liabilities—non-current portion 16,945 — 16,945 16,945 Financial liabilities—current portion 2,142 — 2,142 2,142 Trade payables and others 29,539 — 29,539 29,539 Total financial liabilities 48,624 — 48,624 48,624 As of December 31, 2021 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Receivables Fair value Financial assets Non-current financial assets 39,878 39,878 — 39,878 Trade receivables and others 48,241 — 48,241 48,241 Short-term investments 16,080 16,080 — 16,080 Cash and cash equivalents 103,756 103,756 — 103,756 Total financial assets 207,955 159,714 48,241 207,955 As of December 31, 2021 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Debt at amortized cost (3) Fair value Financial liabilities Financial liabilities—non-current portion 13,503 — 13,503 13,503 Financial liabilities—current portion 30,748 — 30,748 30,748 Trade payables and others 28,573 — 28,573 28,573 Total financial liabilities 72,824 — 72,822 72,822 As of December 31, 2022 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Receivables Fair value Financial assets Non-current financial assets 35,119 35,119 — 35,119 Trade receivables and others 52,445 — 52,445 52,445 Short-term investments 17,260 17,260 — 17,260 Cash and cash equivalents 84,225 84,225 — 84,225 Total financial assets 189,049 136,604 52,445 189,049 As of December 31, 2022 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Debt at amortized cost (3) Fair value Financial liabilities Financial liabilities—non-current portion 40,149 — 40,149 40,149 Financial liabilities—current portion 2,102 — 2,102 2,102 Trade payables and others 20,911 — 20,911 20,911 Total financial liabilities 63,162 — 63,162 63,162 (1) The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. (2) The fair value of financial assets classified as fair value through comprehensive income corresponds to the market value of the assets, which are primarily determined using level 1 measurements. (3) The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value. In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchy of methods used to determine fair value: Level 1: fair value determined based on quoted prices in active markets for assets or liabilities; Level 2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly; |
Revenue and government financin
Revenue and government financing for research expenditures | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of disaggregation of revenue from contracts with customers [abstract] | |
Revenue and government financing for research expenditures | Revenue and government financing for research expenditures Revenue from collaboration and licensing agreements The Company’s revenue from collaboration and licensing agreements amounts to €56,155, €12,112 and €49,580 for the fiscal year ended December 31, 2020, 2021 and 2022, respectively. Year ended December 31, (in thousands of euro) 2020 (1) 2021 2022 Proceeds from collaboration and licensing agreements 54,038 10,497 48,806 of which monalizumab agreement - AstraZeneca 33,620 7,497 22,376 of which IPH5201 agreement - AstraZeneca 13,418 — 4,677 of which preclinical molecules agreement - AstraZeneca — — 17,400 of which Sanofi agreement 7,000 3,000 4,000 of which other agreements — — 353 Invoicing of research and development costs (IPH5201) 2,531 1,613 1,391 Exchange gains (loss) on collaboration agreements (602) — (627) Others 188 — 10 Revenue from collaboration and licensing agreements 56,155 12,112 49,580 (1) The 2020 comparatives have been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17. a) Revenue recognition related to monalizumab AstraZeneca agreements and amendments The Company identified the following promises under the monalizumab AstraZeneca agreements and amendments: (1) a non-exclusive license related to monalizumab restricted to two applications, with an option for an exclusive license related to monalizumab including all applications, (2) the performance of certain initial studies related to Phases 1/2 trials, and participation in certain studies of Phases 1/2 trials and Phase 3 clinical trials through a co-financing. The Company considered the license has a standalone functionality and is capable of being distinct. However the Company determined that the license is not distinct from the performance of initial studies and participation to Phase 3 clinical trials because they increased the utility of the licensed IP. Thus, the licensed IP, the performance of initial studies and participation to Phase 3 clinical trials are combined into a single performance obligation. This performance obligation was considered as satisfied over time as AstraZeneca controls the licensed IP which is being enhanced during the agreement. The revenue is recognized over time, based on the input method (costs incurred). As a result, the Company recognizes the price of the transaction as a revenue on the basis of the progress of studies that the Company has undertaken to carry out under the agreement. Progression is assessed following to actual costs incurred relative to the total budgeted costs to fulfill the obligation. The transaction price was initially estimated to the initial payment of $250,000 thousand, less the amounts that the Company expected to pay to AstraZeneca for co-financing Phase 1/2 clinical studies. The additional payment of $100,000 thousand triggered by AstraZeneca’s exercise of the exclusivity option was treated as a change in the price estimate of the transaction. In addition, the amendment of the contract, which modified the scope and budget of the studies to be carried out by the Company as well as the arrangements for sharing the cost of the other studies, led to a revision of the degree of progress and the price of the transaction. Thus, the exercise of the option and the amendment of the contract resulted in the recognition of a favourable cumulative adjustment of €38,321 thousand in revenue for the year ended December 31, 2019. The additional payment of $50,000 thousand triggered by the dosing of the first patient in the Phase 3 trial evaluating monalizumab was treated in full as a collaboration commitment ("collaboration liability" in the consolidated balance sheet) in view to the commitment linked to the contract for the Phase 1/2 (co-financing) and Phase 3 studies (amendment signed in September 2020). Consequently, this additional payment has no impact on the transaction price. In addition to these amounts, AstraZeneca made an additional payment of $50.0 million (€47.7 million) in June 2022 and triggered by the treatment of the first patient in a second Phase 3 trial “PACIFIC-9” evaluating monalizumab in April 2022. This additional payment has been treated as an increase of the collaboration commitment ("collaboration liabilities" in the consolidated statements of financial position) for an amount of $36.0 million (€34.3 million) in connection to the Phase 3 study co-funding commitment made by the Company and notified to AstraZeneca in July 2019. The remaining amount of $14.0 million (€13.4 million) has been treated as an increase of the transaction price, recognized in the income statement in line with the progress of the Phase 1/2 studies. The subsequent milestones and potential royalty payments are excluded from the transaction price due to the uncertainties of clinical trials results. The Company used the most likely amount to determine variable consideration. Variable consideration for cost-sharing payments related to certain studies of Phases 1/2 trials and Phase 3 clinical trials when applicable are included in the transaction price. As a reminder, the expected payments to AstraZeneca are classified as collaboration liability in the consolidated statement of financial position. Quarterly invoices received from AstraZeneca reduce the collaboration liability and have no impact on the consolidated statement of income. Change in monalizumab deferred revenue (in thousands of euro): As of December 31, 2019 62,657 Revenue for the 2020 financial year (33,620) Transfer from collaboration liabilities (2,465) As of December 31, 2020 26,572 Revenue for the 2021 financial year (7,497) Transfer from collaboration liabilities 1,084 As of December 31, 2021 20,159 Increase in deffered revenu resulting from the $50m milestone relating to the dosage of the first patent in the Phase 3 trial PACIFIC-9 (1) 47,687 Revenue for the 2022 financial year (22,376) Transfer from collaboration liabilities (30,989) As of December 31, 2022 14,481 (1) The increase in deferred revenue relating to monalizumab agreement between December 31, 2021 and December 31, 2022 is explained by the additional payment of €47,687 thousand ($50,000 thousand) made by AstraZeneca in June 2022 and triggered by the launch of the “PACIFIC-9” Phase 3 trial on April 28, 2022. This increase has led to a simultaneous increase in collaboration commitment ("collaboration liability"- see below) of €34,335 thousand ($36,000 thousand) in accordance with the Company’s July 2019 option concerning the co-financing of Phase 3 trials in the field of collaboration. Change in monalizumab collaboration liablities (in thousands of euro): As of December 31, 2019 (1) 21,304 Additions (2) 46,320 Deductions (20,938) As of December 31, 2020 (3) 46,686 Additions 4,262 Deductions (10,534) As of December 31, 2021 (4) 40,415 Additions (5) 37,564 Deductions (14,768) As of December 31, 2022(6) 63,211 (1) Of which €21,304 thousand of current portion. (2) Including €41,227 thousand euros ($ 50,000 thousand) relating to the collaboration commitment following the milestone payment related to the treatment of the first patient in the Phase 3 trial evaluating monalizumab. (3) Of which €1,832 thousand of current portion and €44,854 of non-current portion. (4) Of which €7,418 thousand of current portion and €32,997 thousand of non-current portion. (5) The increase in collaboration liabilities relating to monalizumab agreement between December 31, 2021 and December 31, 2022 mainly results from (i) a €34,335 thousand ($36,000 thousand) increase in collaboration commitments in connection with the launch of the “PACIFIC-9” Phase 3 trial on April 28, 2022, and (ii) a €2,145 thousand net increase in the collaboration commitments in connection with exchange rate fluctuations over the period. (6) Of which €10,223 thousand of current portion and €52,988 thousand of non-current portion. b) Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement Revenue related to IPH5201 for the year ended December 31, 2022 is €4,677 million and results from the entire recognition in revenue of the $5.0 million (€4.7 million) milestone payment received from AstraZeneca following the signature on June 1, 2022 of an amendment to the initial contract signed in October 2018. This amendment sets the terms of the collaboration following AstraZeneca’s decision to advance IPH5201 to a Phase 2 study. The Company will conduct the study. Both parties will share the external cost related to the study and incurred by the Company and AstraZeneca will provide products necessary to conduct the clinical trial. c) Revenue related to collaboration and option agreement related to four to-be-agreed upon molecules (preclinical molecules) Change in deferred revenue relating to the 2018 future programs option agreement (in thousands of euro) Total As of December 31, 2021 17,400 Augmentation — Deductions (17,400) As of December 31, 2022 — During the first half of 2022, the Company received from AstraZeneca a notice that it will not exercise its option to license the four preclinical programs covered in the "Future Programs Option Agreement". This license option was part of the 2018 multi-term agreement between AstraZeneca and the Company under which the Company had received an upfront payment of $20,000 thousand (€17,400 thousand). As the rights related to these four preclinical programs have been returned to the Company, the entire upfront payment of $20,000 thousand (€17,400 thousand) was recognized as revenue as of June 30, 2022. d) Revenue recognition related to collaboration and license agreement signed with Sanofi in 2016 Revenues under the collaboration and license agreement signed with Sanofi in 2016 amounted to €4,000 thousand for the year ended December 31, 2022 as compared to €3,000 thousand for the year ended December 31, 2021. During the period, the Company announced, notably, the decision taken by Sanofi to advance IPH6401/SAR'514 towards regulatory preclinical studies for a new investigational drug. This decision triggered a milestone payment of €3,000 thousand fully recognized in revenue. This amount was received by the Company on September 9, 2022. e) Schedule of variance of deferred revenue The main variance of the global deferred revenue is presented in the following schedule: (in thousands of euro) December 31, 2019 Recognition in P&L Proceeds Transfer from collaboration liabilities December 31, 2020 Monalizumab 62,657 (33,620) — (2,465) 26,572 IPH5201 9,054 (13,418) 4,365 — — Preclinical molecules 17,400 — — — 17,400 Total 89,112 (47,038) 4,365 (2,465) 43,973 (1) (1) Of which €11,299 thousand of current deferred revenue and €32,674 thousand of non-current deferred revenue. (in thousands of euro) December 31, 2020 Recognition in P&L Proceeds Transfer from collaboration liabilities December 31, 2021 Monalizumab 26,572 (7,497) — 1,084 20,159 IPH5201 — — — — — Preclinical molecules 17,400 — — — 17,400 Others — — 353 — 353 Total 43,973 (7,497) 353 1,084 37,913 (2) (2) Of which €12,500 thousand of current deferred revenue and €25,413 thousand of non-current deferred revenue. (in thousands of euro) December 31, 2021 Recognition in P&L Proceeds and other increase Transfer from collaboration liabilities December 31, 2022 Monalizumab 20,159 (22,376) 47,687 (30,989) 14,481 Preclinical molecules 17,400 (17,400) — — — Others 353 (353) — — — Total 37,913 (39,776) 47,687 (30,989) 14,481 (3) (3) Of which €6,560 thousand of current deferred revenue and €7,921 thousand of non-current deferred revenue. Government financing for research expenditures The Company receives grants from the European Commission and the French government and state organizations in several different forms: • Investment and operating grants; and • Research Tax Credits. The total amount for government financing for research expenditures recorded as other income in the income statement can be analyzed as follows: Year ended December 31, (in thousands of euro) 2020 2021 2022 Research Tax Credit(1) 13,084 10,310 7,925 Grant and other tax credit(2) 534 2,281 110 Government financing for research expenditures 13,618 12,591 8,035 (1) As of December 31, 2022, the amount is mainly composed of (i) the research tax credit calculated and recognized for the 2022 financial year for an amount of €9,167 thousand from which is subtracted (ii) a provision amounting to €1,270 thousand following the tax inspection carried out in 2022 by the French tax authorities and relating to the 2019 and 2020 financial years as well as to the research tax credit and the accuracy of its calculation for the 2018 to 2020 financial years. This provision was recognized as a deduction from the 2022 research tax credit, based on estimated amounts and adjustments not disputed by the Company. On March 3, 2023, the Company received from the tax authorities the rectification proposal, confirming the amount of the provision recognized on the amounts of the rectifications not disputed by the Company. |
Operating expenses
Operating expenses | 12 Months Ended |
Dec. 31, 2022 | |
Analysis of income and expense [abstract] | |
Operating expenses | Operating expenses (in thousands of euro) Year ended December 31, 2020 (1) 2021 2022 R&D G&A Total R&D G&A Total R&D G&A Impairment Total Subcontracting costs (2) (19,866) 4 (19,862) (24,189) (101) (24,290) (24,432) — — (24,432) Cost of supplies and consumable materials (3,590) 32 (3,558) (2,533) (532) (3,065) (3,051) (531) — (3,582) Personnel expenses other than share-based compensation (13,825) (6,611) (20,436) (14,859) (8,616) (23,475) (14,329) (8,025) — (22,354) Share-based compensation (836) (1,639) (2,475) (349) (2,267) (2,617) (2,044) (2,204) — (4,249) Personnel expenses (14,661) (8,250) (22,911) (15,208) (10,883) (26,092) (16,373) (10,229) — (26,603) Non-scientific advisory and consulting (3) (342) (4,441) (4,783) (161) (5,108) (5,269) (1,441) (4,244) — (5,685) Leasing and maintenance (559) (1,605) (2,164) (260) (1,754) (2,014) (200) (1,798) — (1,998) Travel expenses and meeting attendance (146) (138) (284) (103) (170) (273) (466) (252) — (718) Marketing, communication and public relations (96) (408) (504) (79) (393) (472) (130) (530) — (660) Scientific advisory and consulting (4) (962) — (962) (288) — (288) (1,263) — — (1,263) Other purchases and external expenses (46) (2,007) (2,053) (30) (2,395) (2,425) (91) (2,557) — (2,648) Depreciation and amortization (8,231) (1,154) (9,385) (3,153) (1,416) (4,569) (2,928) (1,496) — (4,424) Intellectual property expenses (877) (393) (1,270) (1,279) (305) (1,584) (996) (296) — (1,292) Other income and (expenses), net (332) (626) (958) 279 (2,467) (2,188) (292) (503) — (795) Impairment of intangible assets (5) — — — — — — — — (41,000) (41,000) Total net operating expenses (49,708) (18,986) (68,694) (47,004) (25,524) (72,528) (51,663) (22,436) (41,000) (115,099) (1) The 2020 comparative have been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17. (2) The Company subcontracts a significant part of its preclinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. Associated costs are recorded in subcontracting on the basis of the level of completion of the clinical trials. (3) Non-scientific advisory and consulting are services performed to support the selling, general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. (4) Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company. (5) Following the Company's decision in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well as of June 30, 2022), the rights relating to the intangible asset have been fully impaired for their net book value on the date of the decision, i.e. €41,000 thousand (see note 6) Year ended December 31, 2020 2021 2022 (in thousands of euro) Deloitte & Associés Total Deloitte & Associés Total Deloitte & Associés Total Audit fees 684 684 702 702 855 855 Non-audit fees 115 115 78 78 248 248 Total 799 799 780 780 1,103 1,103 * Non-audit fees: these fees correspond to services performed by the auditors related to the production of certification in the context of the declaration of expenses for the obtention of grants; to the verification report of social and environmental information, special reports within the framework of operations on the Company’s capital Personnel expenses other than share-based compensation The line item amounted to €20,436 thousand, €23,475 thousand and €22,354 thousand for the years ended December 31, 2020, 2021 and 2022 respectively. These items do not include personnel expenses relating to the Lumoxiti discontinued operation (see note 17). The Company had 214 employees as of December 31, 2021, compared to 208 as of December 31, 2022. Depreciation and amortization The line item is mainly composed of the amortization of the monalizumab, IPH5201 intangible assets (see Note 6). Cost of supplies and consumable materials |
Net financial loss
Net financial loss | 12 Months Ended |
Dec. 31, 2022 | |
Analysis of income and expense [abstract] | |
Net financial loss | Net financial loss Net financial loss can be analyzed as follows: Year ended December 31, (in thousands of euro) 2020 2021 2022 Interests and gains on financial assets 564 327 546 Unrealized gains on financials assets 313 1,177 418 Foreign exchange gains 3,978 4,839 3,810 Other financial income — — — Financial income 4,855 6,344 4,775 Foreign exchange losses (5,557) (3,591) (2,983) Unrealized losses on financial assets (865) (95) (2,050) Interest on financial liabilities (341) (312) (288) Other financial expenses — — — Financial expenses (6,763) (3,997) (5,321) Net financial income (loss) (1,908) 2,347 (546) For the financial years ended December 31, 2021 and 2022, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the U.S. dollar on U.S. dollars denominated cash and cash equivalent and financial assets accounts. |
Income Tax
Income Tax | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax [Abstract] | |
Income Tax | Income Tax Due to the Company’s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. Temporary differences mainly result from leases, provision for defined benefit obligation and tax losses carryforwards. As of December 31, 2022, the accumulated tax losses carryforwards of Innate Pharma SA were €466,153 thousand with no expiration date (€339,274 and €392,633 thousand as of December 31, 2020 and 2021). As of December 31, 2022, the accumulated tax losses carryforwards of Innate Pharma Inc. was €15,419 thousand, or $16,446 thousand, (€11,955 thousand, or $14,670 thousand and €14,198 thousand, or $16,081 thousand as of December 31, 2020 and 2021, respectively), with a 20-year period expiration. Tax rate reconciliation Year ended December 31, (in thousands of euro) 2020 2021 2022 Net income (loss) before tax (63,984) (52,809) (58,103) Statutory tax rate 28.00 % 26.50 % 25.00 % Income tax benefit / (expense) calculated at statutory tax rate 17,916 13,994 14,526 Increase / (decrease) in income tax benefit / (expenses) arising from: Differences in tax rates 128 62 — Research tax credit 3,961 3,091 1,971 Provision for defined benefit obligations (117) 39 106 Share-based compensation (693) (694) (1,062) Revenue from collaboration agreements 8,824 (3,313) 2,210 Non-recognition of deferred tax assets related to tax losses and temporary differences (15,746) (14,433) (18,290) Carry-back — — — Impact linked to intra-group merger operations (16,288) — — Impact linked to the exercise of a real estate leasing option (1,103) — — Others differences 3,118 1,254 539 Income tax benefit / (expense) (a) — — — Effective tax rate 0 % 0 % 0 % Deferred tax income / (loss) (b) — — — Income tax benefit / (expense) (a) + (b) — — — |
Discontinued Operations
Discontinued Operations | 12 Months Ended |
Dec. 31, 2022 | |
Discontinued Operations [Abstract] | |
Discontinued Operations | Discontinued OperationsFurther to the decision to terminate the Lumoxiti Agreement and termination notice sent in December 2020, a Termination and Transition Agreement was discussed and executed, effective as of June 30, 2021 terminating the Lumoxiti Agreement as well as Lumoxiti related agreements (including the supply agreement, the quality agreement and other related agreements) and transferring of the U.S. marketing authorization and distribution rights of Lumoxiti back to AstraZeneca. Consecutively, the activities related to Lumoxiti are presented as a discontinued operation as of October 1, 2021. As part of the communication of its 2020 consolidated financial statements, the Company had communicated on a contingent liability estimated at a maximum of $12.8 million related to the sharing of certain manufacturing costs. As part of the termination and transition agreement, Innate and AstraZeneca agreed to share manufacturing costs, and Innate had to pay $6.2 million on April 30, 2022. This amount was paid by the Company as part of the agreement in April 2022 for an amount of €5.9 millions ($6.2 million). a) Financial Performance Year ended December 31, 2020 2021 2022 Revenue and other income Revenue from collaboration and licensing agreements — 926 194 Sales 678 874 22 Total revenue and other income 678 1,800 216 Operating expenses Research and development expenses (8,905) (624) — Selling, general and administrative expenses (12,260) (8,507) (346) Impairment of intangible assets (43,529) — — Total operating expenses (21,165) (9,131) (346) Net income (loss) from distribution agreements 861 — — Operating income (loss) (63,155) (7,331) (131) Financial income — — — Financial expenses — — — Net financial income (loss) — — — Net income (loss) before tax (63,155) (7,331) (131) Income tax expense — — — Net income (loss) from discontinued operations (63,155) (7,331) (131) b) Cash-Flows Year ended December 31, 2020 2021 2022 Net cash generated from / (used in) operating activities (22,391) (3,552) (5,097) Net cash generated from / (used in) investing activities (6,620) — — Net cash generated from / (used in) financing activities — — — Net cash flows from discontinued operations (29,011) (3,552) (5,097) |
Commitments, contingencies and
Commitments, contingencies and litigations | 12 Months Ended |
Dec. 31, 2022 | |
Commitments, Contingencies And Litigations [Abstract] | |
Commitments, contingencies and litigations | Commitments, contingencies and litigations Commitments The Company has identified the following off-balance sheet commitments as of December 31, 2022: • non-cancellable purchase commitments as of December 31, 2022 for a total of €8,774 thousand with various suppliers notably contract research organizations (CRO) or contract manufacturing organizations (CMO). These commitments are comprised of non-cancellable purchase orders placed over the period with CRO and CMO for the supply of various services in relation with preclinical work for an amount of €7,421 thousand and clinical work for an amount of €1,353 thousand. The execution and billing of these has not yet started as of December 31, 2022; • On July 3, 2017, Innate Pharma borrowed from the bank Société Générale in order to finance the construction of its future headquarters. As security for the loan, Innate pledged collateral in the form of financial instruments held at Société Générale amounting to €15.2 million. The security interest on the pledged financial instruments will be released in accordance with the following schedule: €4,200 thousand in July 2024, €5,000 thousand in August 2027 and €6,000 thousand in August 2031. Furthermore, under the loan, Innate is subject to a covenant that its total cash, cash equivalents and current and non-current financial assets as of each fiscal year end will be at least equal to the amount of outstanding principal under the loan. As of December 31, 2022, the remaining capital of this loan amounted to €11,338 thousand. The Company was in compliance with this covenant as of December 31, 2022; • The Company has entered into indemnification agreements with its directors & officers (the « Beneficiaries »), under which (1) Company will provide to the Beneficiaries the benefit of one or more director and officer (“D&O”) insurance policies and (2) if not indemnifiable under the D&O insurance policy, the Beneficiary shall be compensated for any indemnifiable claim by the Company to the fullest extent permitted by law. Licensing and collaboration agreements Commitments related the Company’s licensing and collaboration agreements are disclosed in Note 1.1. Contingencies and litigations The Company is exposed to contingent liabilities relating to legal actions before the labor court or intellectual property issues happening in the ordinary course of its activities. Each pre-litigation, known litigation or procedure in ordinary course the Company is involved in was analyzed at the closing date after consultation of advisors. Provisions Provisions amounted to €897 thousand, €900 thousand and €1,740 thousand as of December 31, 2020, 2021 and 2022, respectively. As of December 31, 2022, they mainly consist of (i) a provision amounting to €1,270 thousand following the tax inspection carried out in 2022 by the French tax authorities and relating to the 2019 and 2020 financial years as well as to the research tax credit and the accuracy of its calculation for the 2018 to 2018 financial years 2020. This provision was based on estimated amounts and adjustments not disputed by the Company. On March 3, 2023, the Company received from the tax authorities the rectification proposal, confirming the amount of the provision recognized on the amounts of the rectifications not disputed by the Company, and (ii) provisions for employee departures and provision for charges relating and the employer contribution in respect of the grants of employee equity instruments In accordance with IFRS 2, when a Company decides to provide its employees with shares bought back on the market, a provision has to be recognized upon the decision to allocate free shares that are spread over the vesting period when the plan conditions actions for employees when they join the Company at the end of the plan. |
Related party transactions
Related party transactions | 12 Months Ended |
Dec. 31, 2022 | |
Related party transactions [abstract] | |
Related party transactions | Related party transactions Members of the Executive Board and Executive Committee For each of the periods presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense: Year ended December 31, (in thousands of euro) 2020 2021 2022 Personnel expenses and other short-term employee benefits 3,131 3,456 2,176 Extra pension benefits — 11 43 Share-based compensation 1,363 2,067 1,989 Advisory fees — — 661 Executive Committee members compensation 4,494 5,534 4,869 As of December 31, 2022, two members of the Executive Committee were also members of the Executive Board. Calculation of share-based compensation is detailed in Note 11.b. Members of the Supervisory Board The Company recognized a provision of €348 thousand for attendance fees ( jetons de presence ) relating to the year ended December 31, 2022 which should be paid in 2023. This amount includes the compensation for the Chairman of the Supervisory Board. The company recognized a provision of €274 thousand and €338 thousand as of December 31, 2020 and 2021, respectively. Related parties AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for different drug candidates (monalizumab, avdoralimab, IPH5201) and a termination and transition agreement relating to Lumoxiti. The payments between the two companies as well as the liabilities and receivables as of 31 December 2021 are as follows: As of December 31, 2022 (in thousands of euros) Payments Assets/Liabilities Collection (AstraZeneca towards the Company) / Receivables 54,774 3,078 Payments (the Company towards AstraZeneca) / Liabilities (17,745) (7,298) Total (1) 37,029 (4,220) As a reminder, BPI France is a board member and has granted the Company a €1,500 thousand interest-free loan ( Prêt à Taux Zéro Innovation , or “PTZI”) and a free-interest advance repayable. PTZI loan is fully repaid as of December 31, 2021. Regarding the repayable advance, this is considered non-repayable by the Company as of December 31, 2021 in accordance with the terms specified in the financing contract signed with BPI in August 2020, in view of the technical and commercial failure of the project, in view of the results of the “FORCE” Phase 2 trial evaluating avdoralimab in COVID-19, published on July 6, 2021 (see notes 9 and 13.2). Subsidiaries The business relationships between the Company and its subsidiary Innate Pharma Inc are governed by intra-group agreements, conducted at standard conditions on an arm’s length basis. |
Income (loss) per share
Income (loss) per share | 12 Months Ended |
Dec. 31, 2022 | |
Income (Loss) Per Share [Abstract] | |
Income (loss) per share | Income (loss) per share Basic income (loss) per share Basic income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period. Year ended December 31. (in thousands of euro, except for data share) 2020 2021 2022 Net income (loss) (63,984) (52,809) (58,103) Weighted average number of ordinary shares in circulation 78,934,960 79,542,627 79,639,826 Basic income (loss) per share (€ per share) (0.81) (0.66) (0.73) The instruments that entitle their holders to a portion of the share capital on a deferred basis (BSAs, BSAAR, AGAs and AGAPs) are considered to be anti-dilutive (1,564,662 instruments in 2020, 2,166,829 instruments in 2021 and 2,265,301 instruments in 2022). These instruments are presented in detail in Note 11. Diluted income (loss) per share Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential ordinary shares. Year ended December 31, (in thousands of euro, except for data share) 2020 2021 2022 Net income (loss) (63,984) (52,809) (58,103) Weighted average number of ordinary shares in circulation 78,934,960 79,542,627 79,639,826 Adjustment for share instruments — — — Diluted income (loss) per share (€ per share) (0.81) (0.66) (0.73) |
Events after the reporting date
Events after the reporting date | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of non-adjusting events after reporting period [abstract] | |
Events after the reporting date | Events after the reporting dateOn December 19, 2022, the Company announced that it had entered into a research collaboration and license agreement with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (“Sanofi”) pursuant to which the Company granted Sanofi an exclusive license on the Innate Pharma's B7H3 ANKET® program and options on two additional targets. Once selected, Sanofi will be responsible for all development, manufacturing and marketing. The closing of the transaction was subject to the authorization of the American authorities in accordance with the Hart Scott Rodino Act of 1976. This authorization was obtained on January 24, 2023, the date on which the collaboration was effective. Under the terms of the collaboration and research license agreement, the Company is eligible from the effective date of the contract for an initial payment of €25.0 million. This amount was collected by the Company in March 2023. |
Accounting policies and state_2
Accounting policies and statement of compliance (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Significant Accounting Policies [Abstract] | |
Basis of preparation | Basis of preparation Consolidated financial statements of the Company for the years ended December 31, 2020, 2021 and 2022 (the “Consolidated Financial Statements”) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development Phase. The general accounting conventions were applied in compliance with the principle of prudence, in accordance with the underlying assumptions namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with IFRS, as defined below. Except for share data and per share amounts, the Consolidated Financial Statements are presented in thousands of euro. Amounts are rounded up or down to the nearest whole number for the calculation of certain financial data and other information contained in these accounts. Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures |
Statement of compliance | Statement of compliance The Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standard Board (“IASB”) and were approved and authorized for issuance by the Board of Directors of the Company on March 22, 2023. They will be approved by the General Meeting of the Company on May 12, 2023, which has the right to modify them. Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the Consolidated Financial Statements of the Company for the years ended December 31, 2020, 2021 and 2022 are also prepared in accordance with IFRS, as adopted by the European Union (EU). For the years ended December 31, 2020, 2021 and 2022, all IFRS that the IASB had published and that are mandatory are the same as those endorsed by the EU and mandatory in the EU. As a result, the Consolidated Financial Statements comply with International Financial Reporting Standards as published by the IASB and as adopted by the EU. IFRS include International Financial Reporting Standards (IFRS), International Accounting Standards (“ IAS ”), as well as the interpretations issued by the Standing Interpretations Committee (“SIC”), and the International Financial Reporting Interpretations Committee (“ IFRIC ”). The main accounting methods used to prepare the Consolidated Financial Statements are described below. These methods were used for all periods presented. |
Recently issued accounting standards and interpretations | Recently issued accounting standards and interpretations Application of the following new and amended standards is mandatory for the first time for the financial period beginning on January 1, 2020 and, as such, they have been adopted by the Company: • Amendments to IFRS 3 "Definition of a company", published on October 22, 2018. • Amendment to IFRS 16: "Covid-19-Adjustments to tenants' rents". The entry into force of this amendment had no impact on the Company's financial statements. • Amendments to IAS 1 and IAS 8 relating to the modification of the definition of the term “significant”, published on October 31, 2018. • Amendments to IAS 39, IFRS 7 and IFRS 9 relating to the reform of benchmark interest rates. • Conceptual framework for financial reporting and modification of references to Conceptual Framework in IFRS. Application of the following new and amended standards is mandatory for the first time for the financial period beginning on January 1, 2021 and, as such, they have been adopted by the Company: • Amendments to IFRS 16 : Covid-19-Related Rent Concessions, published on May 22, 2020. • Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 : Interest Rate Benchmark Reform — Phase 2, published on September 26, 2019. • IFRS IC opinion (IFRS / IAS Standards Interpretation Committee) addressed to the IASB in May 2021 and validated in June 2021 proposing to modify the way in which the commitments relating to certain defined benefit plans including an obligation of attendance at the retirement, a ceiling on rights from a certain number of years of seniority and depending on the seniority of the employee on the date of retirement. The changes in the calculation method presented in this opinion have been adopted by the Company from the financial year ended beginning on January 1, 2021 in the assessment of its commitments relating to retirement benefits. The details relating to this change in calculation method are presented in note 10) "Employee benefits" Those standards and interpretations have no impact on the Consolidated Financial statements, except as noted below following IFRS IC opinion addressed to IASB and validated in June 2021. The following new standards, amendments to existing standards and interpretations have been published but are not applicable in 2021 or have not yet been adopted by the European Union, and have not been applied early: • Amendment to IFRS 3 "Update of a reference to the conceptual framework" • Amendment to IAS16 "Products generated before their intended use" • Amendment to IAS37 "Onerous contracts - Costs of performing a contract" • Amendment to IAS1 "Classification of current or non-current liabilities" The accounting rules and valuation principles used for the financial statements at December 31, 2022 are identical to those used for the previous comparative year. Application of the following new and amended standards is mandatory for the first time for the financial period beginning on January 1, 2022 and, as such, they have been adopted by the Company: • Amendment to IFRS 3 "Update of a reference to the conceptual framework" • Amendment to IAS16 "Products generated before their intended use" • Amendment to IAS37 "Onerous contracts - Costs of performing a contract" The following new standards, amendments to existing standards and interpretations have been published but are not applicable in 2022 or have not yet been adopted by the European Union, and have not been applied early: • Amendment to IAS1 "Classification of current or non-current liabilities" |
Change in accounting policies | Change in accounting policiesExcept for the adoption of IFRS 16 as of IFRS IC opinion on certain defined benefit plans validated by the IASB as of January, 2021 (see details in note 10), there has been no change in accounting policies for any of the years presented. |
Translation of transactions denominated in foreign currency | Translation of transactions denominated in foreign currency Pursuant to IAS 21 The effects of changes in foreign exchange rates, transactions performed by consolidated entities in currencies other than their functional currency are translated at the prevailing exchange rate on the transaction date. Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the period-end exchange rate. Unrealized gains and losses arising from translation are recognized in net operating income. Foreign exchange gains and losses arising from the translation of inter-Group transactions or receivables or payables denominated in currencies other than the functional currency of the entity are recognized in the line “net financial income (loss)” of the consolidated statements of income (loss). Foreign currency transactions are translated into the presentation currency using the following exchange rates: December 31, 2020 December 31, 2021 December 31, 2022 €1 EQUALS TO AVERAGE RATE CLOSING RATE AVERAGE RATE CLOSING RATE AVERAGE RATE CLOSING RATE USD 1.1422 1.2271 1.1827 1.1326 1.0530 1.0666 |
Consolidation method | Consolidation methodThe Group applies IFRS 10 Consolidated financial statements. IFRS 10 presents a single consolidation model identifying control as the criteria for consolidating an entity. An investor controls an investee if it has the power over the entity, is exposed or has rights to variable returns from its involvement with the entity and has the ability to use its power over the entity to affect the amount of the investor’s returns. Subsidiaries are entities over which the Company exercises control. They are fully consolidated from the date the Group obtains control and are deconsolidated from the date the Group ceases to exercise control. Intercompany balances and transactions are eliminated. |
Financial instruments | Financial instruments Financial assets Financial assets are initially measured at fair value plus directly attributable transaction costs in the case of instruments not measured at fair value through profit or loss. Directly attributable transaction costs of financial assets measured at fair value through profit or loss are recorded in the consolidated statement of income (loss). Under IFRS 9, financial assets are classified in the following three categories: • Financial assets at amortized cost; • Financial assets at fair value through other comprehensive income (“FVOCI”); and • Financial assets at fair value through profit or loss. The classification of financial assets depends on: • The characteristics of the contractual cash flows of the financial assets; and • The business model that the entity follows for the management of the financial asset. Financial assets at amortized cost Financial assets are measured at amortized cost when (i) they are not designated as financial assets at fair value through profit or loss, (ii) they are held within a business model whose objective is to hold assets in order to collect contractual cash flows and (iii) they give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding (“SPPI” criterion). They are subsequently measured at amortized cost, determined using the effective interest method (“EIR”), less any expected impairment losses in relation to the credit risk. Interest income, exchange gains and losses, impairment losses and gains and losses arising on derecognition are all recorded in the consolidated statement of income (loss). This category primarily includes trade receivables, as well as other loans and receivables. Long-term loans and receivables that are not interest-bearing or that bear interest at a below-market rate are discounted when the amounts involved are material. Financial assets at fair value through other comprehensive income Financial assets at fair value through other comprehensive income is mainly comprised is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses. The Company did not hold this type of instrument as of January 1, 2022 or as of December 31, 2022. Financial assets at fair value through profit or loss Financial assets at fair value through profit or loss is comprised of: • financial assets that are not part of the above categories; and • instruments that management has designated as “fair value through profit or loss” on initial recognition. Gains and losses arising from changes in fair value are recognized in profit or loss within the line items financial income or financial expenses. Impairment of financial assets measured at amortized cost The main assets involved are trade receivables and others. Trade receivables are recognized when the Company has an unconditional right to payment by the customer. Impairment losses on trade receivables and others are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within Operating expenses in the consolidated statement of income (loss). Financial liabilities Financial liabilities comprise deferred revenue, collaboration liabilities, loans and trade and other payables. Financial liabilities are initially recognized on the transaction date, which is the date that the Company becomes a party to the contractual provisions of the instrument. They are derecognized when the Company’s contractual obligations are discharged, cancelled or expire. Loans are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they are measured at amortized cost using the EIR method. All costs related to the issuance of loans, and all differences between the issuance proceeds net of transaction costs and the value on redemption, are recognized within financial expenses in the consolidated statement of income (loss) over the term of the debt using the EIR method. Other financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost. Cash and cash equivalents Cash equivalents are short-term, highly liquid investments, that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Cash and cash equivalents comprise the cash that is held at the bank and petty cash as well as the short-term fixed deposits for which the maturity is less than three months. For the purpose of establishing the statement of cash flows, cash and cash equivalents include cash in hand, demand deposits and short fixed-term deposits with banks and short-term highly liquid investments with original maturities of three months or less, net of bank overdrafts. Cash and cash equivalents are initially recognized at their purchase costs on the transaction date, and are subsequently measured at fair value. Changes in fair value are recognized in profit or loss. Fair value of financial instruments Under IFRS 13 Fair value measurement and IFRS 7 Financial instruments: disclosures, or IFRS 7, fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities; • level 2: fair value calculated using valuation techniques based on observable market data such as prices of similar assets and liabilities or parameters quoted in an active market; and • level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as prices in an inactive market or a valuation based on multiples for unlisted securities. |
Intangible assets | Intangible assets Research and development (R&D) expenses In accordance with IAS 38 Intangible assets, or IAS 38, expenses on research activities are recognized as an expense in the period in which it is incurred. An internally generated intangible asset arising from the Company’s development activities is recognized only if all of the following conditions are met: • Technically feasible to complete the intangible asset so that it will be available for use or sale; • The Company has the intention to complete the intangible assets and use or sell it; • The Company has the ability to use or sell the intangible assets; • The intangible asset will generate probable future economic benefits, or indicate the existence of a market; • Adequate technical, financial and other resources to complete the development are available; and • The Company is able to measure reliably the expenditure attributable to the intangible asset during its development. Because of the risks and uncertainties related to regulatory approval, the R&D process and the availability of technical, financial and human resources necessary to complete the development Phases of the product candidates, the six criteria for capitalization are usually considered not to have been met until the product candidate has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within Research and development expenses. However, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an intangible asset. These related costs are capitalized when they are incurred and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained. Licenses Payments for separately acquired research and development are capitalized within “Other intangible assets” provided that they meet the definition of an intangible asset: a resource that is (i) controlled by the Group, (ii) expected to provide future economic benefits for the Group and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of IAS 38 standard, the first recognition criterion, relating to the likelihood of future economic benefits generated by the intangible asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts paid to third parties in the form of initial payments or milestone payments relating to product candidates that have not yet obtained a regulatory approval are recognized as intangible assets. These rights are amortized on a straight-line basis: (i) after obtaining the regulatory approval, over their useful life; or (ii) after entering in an out-license collaboration agreement with a third-party partner, over their estimated useful life. This estimated useful life takes into consideration the period of protection of the out-licensed exclusivity rights and the anticipated period over which the Company will receive the economic benefits of the asset. Unamortized rights (before marketing authorization) are subject to impairment tests in accordance with the method defined in Note 6. When intangible assets acquired separately are acquired through variable or conditional payments, these payments are recognized as an increase of the carrying amount of the intangible asset when they become due. Royalties due by the Company related to acquired licenses are recognized as operating expenses when the Company recognizes sales subject to royalties. Estimate of the useful life of the acquired licenses: intangible assets are amortized on a straight line basis over their anticipated useful life. The estimated useful life is the period over which the asset provides future economic benefits. It is estimated by management and is regularly revised by taking into consideration the period of development over which it expects to receive economic benefits such as collaboration revenues, royalties, product of sales, etc. However, given the uncertainty surrounding the duration of the R&D activities for the programs in development and their likelihood to generate future economic benefits to the Company, the estimated useful life of the rights related to these programs is rarely longer than the actual development Phase of the product candidate. When a program is in commercialization Phases, the useful life takes into account the protection of the exclusivity rights and the anticipated period of commercialization without taking into account any extension or additional patents. The prospective amendment of the amortization plan of the monalizumab intangible asset, which is modified according to the estimate ending date of the Phase 2 clinical trial is described in Note 6. Other intangible assets Other intangible assets consist of acquired software. Costs related to the acquisition of software licenses are recognized as assets based on the costs incurred to acquire and set up the related software. Software is amortized using the straight-line method over a period of one |
Property and equipment | Property and equipment Property and equipment are carried at acquisition cost. Major renewals and improvements are capitalized while repairs and maintenance are expensed as incurred. Property and equipment are depreciated over their estimated useful lives using the straight-line depreciation method. Leasehold improvements are depreciated over the life of the improvement or the remaining lease term, whichever is shorter. The headquarters of the Company was split into several components (e.g., foundations, structure, electricity, heating and ventilation systems) which are depreciated over different useful lives according to the anticipated useful life of these elements. Depreciation periods are as follows: Buildings and improvements on buildings 20 to 40 years Installations 5 to 20 years Technical installations and equipment 8 years Equipment and office furniture 5 years Computers and IT equipment 3 years |
Impairment of intangibles assets, property, and equipment | Impairment of intangible assets, property, and equipment The Group assesses at the end of each reporting period whether there is an indication that intangible assets, property and equipment may be impaired. If any indication exists, the Group estimates the recoverable amount of the related asset. Whether or not there is any indication of impairment, intangible assets not yet available for use are tested for impairment annually by comparing their carrying amount with their recoverable amount. Pursuant to IAS 36— Impairment of Assets, criteria for assessing indication of loss in value may notably include performance levels lower than forecast, a significant change in market data and/or the regulatory environment, the asset development strategy approved by management, or obsolescence or physical damage of the asset not included in the amortization/depreciation schedule. The recognition of an impairment loss alters the amortizable/depreciable amount and potentially, the amortization/depreciation schedule of the relevant asset. Impairment losses on intangible assets, property and equipment shall be reversed subsequently if the impairment loss no longer exists or has decreased. In such case, the recoverable amount of the asset is to be determined again so that the reversal can be quantified. The asset value after reversal of the impairment loss may not exceed the carrying amount net of depreciation/amortization that would have been recognized if no impairment loss had been recognized in prior periods. The Group does not have any intangible assets with an indefinite useful life. However, as explained in Note 2.h, the Group recognized intangible assets in progress, which will be amortized once marketing authorization is received. |
Employee benefits | Employee benefits Long-term pension benefits Company employees are entitled to pension benefits required by French law: • Pension benefit, paid by the Company upon retirement (i.e. defined benefit plan); and • Pension payments from social security entities, financed by contributions from businesses and employees (i.e. defined contribution plan”). In addition, the Company has implemented an additional, non-mandatory, pension plan (“Article 83”), initially for the benefit of executives only. This plan was extended to the non-executive employees starting on January 1, 2014. This plan meets the definition of defined contribution plan and is financed through a contribution that corresponds to 2.2% of the employee’s annual wage, with the Company paying 1.4% and the employee paying 0.8%. For the defined benefit plan, the costs of the pension benefit are estimated using the “projected unit credit” method. According to this method, the pension cost is accounted for in the consolidated statement of income (loss), so that it is distributed uniformly over the term of the services of the employees. The pension benefit commitments are valued using the actual present value of estimated future payments, adopting the rate of interest of long-term bonds in the private sector (i.e. Euro zone AA or higher rated corporate bonds + 10 years). The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized in the consolidated statement of income (loss) for the portion representing the costs of services rendered and the net interest costs, and through other comprehensive income for the portion representing the actuarial gains and losses. The Company’s commitments under the defined benefit plan are not covered by any plan assets. Payments made by the Company for defined contribution plans are accounted for as expenses in the consolidated statement of income (loss) in the period in which they are incurred. Other long-term benefits The Company pays seniority bonuses to employees reaching 10, 15 and 20 years of seniority. These bonuses represent long-term employee benefits. Under IAS 19R “Employee benefits”, they are recording as a defined benefit obligation in the consolidated statement of financial position, but their remeasurements is not recognized in the consolidated statement of other comprehensive income (loss). Other short-term benefits An accrued expense is recorded for the amount the Company expects to pay its eligible employees in relation to services rendered during the reporting period (actual legal or implicit obligation to make to these payments on a short-term basis). |
Leases | LeasesThe Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise: • fixed lease payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date; • the amount expected to be payable by the lessee under residual value guarantees; • the exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and • payment of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease. The lease liability is included in the financial liabilities in the consolidated statement of financial position and is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Whenever the Company incurs an obligation for costs to dismantle and remove a leased asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease, a provision is recognized and measured under IAS 37. To the extent that the costs relate to a right-of-use asset, the costs are included in the related right-of-use asset, unless those costs are incurred to produce inventories. Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease. The right-of-use assets are included in the property and equipment line item in the consolidated statement of financial position. The Company applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss. |
Provisions and contingent liabilities | Provisions and contingent liabilities In the course of its business, the Company could be exposed to certain risks and litigations, notably in relation to contractual arrangements. Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that the Company is subject to a release of outflow representatives of economic benefits to settle the obligation and a reliable estimate of the amount of the obligation can be made. Management of the Company estimates the probability and the expected amount of a cash outflow associated with risks, together with the other information to be provided on possible liabilities. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is certain. In addition, the Company may assess a potential obligation towards a third party resulting from events the existence of which will only be confirmed by the occurrence, or not, of one or more events. uncertain futures which are not totally under the control of the Company; or an obligation to a third party for which it is not probable or certain that it will result in an outflow of resources without at least equivalent consideration expected from the latter. These elements are mentioned in note 18 of the group's consolidated financial statements as contingent liabilities. |
Capital | CapitalOrdinary shares are classified in shareholders’ equity. Costs associated with the issuance of new shares are directly accounted for in shareholders’ equity in diminution of issuance premium. The Company’s own shares bought in the context of a brokering/liquidity agreement are presented as a reduction in shareholders’ equity until their cancellation, their reissuance or their disposal. |
Share-based compensation | Share-based compensation Since its inception, the Company has established several plans for compensation paid in equity instruments in the form of free shares (“ Attributions gratuites d’actions,” or “AGA” ), free preferred shares convertible into ordinary shares (“ Attributions gratuites d’actions de préférence convertibles en actions ordinaires,” or “AGAP” ), free performance shares (“ Attributions gratuites d’actions de performance,” or “AGA Perf ”), share subscription warrants (“ Bons de souscription d’actions,” or “BSA ”), redeemable share subscription warrants (“ Bons de Souscription et/ou d’Acquisition d’Actions Remboursables,” or “BSAAR”), granted to its employees, executives, members of the Executive Board and scientific consultants. Pursuant to IFRS 2— Share-based Payment, these awards are measured at their fair value on the date of grant. The fair value is calculated with the most relevant formula regarding the conditions and the settlement of each plan. For share-based compensation granted to employees, executives, members of the Executive Board and scientific consultants, the Company uses the Black-Scholes and Monte Carlo approach pricing models to determine the fair value of the share-based compensation. For scientific consultants providing similar services, as the Company cannot estimate reliably the fair value of the goods or services received, it measures the value of share-based compensation and the corresponding increase in equity, indirectly, by reference to the fair value of the equity instruments granted also using the Black-Scholes option pricing model. The fair value of free shares included in the model is determined using the value of the shares at the time of their distribution. In calculating the fair value of share-based compensation, the Company also considers the vesting period and the employee turnover weighted average probability as described in Note 11. Other assumptions used are also detailed in Note 11. |
Revenue | Revenue Revenue from collaboration and license agreements To date, the Company’s revenue results primarily from payments received in relation to research, collaboration and licensing agreements signed with pharmaceutical companies. These contracts generally provide for components such as: • non-refundable upfront payments upon signature; • payments for the exercise of the option to acquire licenses of drug candidates; • milestones payments triggered following stages of development (scientific results obtained by the Company or by the partner, obtaining regulatory marketing approvals); • payments related to the Company’s R&D activities; • payments triggered by the start of the commercialization of products resulting from development work or by crossing cumulative thresholds of product sales, as well as the allocation of royalties on future sales of products or a sharing of profits on sales. Under collaboration and license agreements, the Company may promise its partners licenses on intellectual property, as well as research and development services. According to IFRS 15, the Company has to determine if the promises included in the contract are distinct (therefore recognized separately as revenue) or if they have to be combined as a single performance obligation.We conclude that the license is not distinct from the research and development services when the research and development services involve the Company's own expertise, so that the customer cannot benefit from the license alone or in combination with services provided by third parties, or when the intellectual property is at such a stage of development that the research and development work significantly modifies the initial purpose of the license. When promises in a collaboration and license agreement are considered as a single performance obligation, the Company has to determine if the combined performance obligation is satisfied over time or at point in time. If the combined performance obligation is satisfied over time, revenue recognition is based on the percentage of completion of the costs to be incurred. Non-refundable initial payments are deferred and recognized as revenue during the period the Company is engaged to deliver services to the customer on the basis of the corresponding costs. When promises in a collaboration and license agreement are considered as separate performance obligations, revenue is allocated to each obligation proportionally to its transaction price, which corresponds to a price each performance obligation would have been sold in the context of a separate transaction. In accordance with IFRS 15, variable considerations cannot be included in the estimated transaction price as long as it not highly probable that the related revenue will not reversed in the future. According to the level of uncertainty relating to the results of preclinical and clinical trials and the decisions relating to the regulatory approvals, variable considerations depending on these events are excluded from the transaction price as long as the trigger event is not highly probable. When the trigger event occurs, the corresponding milestone is added to the transaction price. Such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the period of adjustment. Revenues based on royalties, completion of commercialization steps or co-sharing profit from sales are recognized when the corresponding sales of products are carried out by the partner. When a collaboration contract grants a partner an option to acquire a licensed intellectual property (“IP”), the Company determines the date of the transfer of control over the licensed IP. Depending on the Company analysis, revenue related to the option fee will be recognized (i) when control over the licensed IP transfers (payment related to the exercise of the option being therefore considered as a variable consideration), or, (ii) deferred until the exercise of the option or its expiration period. When an agreement only promises development services, the Company will recognize the related revenue when the costs are incurred. Up-front and milestones payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts due by the Company in relation to cost-sharing are recorded as collaboration liability. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. |
Government financing for research expenditures | Government financing for research expenditures Research tax credit The research tax credit ( Crédit d’Impôt Recherche ) (the “Research Tax Credit” or “CIR”) granted by the French tax authorities in order to encourage Companies to conduct technical and scientific research. Companies that can justify that these expenses meet the required criteria receive such grants in the form of a refundable tax credit that can be used for the payment of taxes due for the period in which the expense was incurred and for the next three years. These grants are presented under other income, in “government financing for research expenditures” line item in the consolidated statements of income (loss), as soon as these eligible expenses were conducted. The Company has benefited from a Research Tax Credit since its inception. The reimbursements are made under the European Community tax rules for small and medium sized enterprises (“SME”) in compliance with the applicable regulations in effect. Only companies that meet the definition of SME according to European Union criteria are eligible for early reimbursement of their CIR. Management ensured that the Company was a SME according to European Union criteria and can therefore benefit from this early reimbursement until as of December 31, 2019. As of December 31, 2019, the Company no longer met the eligibility criteria for this status (criteria not met as of December 31, 2018 and 2019). Thus, the CIR for the years 2019 and 2020 represent a receivable against the French Treasury which will in principle be offset against the French corporate income tax due by the company with respect to the three following years. The remaining portion of tax credit not being offset upon expiry of such a period may then be refunded to the Company. For the 2021 and 2022 financial year, the Company met again the definition of an SME according to the criteria of the European Union. As a result, the Company was eligible for the early repayment by the French treasury of the 2021 Research Tax Credit during the fiscal year 2022. The Company will also be eligible to the early repayment by the French treasury of the 2022 Research Tax Credit during the fiscal year 2023. The CIR is presented under other income, in “government financing for research expenditures” line item in the consolidated statements of income (loss) as it meets the definition of government grant as defined in IAS 20 Accounting for government grants and disclosure of government assistance. Subsidies Government grants are recognized when there is a reasonable assurance that: • The Company will comply with the conditions attached to the grants; and that • The grants will be received. A government grant that becomes receivable as compensation for expenses or losses already incurred, or for the purpose of providing immediate financial support to the Company with no future related costs, is recognized as other income of the period in which it becomes receivable. Government grants to subsidize capital expenditures are presented in the statement of financial position as deferred income and are recognized as income on a straight line basis over the useful life of those assets that have been financed through the grants. |
Income tax | Income taxDeferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Main temporary differences are generally associated with the depreciation of property and equipment, provisions for pension benefits and tax losses carried forward and also with the deferred tax liabilities / assets generated by the application of IFRS 15. Currently enacted tax rates are used in the determination of deferred income tax. Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Due to Company’s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. |
Earnings (loss) per share | Earnings (loss) per share In accordance with IAS 33 Earnings per share , basic income (loss) per share is calculated by dividing the income (loss) attributable to equity holders of the Group by the weighted average number of outstanding shares for the period. Diluted income (loss) per share is measured by dividing the income (loss) attributable to holders of equity and dilutive instruments by the weighted average number of outstanding shares and dilutive instruments for the period. |
Other comprehensive income | Other comprehensive income Items of income and expenses for the period that are recognized directly in equity are presented under “other comprehensive income.” The items mainly include : • Foreign currency translation gain (loss); and • Actuarial gains and (losses) related to defined benefit obligations. |
Segment information | Segment information For internal reporting purposes, and in order to comply with IFRS 8 Operating segments , the Company performed an analysis of operating segments. Following this analysis, the Company considers that it operates within a single operating segment being the R&D of pharmaceutical products in order to market them in the future. All R&D activities of the Company are located in France. Key decision makers (the executive committee of the Company) monitor the Company’s performance based on the cash consumption of its activities. For these reasons, the Management of the Group considers it not appropriate to set up separate business segments in its internal reporting. In 2020 revenue was entirely generated by one customer (AstraZeneca). In 2021 and 2022, revenue consisted of revenue from collaboration agreements with AstraZeneca and Sanofi as well as sales of Lumoxiti in the U.S. Lumoxiti sales are also now included in the consolidated statement of income (loss) in the line " net income (loss) from discontinued operations" following the signing of the termination and transition agreement with AstraZeneca in 2021 (see notes 1.1, 2.w and 17). |
Non-current assets held for sale and discontinued operations | Non-current assets held for sale and discontinued operations A discontinued operation is a component of an entity that either has been disposed of, or that is classified as held for sale. It must either: represent a major separate line of business or geographical area of operations; be part of a single coordinated disposal plan; or be a subsidiary acquired exclusively with a view to resale. Intercompany transactions between continuing and discontinued operations are eliminated against discontinuing operations. Non-current assets and disposal groups are classified as assets held for sale if their carrying amount is to be recovered principally through a sale transaction rather than through continuing use. This condition is regarded as met only when the sale is highly probable and the asset (or disposal group) is available for immediate sale in its present condition. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated. The prior-year consolidated balance sheet is not restated. Further to the decision to terminate the Lumoxiti Agreement and termination notice sent in December 2020, a Termination and Transition Agreement was discussed and executed, effective as of June 30, 2021 terminating the Lumoxiti Agreement as well as Lumoxiti related agreements (including the supply agreement, the quality agreement and other related agreements) and transferring of the U.S. marketing authorization and distribution rights of Lumoxiti back to AstraZeneca. Consecutively, the activities related to Lumoxiti are presented as a discontinued operation as of October 1, 2021. Consequently, in accordance with IFRS5 "non-current assets held for sale and discontinued operations", the Lumoxiti operations are presented in the consolidated statement of income (loss) and the notes to the consolidated financial statements as a discontinued operation for the 2021 financial year. The 2019 and 2020 comparatives have been restated compared to previous publications (where applicable), in accordance with the same standard. |
Critical accounting estimates and assumptions | Critical accounting estimates and assumptionsThe preparation of the consolidated financial statements under IFRS requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company’s actual results may differ from these estimates under different assumptions or conditions. These estimates and judgments involve mainly: • the accounting for collaboration and licensing agreements: the revenue results primarily from payments based on several components (e.g., upfront payments, milestone payments) received in relation to research, collaboration and licensing agreements signed with pharmaceutical or other companies. When the Company is committed to perform R&D services, revenue is spread over the period the Company is engaged to deliver these services, more particularly on the basis of the Company’s inputs to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. Milestone payments are dependent upon the achievement of certain scientific, regulatory, or commercial milestones. These variable payments are recognized when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to refund of the payment. The changes in estimate regarding the completion of the works and the variable consideration relating to the contracts signed with customers are described in Note 13. As of December 31, 2022, given the significant progress of the work to be performed (94.5%) and the level of budget consumption, the impact of accounting estimates is no longer a determining factor in the calculation of revenue related to the monalizumab agreement. • the estimate of the recoverable amount of the acquired and under progress licenses: |
Accounting policies and state_3
Accounting policies and statement of compliance (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Significant Accounting Policies [Abstract] | |
Disclosure of effect of changes in foreign exchange rates | Foreign currency transactions are translated into the presentation currency using the following exchange rates: December 31, 2020 December 31, 2021 December 31, 2022 €1 EQUALS TO AVERAGE RATE CLOSING RATE AVERAGE RATE CLOSING RATE AVERAGE RATE CLOSING RATE USD 1.1422 1.2271 1.1827 1.1326 1.0530 1.0666 |
Disclosure of depreciation periods | Depreciation periods are as follows: Buildings and improvements on buildings 20 to 40 years Installations 5 to 20 years Technical installations and equipment 8 years Equipment and office furniture 5 years Computers and IT equipment 3 years |
Cash, cash equivalents and fi_2
Cash, cash equivalents and financial assets (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Disclosure of cash, cash equivalents and financial assets | December 31 (in thousands of euro) 2020 2021 2022 Cash and cash equivalents 136,792 103,756 84,225 Short-term investments 14,845 16,080 17,260 Cash and cash equivalents and short-term investments 151,637 119,836 101,485 Non-current financial assets 38,934 39,878 35,119 Total cash, cash equivalents and financial assets 190,570 159,714 136,604 |
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments | The variation of short-term investments and non-current financial assets for the periods presented, are the following: (in thousands of euro) December 31, 2020 Additions(1) Deductions (2) Variance of fair value through the consolidated statement of income (loss) Variance of accrued interests Foreign currency effect December 31, 2021 Short-term investments 14,845 — — 99 — 1,136 16,080 Non-current financial assets 38,934 — — 888 55 — 39,878 Total 53,779 — — 987 55 1,136 55,958 (in thousands of euro) December 31, 2021 Additions(1) Deductions (2) Variance of fair value through the consolidated statement of income (loss) Variance of accrued interests Foreign currency effect December 31, 2022 Short-term investments 16,080 — — 268 — 912 17,260 Non-current financial assets 39,878 — (3,000) (1,640) (118) — 35,119 Total 55,958 — (3,000) (1,372) (118) 912 52,379 |
Trade receivables and others (T
Trade receivables and others (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Disclosure of trade receivables and other | Trade receivables and others are analyzed as follows: Year ended December 31, (in thousands of euro) 2020 2021 2022 Other receivables 741 814 61 Research tax credit (1) — 10,310 25,904 Other tax credits 333 333 361 Prepaid expenses (2) 6,833 2,582 4,672 VAT refund 2,208 1,170 1,614 Trade account receivables (3) 10,585 846 3,080 Prepayments made to suppliers 1,114 2,364 2,652 Receivables and others - current 21,815 18,420 38,345 Research tax credit (1) 29,821 29,821 13,018 Prepaid expenses (2) — — 1,081 Receivables and others - non-current 29,821 29,821 14,099 Trade receivables and others - excluding rebate related to capital expenditures 51,635 48,241 52,445 (1) In accordance with the principles described in Note 2.q, the research tax credit (Crédit d’Impôt Recherche or “CIR”) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of €13,018 thousand recognized in non-current receivables corresponds to the CIR for the 2020 tax year following the fact that the Company no longer met the eligibility criteria for the SME status as of December 31, 2019. Thus, the CIR for the 2020 represented a non-current receivable which will in principle be offset against the French corporate income tax due by the Company with respect to the three following years, or refunded if necessary upon expiry of such a period. Since December 2020, the Company has ensured that the eligibility criteria for the SME status are met again. As a result, the CIR related to the 2021 tax year which amounted €10,302 thousand has been refunded in advance by the French Treasury to the Company. This amount was received by the Company on November 16, 2022. The Company is also eligible for the early repayment by the French treasury of the 2022 Research Tax Credit during the fiscal year 2023 for an amount of €9,167 thousand and also the CIR related to the 2019 tax year for an amount of €16,737 thousand given the expiry of the three-year period (see note 2.q). (2) As of December 31, 2022, the prepaid expenses include an amount of €1,256 thousand relating to the guarantee fees in line with the two State Guaranteed Loans from Société Générale and BNP Paribas. Following the extension of these two loans repayment for an additional period, the full amount of the guarantee fee over the additional five-year period has been recognized as an operating expense in 2022. As of December 31, 2022, an adjustment is made through the prepaid accounts to reflect the fact that the expenses are related to the fiscal year (see note 9). |
Intangible assets (Tables)
Intangible assets (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Intangible assets other than goodwill [abstract] | |
Disclosure of detailed information about intangible assets | Intangible assets can be broken down as follows: (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2020 56,851 116 40,000 96,968 Acquisitions — 264 — 264 Additional considerations 2,685 (1) — 1,000 (2) 3,685 Disposals — — — — Depreciation (10,904) (3) (195) — (11,099) Impairment (43,529) (4) — — (43,529) Transfers — — — — December 31, 2020 5,103 185 41,000 46,289 (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2021 5,103 185 41,000 46,289 Acquisitions — 13 — 13 Additional considerations 368 (5) — — 368 Disposals — (39) — (39) Depreciation (2,310) (3) (130) — (2,440) Transfers — — — — December 31, 2021 3,161 29 41,000 44,192 (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2022 3,161 29 41,000 44,192 Acquisitions — — — Additional considerations 587 (6) — — 587 Disposals — — — Depreciation (2,195) (3) (29) — (2,224) Impairment — — (41,000) (7) (41,000) Transfers — — — — December 31, 2022 1,553 — — 1,556 (1) This amount of 2,685 thousand euros included two additional payments made to Orega Biotech in April 2020 (2,500 thousand euros) and June 2020 (185 thousand euros) relating to IPH5201 rights following the first patient dosed in Phase 1 clinical trial in Mars 2020. (2) This amount of €1,000 thousand was paid in October 2020 to Novo Nordisk A / S following the launch of the first Phase 2 trial regarding avdoralimab. (3) As of December 31, 2020, this amount included the amortization of rights relating to monalizumab (€2,844 thousand), IPH5201 (€4,314 thousand) and Lumoxiti (€3,746 thousand). The amortization relating to Lumoxiti rights related to the period prior to the decision to return the commercial rights to AstraZeneca. Impact of the decision on the book value of said rights is presented in note 6 below. As of December 31, 2021, the amount includes the amortization of rights relating to monalizumab (€1,942 thousand) and IPH5201 (€368 thousand). As of December 31, 2022, this amount includes the amortization of rights relating to monalizumab (€1,604 thousand) and IPH5201 (€587 thousand). (4) Following the Company's decision to return the commercial rights to Lumoxiti in the United States and in Europe at the end of November 2020, the rights relating to the intangible asset were fully impaired for the carrying amount of the intangible asset to the date of the decision, amounting to €43,529 thousand. (5) This amount relates to an additional consideration paid to Orega Biotech in January 2022 following the arbitration decision rendered in December 2021 relating to the joint ownership of certain patents relating to IPH5201. This additional payment is fully amortized as of December 31, 2021. (6) This amount corresponds to the additional payment made to Orega Biotech in October 2022 for the rights relating to IPH5201, following the amendment to the collaboration and license option agreement IPH5201 concluded with AstraZeneca in October 2018 and the announcement by the Company on June 3, 2022, of the progression of IPH5201 towards a Phase 2 study in lung cancers of which the Company will be a sponsor. (7) Following the Company's decision in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well that as of June 30, 2022), the rights relating to the intangible asset have been fully impaired for their net book value on the date of the decision, i.e. €41,000 thousand (see below "Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S') |
Property and equipment (Tables)
Property and equipment (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Property, plant and equipment [abstract] | |
Disclosure of detailed information about property, plant and equipment | (in thousands of euro) Land and buildings Laboratory equipment and other In progress Total Of which finance leases January 1, 2020 5,356 5,947 369 11,672 6,270 Acquisitions 1,152 944 132 2,228 1,195 Disposals — (9) — (9) — Transfers — 134 (134) — (1,042) Depreciation (757) (1,440) — (2,197) — December 31, 2020 5,751 5,576 367 11,694 6,423 (in thousands of euro) Land and buildings Laboratory equipment and other In progress Total Of which right of use assets January 1, 2021 5,751 5,576 367 11,694 6,423 Acquisitions 11 987 — 998 — Disposals (7) — (7) — Depreciation (781) (1,373) — (2,154) — Transfers 4 (361) (357) — December 31, 2021 4,981 5,187 6 10,174 6,423 (in thousands of euro) Land and buildings Laboratory equipment and other In progress Total Of which right of use assets January 1, 2022 4,981 5,187 6 10,174 6,423 Acquisitions 20 535 556 — Disposals (11) (6) (17) — Depreciation (759) (1,413) (2,171) — Transfers — — — — — December 31, 2022 4,242 4,298 — 8,542 6,423 |
Trade payables and others (Tabl
Trade payables and others (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Disclosure of trade payables and others | This line item is analyzed as follows: December 31, (in thousands of euro) 2020 2021 2022 Suppliers (excluding payables related to capital expenditures) 20,730 14,729 13,656 Tax and employee-related payables 8,325 7,463 5,978 Other payables (1) 463 6,380 1,260 Trade payables and others excluding payables related to capital expenditures 29,519 28,573 20,894 Payables related to capital expenditures 20 — 17 Payables and others 29,539 28,573 20,911 |
Financial liabilities (Tables)
Financial liabilities (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Disclosure of financial liabilities per maturity | This line item was broken down per maturity and is analyzed as follows: In thousand euros December 31, 2019 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings and lease liabilities December 31, 2020 BPI PTZI IPH41 (1) 450 — — (300) 150 BPI Refundable advance - FORCE (2) — 1,360 94 — 1,454 Lease liabilities – Real estate property 418 — — (418) — Property transaction (down-payment) (74) — — 74 — Lease liabilities – Building "Le Virage" 1,437 — 1,114 (164) 2,387 Lease liabilities – Premises Innate Inc 496 — — (49) 447 Lease liabilities – Laboratory equipment 815 — — (176) 639 Lease liabilities – Vehicles 37 — — (16) 21 Lease liabilities - Printers — 41 — 41 Loans – Equipment 319 — — (57) 262 Loans – Building (4) 14,826 — (1,139) 13,687 Total 18,723 1,360 1,249 (2,245) 19,087 In thousand euros December 31, 2020 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings and lease liabilities December 31, 2021 BPI PTZI IPH41 (1) 150 — (150) — BPI Refundable advance - FORCE (2) 1,454 — (1,454) — — State guaranteed loan Société Générale (3) — 20,000 — — 20,000 State guaranteed loan BNP Paribas (3) — 8,700 — — 8,700 Lease liabilities – Building "Le Virage" 2,387 — — (512) 1,875 Lease liabilities – Premises Innate Inc 447 — (16) (40) 391 Lease liabilities – Laboratory equipment 639 — — (175) 464 Lease liabilities – Vehicles 21 — 62 (30) 53 Lease liabilities - Printers 41 — — (6) 35 Loans – Equipment 262 — — (53) 209 Loans – Building (4) 13,687 — — (1,162) 12,525 Total 19,087 28,700 (1,408) (2,128) 44,251 In thousand euros December 31, 2021 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings and lease liabilities December 31, 2022 State guaranteed loan Société Générale (3) 20,000 — — — 20,000 State guaranteed loan BNP Paribas (3) 8,700 — — — 8,700 State guaranteed loans - accrued interest — — 15 — 15 Lease liabilities – Building "Le Virage" 1,875 — — (522) 1,353 Lease liabilities – Premises Innate Inc 391 — 15 (61) 345 Lease liabilities – Laboratory equipment 464 — — (177) 287 Lease liabilities – Vehicles 53 — 12 (32) 33 Lease liabilities - Printers 35 — — (8) 27 Loans – Equipment 209 — — (55) 154 Loans – Building (4) 12,525 — — (1,187) 11,338 Total 44,251 — 42 (2,042) 42,251 (1) In 2013, the Company was granted an interest- free loan for innovation (“PTZI”) by BPI France relating to the program lacutamab IPH4102 for an amount of €1,500 thousand. (2) As a reminder, on August 11, 2020, the Company signed a financing contract with Bpifrance Financement as part of the program set up by the French government to help develop a therapeutic solution with a preventive or curative aim against COVID-19. This funding, for a maximum amount of € 6.8m, consisted of (i) an advance repayable only in the event of technical and commercial success and (ii) a non-repayable grant. This funding should have been received in four successive installments. The first tranche of 1.7 million euros was paid at signing, and the other three tranches should be received after successful completion of certain clinical milestones, particularly around Phase 2 of the FORCE trial. The portion relating to the repayable advance included in this first tranche amounted to €1,454 thousand as of December 31, 2020 (including actualization). As of December 31, 2021, this financing is considered by the Company to be non-refundable, in accordance with the terms of the agreement, in light of the technical and commercial failure of the project based on the results of the Phase 2 "Force" trial evaluating avdoralimab in COVID-19, published on July 6, 2021 (see note 13.2). (3) On January 5, 2022, the Company announced that it had obtained €28.7 million in non-dilutive financing in the form of two State Guaranteed Loans from Société Générale (€20.0 million) and BNP Paribas (€8.7 million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years from August 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtained agreements from Société Générale and BNP Paribas. The effective interest rates applied to these contracts during the additional period are 1.56% and 0.95% for Société Générale and BNP Paribas loans, respectively, excluding insurance and guarantee fees, with an amortization exemption for the entire year 2023. During this grace period, the Company will only be liable for the payment of interest and the guarantee fees, with amortization of the two loans starting in 2024 over a period of four years. The state guarantee fees amounts to €877 thousand and €379 thousand for Société Générale and BNP Paribas loans respectively. (4) On July 3, 2017, the Company borrowed from the Bank “Société Générale” in order to finance the construction of its future headquarters. This loan amounting to a maximum of €15,200 thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of €1,300 thousand. |
Disclosure of schedule for the contractual flows of financial liabilities | The table below shows the schedule for the contractual flows (principal only) as of December 31, 2020, 2021 and 2022 respectively : In thousand euros Year ended December 31, Current financial liabilities 2020 2021 2022 BPI PTZI IPH41 150 — — BPI Refundable advance - FORCE — — — State guaranteed loan Société Générale — 20,000 — State guaranteed loan BNP Paribas — 8,700 — State guaranteed loans - accrued interest — — 15 Lease finance obligations – Rent Le Virage 511 522 532 Lease liabilities – Premises Innate Inc 72 74 90 Lease finance obligations – Laboratory equipment 175 177 177 Lease liabilities – Vehicles 13 23 16 Lease liabilities - Printers 6 8 9 Loans - Equipment 55 55 55 Loans - Building 1,161 1,187 1,210 Total – Current financial liabilities 2,142 30,748 2,102 In thousand euros Year ended December 31, Non-Current financial liabilities 2020 2021 2022 BPI PTZI IPH41(1) — — — BPI Refundable advance - FORCE 1,454 — — State guaranteed loan Société Générale — — 20,000 State guaranteed loan BNP Paribas — — 8,700 State guaranteed loans - accrued interest — — — Lease finance obligations – Building Le Virage 1,876 1,352 820 Lease liabilities – Premises Innate Inc 375 317 255 Lease finance obligations – Laboratory equipment 463 287 110 Lease finance obligations – Vehicles 8 30 17 Lease liabilities - Printers 35 26 18 Loans - Equipment 208 154 99 Loans - Building 12,526 11,338 10,128 Total – Non-Current financial liabilities 16,945 13,503 40,149 |
Disclosure of maturity analysis for non-derivative financial liabilities | The table below shows the schedule for the contractual flows (being principal and interest payments): (in thousands of euro) ≤ 1 year 2 to 5 years included ≥ 5 years Total State guaranteed loan Société Générale 312 20,670 — 20,982 State guaranteed loan BNP Paribas 86 8,884 — 8,970 State guaranteed loans - accrued interest 15 — — 15 Lease finance obligations – Rent Le Virage 558 838 — 1,396 Lease liabilities – Premises Innate Inc. 96 312 — 408 Lease liabilities – Laboratory equipment 179 110 — 289 Lease liabilities – Vehicles 19 20 — 39 Lease liabilities - Printers 9 18 — 27 Loans – Equipment 57 100 — 157 Loan – Building 1,427 5,706 5,112 12,245 Total 2,758 36,658 5,112 44,528 |
Employee benefits (Tables)
Employee benefits (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of information about defined benefit plans [abstract] | |
Disclosure of defined benefit plans | Defined benefit obligations Year ended December 31, (in thousands of euro) 2020 2021 2022 Allowance for retirement defined benefit 3,713 2,544 2,184 Allowance for seniority awards 463 432 366 Total Defined benefit obligations 4,177 2,975 2,550 |
Disclosure of actuarial assumptions for defined benefit plans | The main actuarial assumptions used to evaluate retirement benefits are the following: Year ended December 31, 2020 2021 2022 Economic assumptions Discount rate (iBoxx Corporate AA) for retirement 0.50 % 0.95 % 3.75 % Annual rate of increase in wages 3.00 % 3.00 % 4.00 % Demographical assumptions Type of retirement At the initiative of the employee At the initiative of the employee At the initiative of the employee Annual mobility rate 2.6 % 4.2 % 4.3 % Rate of contributions 45.17 % 48.39 % 47.07 % Rate of wages costs 22.06 % 24.18 % 23.46 % Age at retirement - Executives 64 years 64 years 64 years - Non executives 62 years 62 years 62 years Mortality table TH-TF 00-02 TH-TF 00-02 TH-TF 00-02 Annual turnover by tranche of age All personnel All personnel All personnel 16-24 years 6.0 % 12.0 % 12.0 % 25-29 years 5.0 % 9.0 % 10.0 % 30-34 years 3.7 % 7.0 % 7.0 % 35-39 years 3.0 % 4.5 % 5.0 % 40-44 years 2.0 % 3.0 % 3.0 % 45-49 years 1.0 % 1.5 % 1.5 % +50 years 0 % 0 % 0 % |
Disclosure of net defined benefit liability (asset) | Changes in the projected benefit obligation for the periods presented were as follows (in thousands of euro): As of January 1, 2020 3,760 Service cost 252 Interest costs (35) Actuarial loss 200 As of December 31, 2020 4,177 IAS19 Restatement related to the change in calculation method - IFRIC (1) (1,054) Service cost 484 Interest costs (47) Actuarial gain (584) As of December 31, 2021 2,976 Service cost 427 Interest costs (62) Actuarial loss (790) As of December 31, 2022 2,550 |
Share capital and share based_2
Share capital and share based payments (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Share Capital And Share Based Payments [Abstract] | |
Disclosure of changes in share capital | The table below presents the historical changes in the share capital of the Company as of December 31, 2020, 2021 and 2022, respectively: Number of Date Nature of the Transactions Share Capital Share premium Common shares Preferred shares Nominal value Balance as of January 1, 2020 3,941,281 369,617,017 78,811,114 14,507 €0.05 January 15, 2020 Capital increase by issuance of common shares (exercise of share warrants) 75 2,985 1,500 €0.05 January 27, 2020 Capital increase by issuance of common shares (definitive acquisition of free shares ) 4,283 (4,283) 85,650 €0.05 July 7, 2020 Capital increase by issuance of common shares (exercise of share warrants) 1,250 43,000 25,000 €0.05 July 13, 2020 Capital increase by issuance of common shares (definitive acquisition of free shares ) 2,869 (2,869) 57,376 €0.05 September 11, 2020 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 32 (32) 650 (5) €0.05 September 24, 2020 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 226 (226) 4,550 (35) — December 31, 2020 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 32 (32) 650 (5) €0.05 December 31, 2020 Share based payments — 2,475,422 — €0.05 December 31, 2020 3,950,048 372,130,982 78,986,490 14,462 €0.05 (1) Share issuance costs representing incremental expenses directly attributable to the offering of new shares in the IPO on the Nasdaq and in the European Private Placement (together the “Global Offering”) were recorded through equity for an amount of €621 thousand. They consist mainly of legal, financial, accounting and printing fees associated with drafting and filing the registration statement of Innate Pharma. The other incremental costs incurred in the Global Offering were expensed for an amount of €2,150 thousand. Number of Date Nature of the Transactions Share Capital Share premium Common shares Preferred shares Nominal value Balance as of January 1, 2021 3,950,048 372,130,982 78,986,490 14,462 €0.05 June 4, 2021 Capital increase by issuance of common shares (exercise of share warrants) 1,500 59,700 30,000 — €0.05 July 7, 2021 Capital increase by issuance of common shares (exercise of share warrants) 222 7,637 4,440 — €0.05 July 19, 2021 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 548 (548) 11,050 (85) €0.05 July 22, 2021 Capital increase by issuance of common shares (definitive acquisition of free shares ) 2,418 (2,418) 48,362 — €0.05 July 22, 2021 Capital increase by issuance of common shares (exercise of share warrants) 625 21,500 12,500 — €0.05 August 6, 2021 Capital increase by issuance of common shares (exercise of share warrants) 10,000 398,000 200,000 — €0.05 December 31, 2021 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 1,819 (1,819) 36,660 (282) €0.05 December 31, 2021 Capital increase by issuance of common shares (definitive acquisition of free shares ) 10,656 (10,656) 213,125 — €0.05 December 31, 2021 Share based payments — 2,617,289 — — December 31, 2021 3,977,836 375,219,667 79,542,627 14,095 €0.05 Number of Date Nature of the Transactions Share Capital Share premium Common shares Preferred shares Nominal value Balance as of January 1, 2022 3,977,836 375,219,667 79,542,627 14,095 €0.05 February 14, 2022 Capital increase by issuance of common shares (exercise of share warrants) 38 1,493 750 — €0.05 February 14, 2022 Capital increase by issuance of common shares 2,316 187,596 46,320 — €0.05 February 14, 2022 Capital increase by issuance of common shares (definitive acquisition of free shares ) 6,948 (6,948) 138,960 — €0.05 April 22, 2022 Capital increase by issuance of common shares (definitive acquisition of free shares ) 1,250 (1,250) 25,000 — €0.05 July 13, 2022 Capital increase by issuance of common shares (definitive acquisition of free shares ) 681 (681) 13,614 — €0.05 July 25, 2022 Capital increase by issuance of common shares (exercise of share warrants) 6,287 (6,287) 125,748 — €0.05 December 16, 2022 Subsciption of share warrants — 9,995 — — €— November 7, 2022 Capital increase by issuance of common shares (conversion of preferred shares in common shares) 15,953 (15,953) 319,050 — €0.05 December 31, 2022 Share based payments — 4,249,113 — — — December 31, 2022 4,011,308 379,636,744 80,212,069 14,095 €0.05 |
Disclosure of number and weighted average exercise prices of other equity instruments | The Company has issued BSAs, BSAARs, stock options, AGAs and AGAPs as follows as of December 31, 2020, 2021 and 2022, respectively: : Date Types Number of warrants issued as of 12/31/2020 Number of warrants void as of 12/31/2020 Number of warrants exercised as of 12/31/2020 Number of warrants outstanding as of 12/31/2020 Maximum number of shares to be issued as of 12/31/2020 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 — 395,000 255,000 255,000 €2.04 May 27, 2013 BSAAR 2012 146,050 — 85,950 60,100 60,100 €2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 €7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 — 1,450 188,500 €— October 21, 2016 AGAP Employees 2016-1 2,486 251 50 2,185 284,050 €— October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — €— December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 €— December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — — April 3, 2018 AGAP Employees 2017-1 5,725 833 — 4,892 489,200 — April 3, 2018 AGAP Management 2017-1 2,400 800 — 1,600 160,000 — April 3, 2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — — November 20, 2018 AGAP Perf Employees 2018-1 327,500 85,000 — 242,500 242,500 — November 20, 2018 AGAP Perf Management 2018-1 260,000 60,000 — 200,000 200,000 — January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — — April 29, 2019 AGA New Members 2017-1 25,000 — — 25,000 25,000 — July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — — November 4, 2019 AGAP 2019 Employees 2019 546,700 86,100 — 460,600 460,600 — November 4, 2019 AGAP 2019 Management 2019 355,000 30,000 — 325,000 325,000 — July 13, 2020 AGA Bonus 2020-1 79,861 — — 79,861 79,861 — August 5, 2020 AGA Perf Employees 2020-1 766,650 70,540 — 696,110 696,110 — August 5, 2020 AGA Perf Management 2020-1 710,000 — — 710,000 710,000 — July 21, 2020 Stock Options 2020-1 102,000 72,000 — 30,000 30,000 — July 29, 2011 BSA 2011-2 225,000 — 183,060 41,940 41,940 €1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 €2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 €8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 €9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 €14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 €11.00 Total as of December 31, 2020 6,398,008 418,263 1,552,225 4,427,520 5,869,143 Date Types Number of warrants issued as of 12/31/2021 Number of warrants void as of 12/31/2021 Number of warrants exercised as of 12/31/2021 Number of warrants outstanding as of 12/31/2021 Maximum number of shares to be issued as of 12/31/2021 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 25,000 625,000 — — €2.04 May 27, 2013 BSAAR 2012 146,050 — 85,950 60,100 60,100 €2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 €7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 250 1,200 156,000 €— October 21, 2016 AGAP Employees 2016-1 2,486 251 167 2,068 268,840 €— October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — €— December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 €— December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — — April 3, 2018 AGAP Employees 2017-1 5,725 5,725 — — — — April 3, 2018 AGAP Management 2017-1 2,400 2,400 — — — — April 3, 2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — — November 20, 2018 AGAP Perf Employees 2018-1 327,500 224,375 103,125 — — — November 20, 2018 AGAP Perf Management 2018-1 260,000 150,000 110,000 — — — January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — — April 29, 2019 AGA New Members 2017-1 25,000 — — 25,000 25,000 — July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — — November 4, 2019 AGAP 2019 Employees 2019 546,700 189,900 — 356,800 356,800 — November 4, 2019 AGAP 2019 Management 2019 355,000 30,000 — 325,000 325,000 — July 13, 2020 AGA Bonus 2020-1 79,861 17,885 48,362 13,614 13,614 — August 5, 2020 AGA Perf Employees 2020-1 766,650 249,826 — 516,824 516,824 — August 5, 2020 AGA Perf Management 2020-1 710,000 30,000 — 680,000 680,000 — July 22, 2021 AGA Bonus 2021-1 125,748 — — 125,748 125,748 — October 1, 2021 AGA Perf Employees 2021-1 1,066,600 17,500 — 1,049,100 1,049,100 — October 1, 2021 AGA Perf Management 2021-1 610,000 30,000 — 580,000 580,000 — July 21, 2020 Stock Options 2020-1 102,000 102,000 — — — — July 29, 2011 BSA 2011-2 225,000 25,000 200,000 — — €1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 €2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 €8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 €9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 €14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 €11.00 Total as of December 31, 2021 8,200,356 1,112,601 2,061,019 5,026,736 5,778,308 Date Types Number of warrants issued as of 12/31/2022 Number of warrants void as of 12/31/2022 Number of warrants exercised as of 12/31/2022 Number of warrants outstanding as of 12/31/2022 Maximum number of shares to be issued as of 12/31/2022 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 25,000 625,000 — — €2.04 May 27, 2013 BSAAR 2012 146,050 — 86,700 59,350 59,350 €2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 €7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 250 1,200 156,000 €— October 21, 2016 AGAP Employees 2016-1 2,486 251 167 2,068 268,840 €— October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — €— December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 €— December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — — April 3, 2018 AGAP Employees 2017-1 5,725 5,725 — — — — April 3, 2018 AGAP Management 2017-1 2,400 2,400 — — — — April 3, 2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — — November 20, 2018 AGAP Perf Employees 2018-1 327,500 224,375 103,125 — — — November 20, 2018 AGAP Perf Management 2018-1 260,000 150,000 110,000 — — — January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — — April 29, 2019 AGA New Members 2017-1 25,000 — 25,000 — — — July 3, 2019 AGA Bonus 2019-1 57,376 — 57,376 — — — November 4, 2019 AGAP 2019 Employees 2019 546,700 375,150 171,550 — — — November 4, 2019 AGAP 2019 Management 2019 355,000 207,500 147,500 — — — July 13, 2020 AGA Bonus 2020-1 & 2 79,861 17,885 61,976 — — — August 5, 2020 AGA Perf Employees 2020-1 766,650 286,306 — 480,344 480,344 — August 5, 2020 AGA Perf Management 2020-1 710,000 60,000 — 650,000 650,000 — July 22, 2021 AGA Bonus 2021-1 125,748 — 125,748 — — — October 1, 2021 AGA Perf Employees 2021-1 1,066,600 95,600 — 971,000 971,000 — October 1, 2021 AGA Perf Management 2021-1 610,000 90,000 — 520,000 520,000 — February 12, 2022 AGA "Plan Epargne Entreprise" 2022 138,960 — 138,960 — — — October 3, 2022 AGA Bonus 2022-1 128,061 — — 128,061 128,061 €— December 12, 2022 AGA Perf Employees 2022-1 1,371,500 — — 1,371,500 1,371,500 €— December 12, 2022 AGA Perf Management 2022-1 550,000 — — 550,000 550,000 €— July 21, 2020 Stock Options 2020-1 102,000 102,000 — — — €— July 29, 2011 BSA 2011-2 225,000 25,000 200,000 — — €1.77 July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 €2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 €8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 €9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 €14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 €11.00 December 16, 2022 BSA 2022-1 40,000 31,740 — 8,260 8,260 €2.31 Total as of December 31, 2022 10,428,877 1,711,671 2,684,141 6,033,065 6,784,637 |
Disclosure of terms and conditions of other equity instruments | Details of AGA AGAP Management 2016-1 AGAP Employees 2016-1 AGA Management 2016-1 AGA Employees 2016-1 AGAP Management 2016-2 Date of grant (Board of Directors) October 21, 2016 October 21, 2016 October 21, 2016 October 21, 2016 October 21, 2016 Vesting period (years) 1 year 1 year 3 years 1 year 1 year Non transferability period 2 years after the vesting period end 2 years after the vesting period end None 2 years after the vesting period end 2 years after the vesting period end Number of free shares granted 2,000 2,486 50,000 99,932 3,000 Share entitlement per free share 130 (1) 130 (1) 1 1 111 Grant date share fair value €10.87 €10.87 €10.87 €10.87 €12.73 Expected dividends None None None None None Performance conditions Yes Yes None None Yes Expected turnover (yearly basis) 5 % 5 % — 5 % 9 % Volatility 40 % 40 % — — 40 % Fair value per AGA €911 €911 €10.55 €10.55 €956 AGA Management 2016-2 AGA Employees 2016-2 AGA Bonus 2017 AGA Employee 2017 AGAP Employees 2017-1 Date of grant (Board of Directors) December 30, 2016 December 30, 2016 September 20, 2017 April 3, 2018 April 3, 2018 Vesting period (years) 3 years 1 year 1 year 1 year 1 year Non transferability period None 2 years after the vesting period end 1 year after the vesting period end 1 year after the vesting period end 2 years after the vesting period end Number of free shares granted 250,000 149,943 114,500 28,556 5,725 Share entitlement per free share 1 1 1 1 100 Grant date share fair value €12.73 €12.73 €5.52 €10.90 €5.52 Expected dividends None None None None None Performance conditions None None Yes None Yes Expected turnover (yearly basis) — 5 % 4 — % 5 % Volatility — — 55 — % 55 % Fair value per AGA €14.61 €10.55 €5.83 €10.30 €90 AGAP Management 2017 AGA Bonus 2018 AGA Perf Employees 2018 AGA Perf Management 2018 AGA New Members 2017-1 Date of grant (Board of Directors) April 3, 2018 July 3, 2018 November 20, 2018 November 20, 2018 April 29, 2019 Vesting period (years) 1 year 1 year 3 years 3 years 3 years Non transferability period 2 years after the vesting period end 1 year after the vesting period end None None None Number of free shares granted 2,400 67,028 327,500 260,000 25,000 Share entitlement per free share 100 1 1 1 1 Grant date share fair value €5.52 €5.06 €8.00 €8.00 €5.74 Expected dividends None None None None None Performance conditions Yes Yes Yes Yes No Expected turnover (yearly basis) 11 % — 4 % 10 % 10 % Volatility 55 % — 45 % 45 % — Fair value per AGA €90 €4.69 €3.81 €3.81 €5.74 AGA Employees 2018 AGA Bonus 2019-1 AGA Perf Employees 2019 AGA Perf Management 2019 AGA Bonus 2020 Date of grant (Board of Directors) January 14, 2019 July 3, 2019 November 4, 2019 November 4, 2019 July 13, 2020 Vesting period (years) 1 year 1 year 3 years 3 years 1 year Non transferability period 1 year after the vesting period end 1 year after the vesting period end None None 1 year after the vesting period end Number of free shares granted 90,650 57,376 546,700 355,000 79,861 Share entitlement per free share 1 1 1 1 1 Grant date share fair value €7.31 €5.90 €3.13 €3.13 €6.40 Expected dividends None None None None None Performance conditions No No Yes Yes No Expected turnover (yearly basis) 4.03 % — 10 % 10 % — % Volatility N/A — 45 % 45 % — % Fair value per AGA €7.31 €5.72 €3.13 €3.13 €6.40 AGA Perf Employees 2020-1 AGA Perf Management 2020-1 AGA Bonus 2021-1 AGA Perf Employees 2021-1 AGA Perf Management 2021-1 Date of grant (Board of Directors) August 5, 2020 August 5, 2020 July 22, 2021 October 1, 2021 October 1, 2021 Vesting period (years) 3.5 years 3.5 years 1 year 3.5 years 3.5 years Non transferability period None None 1 year None None Number of free shares granted 769,202 710,000 125,748 1,066,600 610,000 Share entitlement per free share 1 1 1 1 1 Grant date share fair value €2.94 €2.94 €3.43 €1.76 €1.76 Expected dividends None None None None None Performance conditions Yes Yes No Yes Yes Expected turnover (yearly basis) 10.00 % 10.00 — 13.32 13.32 Volatility 45.00 % 45.00 — 50.00 50.00 Fair value per AGA €2.94 €2.94 €3.43 €1.76 €1.76 AGA "Plan Epargne Entreprise" 2022 AGA Bonus 2022-1 AGA Perf Employees 2022-1 AGA Perf Management 2022-1 Date of grant (Board of Directors) February 12, 2022 October 3, 2022 December 12, 2022 December 12, 2022 Vesting period (years) None 1 year 3.1 years 3.1 years Non transferability period None None None None Number of free shares granted 138,960 128,061 1,371,500 550,000 Share entitlement per free share 1 1 1 1 Grant date share fair value €4.10 €3.89 €1.39 €1.39 Expected dividends None None None None Performance conditions No No Yes Yes Expected turnover (yearly basis) — % — 10.50 10.50 Volatility — % — 50.00 50.00 Fair value per AGA €4.10 €3.89 €1.39 €1.39 Details of BSA BSA 2013 BSA 2014 BSA 2015-1 BSA 2015-2 BSA 2017 Date of grant (Board of directors) July 17, 2013 July 16, 2014 April 27, 2015 July 1, 2015 September 20, 2017 Vesting period (years) 2 years 2 years 2 years 2 years 2 years Plan expiration date July 17, 2023 July 16, 2024 April 26, 2025 June 30, 2025 September 20, 2027 Number of BSA granted 237,500 150,000 70,000 14,200 37,000 Share entitlement per BSA 1 1 1 1 1 Exercise price €2.36 €8.65 €9.59 €14.05 €11.00 Valuation method used Black & Scholes Black & Scholes Black & Scholes Black & Scholes Black & Scholes Grant date share fair value €2.45 €6.85 €13.65 €13.64 €10.41 Expected volatility 31.83 % 46.72 % 54.08 % 47.83 % 61.74 % Average life of BSA 5.5 years 5.5 years 5.5 years 5.5 years 6 years Risk-free interest rate 2.42 % 1.00 % 0.25 % 0.25 % 0.20 % Expected dividends None None None None None Performance conditions None None None None None Fair value per BSA €0.87 €2.51 €6.59 €4.73 €0.57 BSA 2022-1 Date of grant (Board of directors) December 16, 2022 Vesting period (years) 2 years Plan expiration date October 3, 2032 Number of BSA granted 40,000 Share entitlement per BSA 1 Exercise price €2.31 Valuation method used Black & Scholes Grant date share fair value €1.31 Expected volatility 50.00 % Average life of BSA 5.5 years Risk-free interest rate 2.40 % Expected dividends None Performance conditions None Fair value per BSA €1.21 BSAAR 2015 Date of grant (Board of directors) July 1, 2015 Vesting period (years) 2 years Plan expiration date June 30, 2025 Number of BSAAR granted 1,050,382 Share entitlement per BSAAR 1 Exercise price €7.20 Valuation method used Black & Scholes Grant date share fair value €13.77 Expected volatility 41 % Average life of BSAAR 10 years Risk-free interest rate 1.22 % Expected dividends None Performance conditions No Fair value per BSA €1.15 |
Disclosure of change in number of other equity instruments outstanding | Change in Number of AGAs Outstanding Year ended December 31, Number of AGAs 2020 2021 2022 Balance at beginning of period 1,607,345 2,752,198 3,678,354 Granted during the period 1,556,511 1,802,348 2,188,521 Forfeited during the period (268,587) (614,338) (567,330) Exercised during the period (143,071) (261,854) (622,372) Expired during the period — — — Balance at end of period 2,752,198 3,678,354 4,677,173 Change in Number of BSA Outstanding Year ended December 31, Number of BSA 2020 2021 2022 Balance at beginning of period 309,500 284,500 242,560 Granted during the period — — 40,000 Forfeited during the period — — (31,740) Exercised during the period (25,000) (16,940) — Expired during the period — (25,000) — Balance at end of period 284,500 242,560 250,820 Change in Number of BSAAR Outstanding Year ended December 31, Number of BSAAR 2020 2021 2022 Balance at beginning of period 1,362,322 1,360,822 1,105,822 Granted during the period — — — Forfeited during the period — — — Exercised during the period (1,500) (230,000) (750) Expired during the period — (25,000) — Balance at end of period 1,360,822 1,105,822 1,105,072 |
Disclosure of closing balance of share-based payment arrangements | Breakdown of the Closing Balance Year ended December 31, 2020 2021 2022 Number of AGAs Outstanding Outstanding Outstanding AGAP Management 2016-1 1,450 1,200 1,200 AGAP Employees 2016-1 2,185 2,068 2,068 AGAP 2016-2 3,000 3,000 3,000 AGAP Management 2017 1,600 — — AGAP Perf Employees 2018 242,500 — — AGAP Perf Management 2018 200,000 — — AGA New Members 2017-1 25,000 25,000 — AGA Perf Employees 2019-1 460,600 356,800 — AGA Perf Management 2019-1 325,000 325,000 — AGA Bonus 2020-1 79,861 13,614 — AGA Perf Employees 2020-1 696,110 516,824 480,344 AGA Perf Management 2020-1 710,000 680,000 650,000 AGA Bonus 2021-1 — 125,748 — AGA Perf Employees 2021-1 — 1,049,100 971,000 AGA Perf Management 2021-1 — 580,000 520,000 AGA Bonus 2022-1 — — 128,061 AGA Perf Employees 2022-1 — — 1,371,500 AGA Perf Management 2022-1 — — 550,000 TOTAL 2,752,198 3,678,354 4,677,173 Breakdown of the Closing Balance Year ended December 31, 2020 2021 2022 Number of BSA Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BSA 2011-2 41,940 41,940 — — — — BSA 2013 46,360 46,360 46,360 46,360 46,360 46,360 BSA 2014 75,000 75,000 75,000 75,000 75,000 75,000 BSA 2015-1 70,000 70,000 70,000 70,000 70,000 70,000 BSA 2015-2 14,200 14,200 14,200 14,200 14,200 14,200 BSA 2017 37,000 37,000 37,000 37,000 37,000 37,000 BSA 2022-1 — — — — 8,260 8,260 TOTAL 284,500 284,500 242,560 242,560 250,820 250,820 Year ended December 31, 2020 2021 2022 Number of BSAAR Outstanding Exercisable Outstanding Exercisable Outstanding Exercisable BSAAR 2011 255,000 255,000 — — — — BSAAR 2012 60,100 60,100 60,100 60,100 59,350 59,350 BSAAR 2015 1,045,722 1,045,722 1,045,722 1,045,722 1,045,722 1,045,722 TOTAL 1,360,822 1,360,822 1,105,822 1,105,822 1,105,072 1,105,072 |
Disclosure of breakdown of expenses per financial year | The share-based compensation expenses are broken down as follows (in thousands of euro): Year ended December 31, (in thousands of euro) 2020 2021 2022 AGA Perf Management 2018 / AGA Perf Employees 2018 618 (232) — AGA 2018-1 Employees 23 — — AGA 2017-1 Management (New Members) 43 71 — AGAP Employee 2019 / AGAP Management 2019 867 649 (181) AGA Bonus 2019-1 — — — AGA Bonus 2020 394 — — AGAP Employee 2020 / AGAP Management 2020 502 1,253 1,738 Stock Options 2020 28 (28) — AGA Bonus 2021-1 — 432 — AGAP Employee 2021 / AGAP Management 2021 — 473 1,577 AGA "Plan Epargne Entreprise" 2022 — — 570 AGA Bonus 2022-1 — — 499 AGAP Employee 2022 / AGAP Management 2022 — — 46 Share based compensation 2,475 2,617 4,249 |
Financial instruments recogni_2
Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of detailed information about financial instruments [abstract] | |
Disclosure of detailed information about financial instruments | The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. As of December 31, 2020 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Receivables Fair value Financial assets Non-current financial assets 38,934 38,934 38,934 Trade receivables and others 51,635 — 51,635 51,635 Short-term investments 14,845 14,845 — 14,845 Cash and cash equivalents 136,792 136,792 — 136,792 Total financial assets 242,206 190,571 51,635 242,206 As of December 31, 2020 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Debt at amortized cost (3) Fair value Financial liabilities Financial liabilities—non-current portion 16,945 — 16,945 16,945 Financial liabilities—current portion 2,142 — 2,142 2,142 Trade payables and others 29,539 — 29,539 29,539 Total financial liabilities 48,624 — 48,624 48,624 As of December 31, 2021 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Receivables Fair value Financial assets Non-current financial assets 39,878 39,878 — 39,878 Trade receivables and others 48,241 — 48,241 48,241 Short-term investments 16,080 16,080 — 16,080 Cash and cash equivalents 103,756 103,756 — 103,756 Total financial assets 207,955 159,714 48,241 207,955 As of December 31, 2021 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Debt at amortized cost (3) Fair value Financial liabilities Financial liabilities—non-current portion 13,503 — 13,503 13,503 Financial liabilities—current portion 30,748 — 30,748 30,748 Trade payables and others 28,573 — 28,573 28,573 Total financial liabilities 72,824 — 72,822 72,822 As of December 31, 2022 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Receivables Fair value Financial assets Non-current financial assets 35,119 35,119 — 35,119 Trade receivables and others 52,445 — 52,445 52,445 Short-term investments 17,260 17,260 — 17,260 Cash and cash equivalents 84,225 84,225 — 84,225 Total financial assets 189,049 136,604 52,445 189,049 As of December 31, 2022 (in thousands of euro) Book value on the statement of financial position Fair value through profit and loss (1) Debt at amortized cost (3) Fair value Financial liabilities Financial liabilities—non-current portion 40,149 — 40,149 40,149 Financial liabilities—current portion 2,102 — 2,102 2,102 Trade payables and others 20,911 — 20,911 20,911 Total financial liabilities 63,162 — 63,162 63,162 (1) The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. (2) The fair value of financial assets classified as fair value through comprehensive income corresponds to the market value of the assets, which are primarily determined using level 1 measurements. (3) The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value. |
Revenue and government financ_2
Revenue and government financing for research expenditures (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure of disaggregation of revenue from contracts with customers [abstract] | |
Disclosure of revenue from collaboration and licensing agreements | Year ended December 31, (in thousands of euro) 2020 (1) 2021 2022 Proceeds from collaboration and licensing agreements 54,038 10,497 48,806 of which monalizumab agreement - AstraZeneca 33,620 7,497 22,376 of which IPH5201 agreement - AstraZeneca 13,418 — 4,677 of which preclinical molecules agreement - AstraZeneca — — 17,400 of which Sanofi agreement 7,000 3,000 4,000 of which other agreements — — 353 Invoicing of research and development costs (IPH5201) 2,531 1,613 1,391 Exchange gains (loss) on collaboration agreements (602) — (627) Others 188 — 10 Revenue from collaboration and licensing agreements 56,155 12,112 49,580 |
Disclosure of changes in deferred revenue and collaboration liabilities | Change in monalizumab deferred revenue (in thousands of euro): As of December 31, 2019 62,657 Revenue for the 2020 financial year (33,620) Transfer from collaboration liabilities (2,465) As of December 31, 2020 26,572 Revenue for the 2021 financial year (7,497) Transfer from collaboration liabilities 1,084 As of December 31, 2021 20,159 Increase in deffered revenu resulting from the $50m milestone relating to the dosage of the first patent in the Phase 3 trial PACIFIC-9 (1) 47,687 Revenue for the 2022 financial year (22,376) Transfer from collaboration liabilities (30,989) As of December 31, 2022 14,481 (1) The increase in deferred revenue relating to monalizumab agreement between December 31, 2021 and December 31, 2022 is explained by the additional payment of €47,687 thousand ($50,000 thousand) made by AstraZeneca in June 2022 and triggered by the launch of the “PACIFIC-9” Phase 3 trial on April 28, 2022. This increase has led to a simultaneous increase in collaboration commitment ("collaboration liability"- see below) of €34,335 thousand ($36,000 thousand) in accordance with the Company’s July 2019 option concerning the co-financing of Phase 3 trials in the field of collaboration. Change in monalizumab collaboration liablities (in thousands of euro): As of December 31, 2019 (1) 21,304 Additions (2) 46,320 Deductions (20,938) As of December 31, 2020 (3) 46,686 Additions 4,262 Deductions (10,534) As of December 31, 2021 (4) 40,415 Additions (5) 37,564 Deductions (14,768) As of December 31, 2022(6) 63,211 (1) Of which €21,304 thousand of current portion. (2) Including €41,227 thousand euros ($ 50,000 thousand) relating to the collaboration commitment following the milestone payment related to the treatment of the first patient in the Phase 3 trial evaluating monalizumab. (3) Of which €1,832 thousand of current portion and €44,854 of non-current portion. (4) Of which €7,418 thousand of current portion and €32,997 thousand of non-current portion. (5) The increase in collaboration liabilities relating to monalizumab agreement between December 31, 2021 and December 31, 2022 mainly results from (i) a €34,335 thousand ($36,000 thousand) increase in collaboration commitments in connection with the launch of the “PACIFIC-9” Phase 3 trial on April 28, 2022, and (ii) a €2,145 thousand net increase in the collaboration commitments in connection with exchange rate fluctuations over the period. (6) Of which €10,223 thousand of current portion and €52,988 thousand of non-current portion. Change in deferred revenue relating to the 2018 future programs option agreement (in thousands of euro) Total As of December 31, 2021 17,400 Augmentation — Deductions (17,400) As of December 31, 2022 — |
Disclosure of variance of deferred revenue | The main variance of the global deferred revenue is presented in the following schedule: (in thousands of euro) December 31, 2019 Recognition in P&L Proceeds Transfer from collaboration liabilities December 31, 2020 Monalizumab 62,657 (33,620) — (2,465) 26,572 IPH5201 9,054 (13,418) 4,365 — — Preclinical molecules 17,400 — — — 17,400 Total 89,112 (47,038) 4,365 (2,465) 43,973 (1) (1) Of which €11,299 thousand of current deferred revenue and €32,674 thousand of non-current deferred revenue. (in thousands of euro) December 31, 2020 Recognition in P&L Proceeds Transfer from collaboration liabilities December 31, 2021 Monalizumab 26,572 (7,497) — 1,084 20,159 IPH5201 — — — — — Preclinical molecules 17,400 — — — 17,400 Others — — 353 — 353 Total 43,973 (7,497) 353 1,084 37,913 (2) (2) Of which €12,500 thousand of current deferred revenue and €25,413 thousand of non-current deferred revenue. (in thousands of euro) December 31, 2021 Recognition in P&L Proceeds and other increase Transfer from collaboration liabilities December 31, 2022 Monalizumab 20,159 (22,376) 47,687 (30,989) 14,481 Preclinical molecules 17,400 (17,400) — — — Others 353 (353) — — — Total 37,913 (39,776) 47,687 (30,989) 14,481 (3) (3) Of which €6,560 thousand of current deferred revenue and €7,921 thousand of non-current deferred revenue. |
Disclosure of government financing for research expenditures | The total amount for government financing for research expenditures recorded as other income in the income statement can be analyzed as follows: Year ended December 31, (in thousands of euro) 2020 2021 2022 Research Tax Credit(1) 13,084 10,310 7,925 Grant and other tax credit(2) 534 2,281 110 Government financing for research expenditures 13,618 12,591 8,035 (1) As of December 31, 2022, the amount is mainly composed of (i) the research tax credit calculated and recognized for the 2022 financial year for an amount of €9,167 thousand from which is subtracted (ii) a provision amounting to €1,270 thousand following the tax inspection carried out in 2022 by the French tax authorities and relating to the 2019 and 2020 financial years as well as to the research tax credit and the accuracy of its calculation for the 2018 to 2020 financial years. This provision was recognized as a deduction from the 2022 research tax credit, based on estimated amounts and adjustments not disputed by the Company. On March 3, 2023, the Company received from the tax authorities the rectification proposal, confirming the amount of the provision recognized on the amounts of the rectifications not disputed by the Company. |
Operating expenses (Tables)
Operating expenses (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Analysis of income and expense [abstract] | |
Disclosure of expenses by nature | (in thousands of euro) Year ended December 31, 2020 (1) 2021 2022 R&D G&A Total R&D G&A Total R&D G&A Impairment Total Subcontracting costs (2) (19,866) 4 (19,862) (24,189) (101) (24,290) (24,432) — — (24,432) Cost of supplies and consumable materials (3,590) 32 (3,558) (2,533) (532) (3,065) (3,051) (531) — (3,582) Personnel expenses other than share-based compensation (13,825) (6,611) (20,436) (14,859) (8,616) (23,475) (14,329) (8,025) — (22,354) Share-based compensation (836) (1,639) (2,475) (349) (2,267) (2,617) (2,044) (2,204) — (4,249) Personnel expenses (14,661) (8,250) (22,911) (15,208) (10,883) (26,092) (16,373) (10,229) — (26,603) Non-scientific advisory and consulting (3) (342) (4,441) (4,783) (161) (5,108) (5,269) (1,441) (4,244) — (5,685) Leasing and maintenance (559) (1,605) (2,164) (260) (1,754) (2,014) (200) (1,798) — (1,998) Travel expenses and meeting attendance (146) (138) (284) (103) (170) (273) (466) (252) — (718) Marketing, communication and public relations (96) (408) (504) (79) (393) (472) (130) (530) — (660) Scientific advisory and consulting (4) (962) — (962) (288) — (288) (1,263) — — (1,263) Other purchases and external expenses (46) (2,007) (2,053) (30) (2,395) (2,425) (91) (2,557) — (2,648) Depreciation and amortization (8,231) (1,154) (9,385) (3,153) (1,416) (4,569) (2,928) (1,496) — (4,424) Intellectual property expenses (877) (393) (1,270) (1,279) (305) (1,584) (996) (296) — (1,292) Other income and (expenses), net (332) (626) (958) 279 (2,467) (2,188) (292) (503) — (795) Impairment of intangible assets (5) — — — — — — — — (41,000) (41,000) Total net operating expenses (49,708) (18,986) (68,694) (47,004) (25,524) (72,528) (51,663) (22,436) (41,000) (115,099) (1) The 2020 comparative have been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17. (2) The Company subcontracts a significant part of its preclinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. Associated costs are recorded in subcontracting on the basis of the level of completion of the clinical trials. (3) Non-scientific advisory and consulting are services performed to support the selling, general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. (4) Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company. (5) Following the Company's decision in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well as of June 30, 2022), the rights relating to the intangible asset have been fully impaired for their net book value on the date of the decision, i.e. €41,000 thousand (see note 6) |
Disclosure of audit and non-audit fees | Year ended December 31, 2020 2021 2022 (in thousands of euro) Deloitte & Associés Total Deloitte & Associés Total Deloitte & Associés Total Audit fees 684 684 702 702 855 855 Non-audit fees 115 115 78 78 248 248 Total 799 799 780 780 1,103 1,103 * Non-audit fees: these fees correspond to services performed by the auditors related to the production of certification in the context of the declaration of expenses for the obtention of grants; to the verification report of social and environmental information, special reports within the framework of operations on the Company’s capital |
Net financial loss (Tables)
Net financial loss (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Analysis of income and expense [abstract] | |
Disclosure of net financial loss | Net financial loss can be analyzed as follows: Year ended December 31, (in thousands of euro) 2020 2021 2022 Interests and gains on financial assets 564 327 546 Unrealized gains on financials assets 313 1,177 418 Foreign exchange gains 3,978 4,839 3,810 Other financial income — — — Financial income 4,855 6,344 4,775 Foreign exchange losses (5,557) (3,591) (2,983) Unrealized losses on financial assets (865) (95) (2,050) Interest on financial liabilities (341) (312) (288) Other financial expenses — — — Financial expenses (6,763) (3,997) (5,321) Net financial income (loss) (1,908) 2,347 (546) |
Income Tax (Tables)
Income Tax (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax [Abstract] | |
Disclosure of tax rate reconciliation | Tax rate reconciliation Year ended December 31, (in thousands of euro) 2020 2021 2022 Net income (loss) before tax (63,984) (52,809) (58,103) Statutory tax rate 28.00 % 26.50 % 25.00 % Income tax benefit / (expense) calculated at statutory tax rate 17,916 13,994 14,526 Increase / (decrease) in income tax benefit / (expenses) arising from: Differences in tax rates 128 62 — Research tax credit 3,961 3,091 1,971 Provision for defined benefit obligations (117) 39 106 Share-based compensation (693) (694) (1,062) Revenue from collaboration agreements 8,824 (3,313) 2,210 Non-recognition of deferred tax assets related to tax losses and temporary differences (15,746) (14,433) (18,290) Carry-back — — — Impact linked to intra-group merger operations (16,288) — — Impact linked to the exercise of a real estate leasing option (1,103) — — Others differences 3,118 1,254 539 Income tax benefit / (expense) (a) — — — Effective tax rate 0 % 0 % 0 % Deferred tax income / (loss) (b) — — — Income tax benefit / (expense) (a) + (b) — — — |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Discontinued Operations [Abstract] | |
Disclosure of analysis of financial performance and cash-flows from discontinued operations | a) Financial Performance Year ended December 31, 2020 2021 2022 Revenue and other income Revenue from collaboration and licensing agreements — 926 194 Sales 678 874 22 Total revenue and other income 678 1,800 216 Operating expenses Research and development expenses (8,905) (624) — Selling, general and administrative expenses (12,260) (8,507) (346) Impairment of intangible assets (43,529) — — Total operating expenses (21,165) (9,131) (346) Net income (loss) from distribution agreements 861 — — Operating income (loss) (63,155) (7,331) (131) Financial income — — — Financial expenses — — — Net financial income (loss) — — — Net income (loss) before tax (63,155) (7,331) (131) Income tax expense — — — Net income (loss) from discontinued operations (63,155) (7,331) (131) Year ended December 31, 2020 2021 2022 Net cash generated from / (used in) operating activities (22,391) (3,552) (5,097) Net cash generated from / (used in) investing activities (6,620) — — Net cash generated from / (used in) financing activities — — — Net cash flows from discontinued operations (29,011) (3,552) (5,097) |
Related party transactions (Tab
Related party transactions (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Related party transactions [abstract] | |
Disclosure of key management personnel compensation | For each of the periods presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense: Year ended December 31, (in thousands of euro) 2020 2021 2022 Personnel expenses and other short-term employee benefits 3,131 3,456 2,176 Extra pension benefits — 11 43 Share-based compensation 1,363 2,067 1,989 Advisory fees — — 661 Executive Committee members compensation 4,494 5,534 4,869 |
Disclosure of transactions between related parties | The payments between the two companies as well as the liabilities and receivables as of 31 December 2021 are as follows: As of December 31, 2022 (in thousands of euros) Payments Assets/Liabilities Collection (AstraZeneca towards the Company) / Receivables 54,774 3,078 Payments (the Company towards AstraZeneca) / Liabilities (17,745) (7,298) Total (1) 37,029 (4,220) |
Income (loss) per share (Tables
Income (loss) per share (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income (Loss) Per Share [Abstract] | |
Summary of income (loss) per share | Year ended December 31. (in thousands of euro, except for data share) 2020 2021 2022 Net income (loss) (63,984) (52,809) (58,103) Weighted average number of ordinary shares in circulation 78,934,960 79,542,627 79,639,826 Basic income (loss) per share (€ per share) (0.81) (0.66) (0.73) Year ended December 31, (in thousands of euro, except for data share) 2020 2021 2022 Net income (loss) (63,984) (52,809) (58,103) Weighted average number of ordinary shares in circulation 78,934,960 79,542,627 79,639,826 Adjustment for share instruments — — — Diluted income (loss) per share (€ per share) (0.81) (0.66) (0.73) |
The company - The company (Deta
The company - The company (Details) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2022 EUR (€) subsidiary | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2019 EUR (€) | ||
Company Information [Abstract] | |||||
Net loss for the period | € 58,103 | € 52,809 | € 63,984 | [1] | |
Total equity | € 54,151 | € 107,440 | € 155,976 | € 217,416 | |
Number of subsidiaries | subsidiary | 1 | ||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
The company - 2014 Novo Nordisk
The company - 2014 Novo Nordisk A/S monalizumab &greement (Details) € / shares in Units, € in Thousands, $ in Millions | 1 Months Ended | 12 Months Ended | ||||||
Feb. 05, 2014 EUR (€) € / shares shares | Apr. 30, 2016 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2019 EUR (€) | Dec. 31, 2018 EUR (€) | Dec. 31, 2018 USD ($) | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||
Purchase of intangible assets | € 587 | € 401 | € 10,375 | |||||
Total financial liabilities | 42,251 | 44,251 | 19,087 | € 18,723 | ||||
Intangible assets | 1,556 | € 44,192 | € 46,289 | € 96,968 | ||||
2014 Novo Nordisk A/S monalizumab agreement | ||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||
Purchase of intangible assets | € 2,000 | € 6,500 | ||||||
Shares issued for the acquisition of C5aR intangible asset (in shares) | shares | 600,000 | |||||||
Share issued, price per share (in EUR per share) | € / shares | € 8.33 | |||||||
Issue shares for licenses | € 5,000 | |||||||
Maximum potential regulatory milestones and single-digit tiered royalties on sale of products | 20,000 | |||||||
Total financial liabilities | € 13,100 | $ 15 | ||||||
Intangible assets | € 7,000 | € 1,600 |
The company - 2015 AstraZeneca
The company - 2015 AstraZeneca monalizumab agreements (Details) - 2015 monalizumab agreement, with AstraZeneca € in Thousands, $ in Thousands | 1 Months Ended | 12 Months Ended | |||||||||
Aug. 01, 2022 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2022 EUR (€) | Jun. 17, 2022 USD ($) | Jun. 17, 2022 EUR (€) | Dec. 07, 2020 USD ($) | Dec. 07, 2020 EUR (€) | Sep. 30, 2020 USD ($) | Jan. 31, 2019 USD ($) | Jun. 30, 2015 USD ($) | Dec. 31, 2022 USD ($) | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||||||
Receipts from co-development agreement and option agreement | $ 250,000 | ||||||||||
Receipts from co-development agreement | 100,000 | ||||||||||
Receipts from option agreement | 150,000 | ||||||||||
Proceeds from exercise of option agreement | $ 100,000 | ||||||||||
Maximum potential regulatory milestones | 100,000 | ||||||||||
Milestone payment received | $ 50,000 | € 47,700 | $ 50,000 | € 47,700 | $ 50,000 | € 41,227 | $ 50,000 | ||||
Additional milestones payment receivable | $ 50,000 | ||||||||||
Additional milestones payment, not eligible | $ 50,000 | ||||||||||
Maximum amount receivable from counter party upon achievement of certain milestones | 775,000 | ||||||||||
Development and regulatory milestones | 350,000 | ||||||||||
Commercialization milestones | $ 425,000 | ||||||||||
Co-fund percentage of trials of licensed product | 30% | ||||||||||
Percentage of profits in Europe | 50% |
The company - Agreement related
The company - Agreement related to Lumoxiti with AstraZeneca (Details) - Lumoxiti, with AstraZeneca € in Millions, $ in Millions | 1 Months Ended | |||||||
Apr. 30, 2022 USD ($) | Apr. 30, 2022 USD ($) | Apr. 30, 2022 EUR (€) | Jan. 31, 2020 USD ($) | Jan. 31, 2020 EUR (€) | Jan. 31, 2019 USD ($) | Jan. 31, 2019 EUR (€) | Dec. 31, 2020 USD ($) | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||
Payments for licenses | $ 15 | € 13.4 | $ 50 | € 43.8 | ||||
Payments for manufacturing costs | $ 6.2 | $ 6.2 | € 5.9 | |||||
Manufacturing costs split | ||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||
Estimated financial effect of contingent liabilities | $ 12.8 |
The company - Agreement relat_2
The company - Agreement related to IPH5201 with AstraZeneca (Details) € in Thousands, $ in Millions | 1 Months Ended | 4 Months Ended | 12 Months Ended | ||||||||||
Aug. 02, 2022 EUR (€) | Aug. 02, 2022 USD ($) | Jun. 01, 2022 USD ($) | Jun. 30, 2020 USD ($) | Jan. 31, 2019 USD ($) | Oct. 31, 2018 USD ($) | Jan. 31, 2019 USD ($) | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2020 USD ($) | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||||||||
Revenue from collaboration and licensing agreements | € | € 49,580 | € 12,112 | € 56,155 | [1] | |||||||||
IPH5201 agreement, with AstraZeneca | |||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||||||||
Receipts from co-development agreement and option agreement | $ 24 | $ 26 | $ 50 | ||||||||||
Milestone payment received | € 4,900 | $ 5 | $ 5 | $ 5 | 4,700 | $ 5 | |||||||
Maximum amount receivable from counter party upon achievement of certain development milestones | 5 | ||||||||||||
Option exercise fee payable by counter party | 25 | ||||||||||||
Maximum amount receivable from counter party upon achievement of certain milestones | 800 | ||||||||||||
Development and regulatory milestones | 300 | ||||||||||||
Commercialization milestones | $ 500 | ||||||||||||
Percentage of profits in Europe | 50% | ||||||||||||
Revenue from collaboration and licensing agreements | € | € 4,677 | € 0 | € 13,418 | ||||||||||
Co-fund percentage of trials of licensed product | 30% | ||||||||||||
IPH5201 agreement, with AstraZeneca, initial payment | |||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||||||||
Revenue from collaboration and licensing agreements | $ 50 | ||||||||||||
IPH5201 agreement, with AstraZeneca, milestone payment | |||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||||||||
Revenue from collaboration and licensing agreements | $ 5 | ||||||||||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
The company - Agreement relat_3
The company - Agreement related to additional preclinical molecules with AstraZeneca (Details) € in Thousands, $ in Thousands | 1 Months Ended | 5 Months Ended | 12 Months Ended | ||||||
Jun. 30, 2022 EUR (€) | Jun. 30, 2022 USD ($) | Oct. 31, 2018 EUR (€) option | Oct. 31, 2018 USD ($) option | Jun. 01, 2022 preclinicalMolecules | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | [1] | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||||
Number of preclinical molecules | preclinicalMolecules | 4 | ||||||||
Revenue from collaboration and licensing agreements | € | € 49,580 | € 12,112 | € 56,155 | ||||||
Agreement related to additional preclinical molecules with AstraZeneca | |||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||||
Number of exclusive options granted | option | 4 | 4 | |||||||
Advance received | € 17,400 | $ 20,000 | |||||||
Revenue from collaboration and licensing agreements | € 17,400 | $ 20,000 | |||||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
The company - Agreements relate
The company - Agreements related to avdoralimab with Novo Nordisk and with AstraZeneca (Details) - IPH5201 agreement, with AstraZeneca - EUR (€) € in Millions | 1 Months Ended | |
Oct. 31, 2020 | Jul. 31, 2017 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Upfront payment | € 40 | |
Upfront payment, shares issued | 37.2 | |
Upfront payment, cash | 2.8 | |
Payments for milestone | € 1 | |
Maximum payments to counter party upon achievement of certain milestones | € 369 |
The company - Collaboration and
The company - Collaboration and license agreements concluded with Sanofi for the development of "NK Cell engages" in oncology (Details) € in Millions, $ in Millions | 1 Months Ended | 6 Months Ended | |||||
Dec. 19, 2022 EUR (€) | Sep. 09, 2022 EUR (€) | Jan. 05, 2021 USD ($) | Mar. 31, 2023 EUR (€) | Dec. 31, 2021 USD ($) | Jan. 31, 2016 USD ($) Agreements | Jun. 30, 2022 EUR (€) | |
Agreements with Sanofi for NK Cell engages | |||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Number of agreement with Sanofi | Agreements | 2 | ||||||
Maximum amount receivable from counter party upon achievement of certain milestones | $ | $ 400 | ||||||
Milestone payment received | € 3 | $ 7 | $ 3 | € 3 | |||
Agreements with Genzyme for NK Cell engages | |||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Maximum amount receivable from counter party upon achievement of certain milestones | € 1,350 | ||||||
Milestone payment received | € 25 |
The company - Key events (Detai
The company - Key events (Details) € / shares in Units, $ in Thousands | 1 Months Ended | 5 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
Dec. 16, 2022 EUR (€) € / shares | Nov. 07, 2022 EUR (€) shares € / shares | Sep. 09, 2022 EUR (€) | Aug. 31, 2022 EUR (€) loan | Aug. 02, 2022 EUR (€) | Aug. 02, 2022 USD ($) | Jul. 27, 2022 EUR (€) shares € / shares | Jul. 25, 2022 EUR (€) | Jul. 13, 2022 EUR (€) shares € / shares | Jun. 30, 2022 EUR (€) | Jun. 30, 2022 USD ($) | Jun. 17, 2022 EUR (€) | Jun. 17, 2022 USD ($) | Jun. 01, 2022 USD ($) | Apr. 22, 2022 EUR (€) shares € / shares | Feb. 14, 2022 EUR (€) shares € / shares | Dec. 31, 2021 EUR (€) € / shares | Aug. 06, 2021 EUR (€) € / shares | Jul. 07, 2021 EUR (€) € / shares | Jun. 04, 2021 EUR (€) € / shares | Jan. 05, 2021 USD ($) | Dec. 07, 2020 EUR (€) | Dec. 07, 2020 USD ($) | Jul. 13, 2020 EUR (€) € / shares | Jul. 07, 2020 EUR (€) € / shares | Jan. 27, 2020 EUR (€) € / shares | Jan. 15, 2020 EUR (€) € / shares | Dec. 31, 2022 EUR (€) shares | Aug. 31, 2022 EUR (€) loan | Dec. 31, 2021 USD ($) | Jun. 30, 2020 USD ($) | Oct. 31, 2018 EUR (€) | Oct. 31, 2018 USD ($) | Jun. 01, 2022 preclinicalMolecules | Jun. 30, 2022 EUR (€) | Dec. 31, 2022 EUR (€) shares | Dec. 31, 2022 USD ($) shares | Dec. 31, 2021 EUR (€) shares € / shares | Dec. 31, 2020 EUR (€) shares € / shares | Dec. 31, 2022 € / shares | Dec. 31, 2022 loan | Dec. 31, 2022 loan_agreement | Jul. 22, 2021 € / shares | Jul. 19, 2021 € / shares | Sep. 24, 2020 € / shares | Sep. 11, 2020 € / shares | Dec. 31, 2019 € / shares | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 202,000 | € 499,000 | € 47,000 | |||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 185,280 | |||||||||||||||||||||||||||||||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0 | € 0.05 | € 0.05 | |||||||||||||||||||||||||||
Provisions | € 900,000 | € 1,740,000 | 1,740,000 | € 900,000 | € 897,000 | |||||||||||||||||||||||||||||||||||||||||||
Number of preclinical molecules | preclinicalMolecules | 4 | |||||||||||||||||||||||||||||||||||||||||||||||
Total revenue and other income | 57,674,000 | 24,703,000 | 69,773,000 | [1] | ||||||||||||||||||||||||||||||||||||||||||||
Impairment of intangible assets | 41,000,000 | € 0 | € 0 | [1] | ||||||||||||||||||||||||||||||||||||||||||||
Provision for taxes other than income tax [member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Provisions | € 1,270,000 | € 1,270,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Common shares | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||
Exercise of share warrants | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||
PGE loan agreement, Societe Generale and BNP Paribas | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Notional amount | € 28,700,000 | € 28,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Borrowing, number of loan agreement | 2 | 2 | 2 | 2 | ||||||||||||||||||||||||||||||||||||||||||||
Borrowing, maturity | 5 years | 5 years | 5 years | |||||||||||||||||||||||||||||||||||||||||||||
Borrowing, grace period | 1 year | |||||||||||||||||||||||||||||||||||||||||||||||
PGE loan agreement, Societe Generale | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Notional amount | € 20,000,000 | € 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Borrowing, maturity | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||
Borrowings, interest rate | 1.56% | 1.56% | ||||||||||||||||||||||||||||||||||||||||||||||
Number of loans | loan | 2 | |||||||||||||||||||||||||||||||||||||||||||||||
PGE loan agreement, BNP Paribas | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Notional amount | € 8,700,000 | € 8,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Borrowings, interest rate | 0.95% | 0.95% | ||||||||||||||||||||||||||||||||||||||||||||||
2015 monalizumab agreement, with AstraZeneca | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Milestone payment received | € 47,700,000 | $ 50,000 | € 47,700,000 | $ 50,000 | € 41,227,000 | $ 50,000 | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||
IPH5201 agreement, with AstraZeneca | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Milestone payment received | € 4,900,000 | $ 5,000 | $ 5,000 | $ 5,000 | € 4,700,000 | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||
Agreement related to additional preclinical molecules with AstraZeneca | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Milestone payment received | € 17,400,000 | $ 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Advance received | € 17,400,000 | $ 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Total revenue and other income | € 17,400,000 | $ 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Agreements with Sanofi for NK Cell engages | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Milestone payment received | € 3,000,000 | $ 7,000 | $ 3,000 | € 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||
BSAAR 2012 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 86,700 | 86,700 | 85,950 | 85,950 | ||||||||||||||||||||||||||||||||||||||||||||
AGA New Members 2017-1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 25,000 | 25,000 | 25,000 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||
AGA Bonus 2021-1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 125,748 | 125,748 | 125,748 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
AGA Perf Employees 2019-1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 15,952.5 | |||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 147,500 | |||||||||||||||||||||||||||||||||||||||||||||||
Free performances shares plans, performance (in percents) | 50% | |||||||||||||||||||||||||||||||||||||||||||||||
AGA Perf Management 2019-1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 171,550 | |||||||||||||||||||||||||||||||||||||||||||||||
Free performances shares plans, performance (in percents) | 50% | |||||||||||||||||||||||||||||||||||||||||||||||
AGA Perf Employees 2022-1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 1,371,500 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
AGA Bonus 2020-2 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 13,614 | |||||||||||||||||||||||||||||||||||||||||||||||
AGA Perf Management 2022-1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 550,000 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
Common shares | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 319,050 | 125,748 | 13,614 | 25,000 | 46,320 | |||||||||||||||||||||||||||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||
Common shares | Exercise of share warrants | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 750 | |||||||||||||||||||||||||||||||||||||||||||||||
Free Shares | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 138,960 | |||||||||||||||||||||||||||||||||||||||||||||||
Share issued, price per share (in EUR per share) | € / shares | € 4.10 | |||||||||||||||||||||||||||||||||||||||||||||||
Share premium | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 9,995 | € (6,287) | € (681) | € (1,250) | € 182,141 | (10,656) | € 398,000 | € 7,637 | € 59,700 | € (2,869) | € 43,000 | € (4,283) | € 2,985 | € 168,000 | € 471,000 | € 38,000 | ||||||||||||||||||||||||||||||||
Share premium | Common shares | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | 187,596 | |||||||||||||||||||||||||||||||||||||||||||||||
Share premium | Exercise of share warrants | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | 1,493 | |||||||||||||||||||||||||||||||||||||||||||||||
Share premium | Common shares | Exercise of share warrants | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | 1,492.5 | |||||||||||||||||||||||||||||||||||||||||||||||
Share premium | Free Shares | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | 180,648 | |||||||||||||||||||||||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 0 | € 6,287.7 | € 6,287 | € 680.70 | € 1,250 | 9,301.5 | € 10,656 | € 10,000 | € 222 | € 1,500 | € 2,869 | € 1,250 | € 4,283 | € 75 | € 34,000 | € 28,000 | € 9,000 | |||||||||||||||||||||||||||||||
Share capital | Common shares | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | 2,316 | |||||||||||||||||||||||||||||||||||||||||||||||
Share capital | Exercise of share warrants | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 38 | |||||||||||||||||||||||||||||||||||||||||||||||
Issued Capital Free Of Subscription | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | shares | 138,960 | |||||||||||||||||||||||||||||||||||||||||||||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Accounting policies and state_4
Accounting policies and statement of compliance - Additional Information (Details) - EUR (€) | 12 Months Ended | 53 Months Ended | ||||
Mar. 24, 2016 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | [1] | Dec. 31, 2022 | |
Disclosure of initial application of standards or interpretations [Line Items] | ||||||
Defined contribution plan, contribution percentage | 2.20% | |||||
Defined contribution plan, contribution percentage by employer | 1.40% | |||||
Defined contribution plan, contribution percentage by employee | 0.80% | |||||
Other long term benefits, years of service, threshold one | 10 years | 10 years | ||||
Other long term benefits, years of service, threshold two | 15 years | 15 years | ||||
Other long term benefits, years of service, threshold three | 20 years | 20 years | ||||
Percentage of work to be performed | 94.50% | 94.50% | ||||
Impairment of intangible assets | € 41,000,000 | € 0 | € 0 | |||
PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S | ||||||
Disclosure of initial application of standards or interpretations [Line Items] | ||||||
Impairment of intangible assets | 41,000,000 | € 0 | ||||
Other intangible assets | ||||||
Disclosure of initial application of standards or interpretations [Line Items] | ||||||
Impairment of intangible assets | € 0 | |||||
Other intangible assets | Bottom of range | ||||||
Disclosure of initial application of standards or interpretations [Line Items] | ||||||
Amortisation period, intangible assets other than goodwill | 1 year | |||||
Other intangible assets | Top of range | ||||||
Disclosure of initial application of standards or interpretations [Line Items] | ||||||
Amortisation period, intangible assets other than goodwill | 3 years | |||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Accounting policies and state_5
Accounting policies and statement of compliance - Disclosure of Effect of Changes in Foreign Exchange Rates (Details) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Significant Accounting Policies [Abstract] | |||
Average rate (€1 equals to USD) | 1.0530 | 1.1827 | 1.1422 |
Closing rate (€1 equals to USD) | 1.0666 | 1.1326 | 1.2271 |
Accounting policies and state_6
Accounting policies and statement of compliance - Disclosure of Depreciation Periods (Details) | 12 Months Ended |
Dec. 31, 2022 | |
Buildings and improvements on buildings | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |
Depreciation period, property, plant and equipment | 20 years |
Buildings and improvements on buildings | Top of range | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |
Depreciation period, property, plant and equipment | 40 years |
Installations | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |
Depreciation period, property, plant and equipment | 5 years |
Installations | Top of range | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |
Depreciation period, property, plant and equipment | 20 years |
Technical installations and equipment | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |
Depreciation period, property, plant and equipment | 8 years |
Equipment and office furniture | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |
Depreciation period, property, plant and equipment | 5 years |
Computers and IT equipment | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |
Depreciation period, property, plant and equipment | 3 years |
Management of financial risks_2
Management of financial risks and fair value (Details) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) loan | Dec. 31, 2020 EUR (€) | |
Disclosure of detailed information about financial instruments [line items] | |||
Cash, cash equivalents and short-term investments | € | € 101,485 | € 119,836 | € 151,637 |
Percentage of revenue denominated in US dollars | 92% | 78% | 88% |
Percentage of payments in US dollars | 50% | 50% | 48% |
State Guaranteed Loans | |||
Disclosure of detailed information about financial instruments [line items] | |||
Borrowing, number of loan agreement | loan | 2 |
Cash, cash equivalents and fi_3
Cash, cash equivalents and financial assets - Disclosure of Cash, Cash Equivalents and Financial Assets (Details) - EUR (€) € in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Subclassifications of assets, liabilities and equities [abstract] | ||||
Cash and cash equivalents | € 84,225 | € 103,756 | € 136,792 | € 202,887 |
Short-term investments | 17,260 | 16,080 | 14,845 | |
Cash and cash equivalents and short-term investments | 101,485 | 119,836 | 151,637 | |
Non-current financial assets | 35,119 | 39,878 | 38,934 | |
Total cash, cash equivalents and financial assets | € 136,604 | € 159,714 | € 190,570 |
Cash, cash equivalents and fi_4
Cash, cash equivalents and financial assets - Additional Information (Details) - EUR (€) € in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of financial assets [Line Items] | |||
Cash, cash equivalents and financial assets | € 136,604 | € 159,714 | € 190,570 |
Cash, cash equivalents, and financial assets denominated in US dollars | |||
Disclosure of financial assets [Line Items] | |||
Cash, cash equivalents and financial assets | € 34,735 | € 47,164 | € 64,654 |
Cash, cash equivalents and fi_5
Cash, cash equivalents and financial assets - Disclosure of Reconciliation of Changes in Loss Allowance and Explanation of Changes in Gross Carrying Amount for Financial Instruments (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Subclassifications of assets, liabilities and equities [abstract] | ||
Beginning balance, current investments | € 16,080 | € 14,845 |
Short-term investments, acquisitions | 0 | 0 |
Short-term investments, disposals | 0 | 0 |
Short-term investments, variation of fair value through the consolidated statement of income (loss) | 268 | 99 |
Short-term investments, variation of accrued interest | 0 | 0 |
Short-term investments, foreign currency effect | 912 | 1,136 |
Ending balance, current investments | 17,260 | 16,080 |
Beginning balance, non-current financial assets | 39,878 | 38,934 |
Non-current financial assets, acquisitions | 0 | 0 |
Non-current financial assets, disposals | (3,000) | 0 |
Non-current financial assets, variation of fair value through the consolidated statement of income (loss) | (1,640) | 888 |
Non-current financial assets, variation of accrued interest | (118) | 55 |
Non-current financial assets, foreign currency effect | 0 | 0 |
Ending balance, non-current financial assets | 35,119 | 39,878 |
Beginning balance, total | 55,958 | 53,779 |
Total, acquisitions | 0 | 0 |
Total, disposals | (3,000) | 0 |
Total, variation of fair value through the consolidated statement of income (loss) | (1,372) | 987 |
Total, variance of accrued interest | (118) | 55 |
Total, foreign currency effect | 912 | 1,136 |
Ending balance, total | € 52,379 | € 55,958 |
Trade receivables and others (D
Trade receivables and others (Details) € in Thousands | 12 Months Ended | ||||||
Aug. 31, 2022 loan | Dec. 31, 2022 EUR (€) loan | Dec. 31, 2021 EUR (€) | Dec. 31, 2019 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 loan_agreement | Dec. 31, 2020 EUR (€) | |
Disclosure of financial assets [Line Items] | |||||||
Other receivables | € 814 | € 61 | € 741 | ||||
Research tax credit | 10,310 | 25,904 | 0 | ||||
Other tax credits | 333 | 361 | 333 | ||||
Prepaid expenses | 2,582 | 4,672 | 6,833 | ||||
VAT refund | 1,170 | 1,614 | 2,208 | ||||
Trade account receivables | 846 | 3,080 | 10,585 | ||||
Prepayments made to suppliers | 2,364 | 2,652 | 1,114 | ||||
Receivables and others - current | 18,420 | 38,345 | 21,815 | ||||
Research tax credit | 29,821 | 13,018 | 29,821 | ||||
Prepaid expenses | 0 | 1,081 | 0 | ||||
Receivables and others - non-current | 29,821 | 14,099 | 29,821 | ||||
Trade receivables and others - excluding rebate related to capital expenditures | 48,241 | 52,445 | 51,635 | ||||
Income from research tax credit 2021 | € 10,302 | ||||||
Income from research tax credit 2022 | € 9,167 | ||||||
Income from research tax credit 2019 | € 16,737 | ||||||
Income from research tax credit 2019, maturity | 3 years | ||||||
2015 monalizumab agreement, with AstraZeneca | |||||||
Disclosure of financial assets [Line Items] | |||||||
Trade account receivables | 1,775 | ||||||
IPH5201 agreement, with AstraZeneca | |||||||
Disclosure of financial assets [Line Items] | |||||||
Trade account receivables | 1,303 | ||||||
IPH6101 agreement, with Sanofi | |||||||
Disclosure of financial assets [Line Items] | |||||||
VAT refund | 1,400 | ||||||
Trade account receivables | € 8,400 | ||||||
PGE loan agreement, Societe Generale and BNP Paribas | |||||||
Disclosure of financial assets [Line Items] | |||||||
Borrowing, number of loan agreement | 2 | 2 | 2 | ||||
Borrowing, maturity | 5 years | 5 years | |||||
Guarantees [member] | |||||||
Disclosure of financial assets [Line Items] | |||||||
Prepaid expenses | € 1,256 |
Intangible assets - Disclosure
Intangible assets - Disclosure of Detailed Information about Intangible Assets (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 53 Months Ended | ||||||||
Oct. 31, 2022 EUR (€) | Jan. 31, 2022 EUR (€) | Oct. 31, 2020 EUR (€) | Jun. 30, 2020 EUR (€) | Apr. 30, 2020 EUR (€) | Jun. 30, 2019 EUR (€) | Jun. 30, 2020 EUR (€) payment | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2022 EUR (€) | ||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Intangible assets other than goodwill at beginning of period | € 44,192,000 | € 44,192,000 | € 46,289,000 | € 96,968,000 | ||||||||
Acquisitions | 0 | 13,000 | 264,000 | |||||||||
Additional considerations | 587,000 | 368,000 | 3,685,000 | |||||||||
Disposals | 0 | (39,000) | 0 | |||||||||
Depreciation | (2,224,000) | (2,440,000) | (11,099,000) | |||||||||
Impairment of intangible assets | (41,000,000) | 0 | 0 | [1] | ||||||||
Transfers | 0 | 0 | 0 | |||||||||
Intangible assets other than goodwill at end of period | 1,556,000 | 44,192,000 | 46,289,000 | € 1,556,000 | ||||||||
Discontinued operations | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Impairment of intangible assets | 0 | 0 | (43,529,000) | |||||||||
IPH5201 (Anti-CD39) rights acquired from Orega Biotech | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Intangible assets other than goodwill at beginning of period | 1,800,000 | 1,800,000 | ||||||||||
Additional considerations | € 600,000 | 400,000 | € 200,000 | € 2,500,000 | € 7,000,000 | |||||||
Intangible assets other than goodwill at end of period | 1,800,000 | |||||||||||
Lumoxiti, with AstraZeneca | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Intangible assets other than goodwill at beginning of period | 47,276,000 | |||||||||||
Depreciation | (3,746,000) | |||||||||||
Impairment of intangible assets | (43,529,000) | |||||||||||
of which monalizumab agreement - AstraZeneca | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Depreciation | (1,604,000) | (1,942,000) | (2,844,000) | |||||||||
IPH5201 | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Depreciation | (587,000) | (368,000) | (4,314,000) | |||||||||
Agreement with Orega Biotech | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Additional considerations | € 185,000 | € 2,500,000 | € 2,685,000 | |||||||||
Number of additional payment | payment | 2 | |||||||||||
2014 Novo Nordisk A/S monalizumab agreement | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Additional considerations | € 1,000,000 | |||||||||||
Intangible assets other than goodwill at end of period | 1,600,000 | 1,600,000 | ||||||||||
PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Impairment of intangible assets | (41,000,000) | 0 | ||||||||||
Purchased licenses | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Intangible assets other than goodwill at beginning of period | 3,161,000 | 3,161,000 | 5,103,000 | 56,851,000 | ||||||||
Acquisitions | 0 | 0 | 0 | |||||||||
Additional considerations | 587,000 | 368,000 | 2,685,000 | |||||||||
Disposals | 0 | 0 | 0 | |||||||||
Depreciation | (2,195,000) | (2,310,000) | (10,904,000) | |||||||||
Impairment of intangible assets | 0 | |||||||||||
Transfers | 0 | 0 | 0 | |||||||||
Intangible assets other than goodwill at end of period | 1,553,000 | 3,161,000 | 5,103,000 | 1,553,000 | ||||||||
Purchased licenses | Discontinued operations | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Impairment of intangible assets | (43,529,000) | |||||||||||
Other intangible assets | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Intangible assets other than goodwill at beginning of period | 29,000 | 29,000 | 185,000 | 116,000 | ||||||||
Acquisitions | 13,000 | 264,000 | ||||||||||
Additional considerations | 0 | 0 | 0 | |||||||||
Disposals | (39,000) | 0 | ||||||||||
Depreciation | (29,000) | (130,000) | (195,000) | |||||||||
Impairment of intangible assets | 0 | |||||||||||
Transfers | 0 | 0 | 0 | |||||||||
Intangible assets other than goodwill at end of period | 0 | 29,000 | 185,000 | 0 | ||||||||
Other intangible assets | Discontinued operations | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Impairment of intangible assets | 0 | |||||||||||
In progress | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Intangible assets other than goodwill at beginning of period | € 41,000,000 | 41,000,000 | 41,000,000 | 40,000,000 | ||||||||
Acquisitions | 0 | 0 | 0 | |||||||||
Additional considerations | 0 | 0 | 1,000,000 | |||||||||
Disposals | 0 | 0 | 0 | |||||||||
Depreciation | 0 | 0 | 0 | |||||||||
Impairment of intangible assets | (41,000,000) | |||||||||||
Transfers | 0 | 0 | 0 | |||||||||
Intangible assets other than goodwill at end of period | € 0 | € 41,000,000 | 41,000,000 | € 0 | ||||||||
In progress | Discontinued operations | ||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||
Impairment of intangible assets | € 0 | |||||||||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Intangible assets - Additional
Intangible assets - Additional Information (Details) $ in Thousands | 1 Months Ended | 12 Months Ended | 53 Months Ended | |||||||||||||||||||||
Aug. 02, 2022 EUR (€) | Aug. 02, 2022 USD ($) | Jun. 01, 2022 USD ($) | Oct. 31, 2022 EUR (€) | Jan. 31, 2022 EUR (€) | Oct. 31, 2020 EUR (€) | Jun. 30, 2020 EUR (€) | Jun. 30, 2020 USD ($) | Apr. 30, 2020 EUR (€) | Jun. 30, 2019 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2018 EUR (€) | Dec. 31, 2018 USD ($) | Dec. 31, 2015 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 EUR (€) | Jul. 31, 2017 EUR (€) | Feb. 05, 2014 EUR (€) | ||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||||||||||||||
Intangible assets other than goodwill | € 1,556,000 | € 44,192,000 | € 46,289,000 | € 1,556,000 | € 96,968,000 | |||||||||||||||||||
Purchase of intangible assets | 587,000 | 401,000 | 10,375,000 | |||||||||||||||||||||
Additional considerations | 587,000 | 368,000 | 3,685,000 | |||||||||||||||||||||
Impairment of intangible assets | 41,000,000 | 0 | 0 | [1] | ||||||||||||||||||||
Financial liabilities | 42,251,000 | 44,251,000 | 19,087,000 | 42,251,000 | 18,723,000 | |||||||||||||||||||
Trade and other payables | 20,911,000 | 28,573,000 | 29,519,000 | 20,911,000 | ||||||||||||||||||||
Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement | ||||||||||||||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||||||||||||||
Intangible assets other than goodwill | 1,551,000 | 3,155,000 | 1,551,000 | € 7,000,000 | ||||||||||||||||||||
Purchase of intangible assets | € 13,050,000 | $ 15,000 | € 6,325,000 | |||||||||||||||||||||
IPH5201 (Anti-CD39) rights acquired from Orega Biotech | ||||||||||||||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||||||||||||||
Intangible assets other than goodwill | 1,800,000 | |||||||||||||||||||||||
Additional considerations | € 600,000 | € 400,000 | € 200,000 | € 2,500,000 | € 7,000,000 | |||||||||||||||||||
Licensing agreement, maximum milestone payment | 48,200,000 | |||||||||||||||||||||||
PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S | ||||||||||||||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||||||||||||||
Intangible assets other than goodwill | € 40,000,000 | |||||||||||||||||||||||
Payments for milestone | € 1,000,000 | |||||||||||||||||||||||
Impairment of intangible assets | 41,000,000 | 0 | ||||||||||||||||||||||
Financial liabilities | 0 | € 0 | ||||||||||||||||||||||
Lumoxiti, with AstraZeneca | ||||||||||||||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||||||||||||||
Intangible assets other than goodwill | € 47,276,000 | |||||||||||||||||||||||
Impairment of intangible assets | € 43,529,000 | |||||||||||||||||||||||
Trade and other payables | € 5,474,000 | $ 6,200 | ||||||||||||||||||||||
Lumoxiti, with AstraZeneca | Manufacturing costs split | ||||||||||||||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||||||||||||||
Estimated financial effect of contingent liabilities | $ | $ 12,800 | |||||||||||||||||||||||
IPH5201 agreement, with AstraZeneca | ||||||||||||||||||||||||
Disclosure of detailed information about intangible assets [line items] | ||||||||||||||||||||||||
Milestone payment received | € 4,900,000 | $ 5,000 | $ 5,000 | $ 5,000 | € 4,700,000 | $ 5,000 | ||||||||||||||||||
Payments for milestone | € 1,000,000 | |||||||||||||||||||||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Property and equipment (Details
Property and equipment (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about property, plant and equipment [Line Items] | |||
Property, plant and equipment at beginning of period | € 10,174 | € 11,694 | € 11,672 |
Acquisitions | 556 | 998 | 2,228 |
Disposals | (17) | (7) | (9) |
Transfers | 0 | (357) | 0 |
Depreciation | (2,171) | (2,154) | (2,197) |
Property, plant and equipment at end of period | 8,542 | 10,174 | 11,694 |
Right-of-use assets | |||
Disclosure of detailed information about property, plant and equipment [Line Items] | |||
Property, plant and equipment at beginning of period | 6,423 | 6,423 | 6,270 |
Acquisitions | 0 | 0 | 1,195 |
Disposals | 0 | 0 | 0 |
Transfers | 0 | 0 | (1,042) |
Depreciation | 0 | 0 | 0 |
Property, plant and equipment at end of period | 6,423 | 6,423 | 6,423 |
Land and buildings | |||
Disclosure of detailed information about property, plant and equipment [Line Items] | |||
Property, plant and equipment at beginning of period | 4,981 | 5,751 | 5,356 |
Acquisitions | 20 | 11 | 1,152 |
Disposals | 0 | ||
Transfers | 0 | 0 | |
Depreciation | (759) | (781) | (757) |
Property, plant and equipment at end of period | 4,242 | 4,981 | 5,751 |
Laboratory equipment and other | |||
Disclosure of detailed information about property, plant and equipment [Line Items] | |||
Property, plant and equipment at beginning of period | 5,187 | 5,576 | 5,947 |
Acquisitions | 535 | 987 | 944 |
Disposals | (11) | (7) | (9) |
Transfers | 0 | 4 | 134 |
Depreciation | (1,413) | (1,373) | (1,440) |
Property, plant and equipment at end of period | 4,298 | 5,187 | 5,576 |
In progress | |||
Disclosure of detailed information about property, plant and equipment [Line Items] | |||
Property, plant and equipment at beginning of period | 6 | 367 | 369 |
Acquisitions | 0 | 132 | |
Disposals | (6) | 0 | 0 |
Transfers | 0 | (361) | (134) |
Depreciation | 0 | 0 | |
Property, plant and equipment at end of period | € 0 | € 6 | € 367 |
Trade payables and others (Deta
Trade payables and others (Details) € in Thousands, $ in Thousands | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 loan | Dec. 31, 2022 loan_agreement | Aug. 31, 2022 loan | Dec. 31, 2021 EUR (€) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 EUR (€) |
Disclosure Of Detailed Information About Trade Payables And Others [Line Items] | |||||||
Suppliers (excluding payables related to capital expenditures) | € 13,656 | € 14,729 | € 20,730 | ||||
Tax and employee-related payables | 5,978 | 7,463 | 8,325 | ||||
Other payables | 1,260 | 6,380 | 463 | ||||
Trade payables and others excluding payables related to capital expenditures | 20,894 | 28,573 | 29,519 | ||||
Payables related to capital expenditures | 17 | 0 | 20 | ||||
Payables and others | 20,911 | 28,573 | 29,539 | ||||
Trade and other payables | € 20,911 | 28,573 | € 29,519 | ||||
PGE loan agreement, Societe Generale and BNP Paribas | |||||||
Disclosure Of Detailed Information About Trade Payables And Others [Line Items] | |||||||
Borrowing, number of loan agreement | 2 | 2 | 2 | ||||
Lumoxiti, with AstraZeneca | |||||||
Disclosure Of Detailed Information About Trade Payables And Others [Line Items] | |||||||
Trade and other payables | € 5,474 | $ 6,200 |
Financial liabilities - Disclos
Financial liabilities - Disclosure of Financial Liabilities Per Maturity (Details) € in Thousands | 1 Months Ended | 12 Months Ended | ||||||||
Jan. 05, 2022 EUR (€) loan_agreement | Aug. 11, 2020 EUR (€) installment | Aug. 30, 2019 EUR (€) | Aug. 31, 2022 EUR (€) loan | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2018 EUR (€) | Jul. 03, 2017 EUR (€) | Dec. 31, 2013 EUR (€) | |
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | € 44,251 | € 19,087 | € 18,723 | |||||||
Proceeds from borrowings | 0 | 28,700 | 1,360 | |||||||
Proceeds from lease liabilities and other non cash effects | 42 | (1,408) | 1,249 | |||||||
Repayments of borrowings and lease liabilities | (2,042) | (2,128) | (2,245) | |||||||
Financial liabilities at end of period | 42,251 | 44,251 | 19,087 | |||||||
Financial liabilities | 42,251 | 44,251 | 19,087 | |||||||
Current prepaid expenses | 4,672 | 2,582 | 6,833 | |||||||
Guarantees [member] | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Current prepaid expenses | 1,256 | |||||||||
PGE loan agreement, Societe Generale | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Notional amount | € 20,000 | |||||||||
Borrowing, maturity | 4 years | |||||||||
Borrowings, interest rate | 1.56% | |||||||||
Number of loans | loan | 2 | |||||||||
PGE loan agreement, Societe Generale | Guarantees [member] | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Current prepaid expenses | € 877 | |||||||||
PGE loan agreement, BNP Paribas | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Notional amount | € 8,700 | |||||||||
Borrowings, interest rate | 0.95% | |||||||||
PGE loan agreement, BNP Paribas | Guarantees [member] | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Current prepaid expenses | € 379 | |||||||||
BPI PTZI IPH41 | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 0 | 150 | 450 | |||||||
Proceeds from borrowings | 0 | 0 | ||||||||
Proceeds from lease liabilities and other non cash effects | 0 | |||||||||
Repayments of borrowings and lease liabilities | (150) | (300) | ||||||||
Financial liabilities at end of period | 0 | 150 | ||||||||
Financial liabilities | 0 | 150 | ||||||||
BPI Refundable advance - FORCE | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 0 | 1,454 | 0 | |||||||
Proceeds from borrowings | 0 | 1,360 | ||||||||
Proceeds from lease liabilities and other non cash effects | (1,454) | 94 | ||||||||
Repayments of borrowings and lease liabilities | 0 | 0 | ||||||||
Financial liabilities at end of period | 0 | 1,454 | ||||||||
Financial liabilities | 0 | 1,454 | ||||||||
Notional amount | € 6,800 | |||||||||
Financing agreement, number of instalments | installment | 4 | |||||||||
Financing agreement, funding in tranche | € 1,700 | |||||||||
Financing agreement, remaining number of instalments | installment | 3 | |||||||||
Repayable advance received | 1,454 | |||||||||
PGE loan agreement, Societe Generale | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 20,000 | 0 | ||||||||
Proceeds from borrowings | 0 | 20,000 | ||||||||
Proceeds from lease liabilities and other non cash effects | 0 | 0 | ||||||||
Repayments of borrowings and lease liabilities | 0 | 0 | ||||||||
Financial liabilities at end of period | 20,000 | 20,000 | 0 | |||||||
Financial liabilities | 20,000 | 20,000 | 0 | |||||||
Notional amount | € 20,000 | |||||||||
PGE loan agreement, BNP Paribas | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 8,700 | 0 | ||||||||
Proceeds from borrowings | 0 | 8,700 | ||||||||
Proceeds from lease liabilities and other non cash effects | 0 | 0 | ||||||||
Repayments of borrowings and lease liabilities | 0 | 0 | ||||||||
Financial liabilities at end of period | 8,700 | 8,700 | 0 | |||||||
Financial liabilities | 8,700 | 8,700 | 0 | |||||||
Notional amount | 8,700 | |||||||||
State guaranteed loans - accrued interest | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 0 | |||||||||
Proceeds from borrowings | 0 | |||||||||
Proceeds from lease liabilities and other non cash effects | 15 | |||||||||
Repayments of borrowings and lease liabilities | 0 | |||||||||
Financial liabilities at end of period | 15 | 0 | ||||||||
Financial liabilities | 15 | 0 | ||||||||
Lease liabilities – Real estate property | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 0 | 418 | ||||||||
Proceeds from borrowings | 0 | |||||||||
Proceeds from lease liabilities and other non cash effects | 0 | |||||||||
Repayments of borrowings and lease liabilities | (418) | |||||||||
Financial liabilities at end of period | 0 | |||||||||
Financial liabilities | 0 | |||||||||
Property transaction (down-payment) | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities down payment at beginning of period | 0 | (74) | ||||||||
Proceeds from borrowings | 0 | |||||||||
Proceeds from lease liabilities and other non cash effects | 0 | |||||||||
Repayments of borrowings, down payment | 74 | |||||||||
Financial liabilities down payment at end of period | 0 | |||||||||
Lease liabilities – Building "Le Virage" | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 1,875 | 2,387 | 1,437 | |||||||
Proceeds from borrowings | 0 | 0 | 0 | |||||||
Proceeds from lease liabilities and other non cash effects | 0 | 0 | 1,114 | |||||||
Repayments of borrowings and lease liabilities | (522) | (512) | (164) | |||||||
Financial liabilities at end of period | 1,353 | 1,875 | 2,387 | |||||||
Financial liabilities | 1,353 | 1,875 | 2,387 | |||||||
Lease liabilities – Premises Innate Inc | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 391 | 447 | 496 | |||||||
Proceeds from borrowings | 0 | 0 | 0 | |||||||
Proceeds from lease liabilities and other non cash effects | 15 | (16) | 0 | |||||||
Repayments of borrowings and lease liabilities | (61) | (40) | (49) | |||||||
Financial liabilities at end of period | 345 | 391 | 447 | |||||||
Financial liabilities | 345 | 391 | 447 | |||||||
Lease liabilities – Laboratory equipment | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 464 | 639 | 815 | |||||||
Proceeds from borrowings | 0 | 0 | 0 | |||||||
Proceeds from lease liabilities and other non cash effects | 0 | 0 | 0 | |||||||
Repayments of borrowings and lease liabilities | (177) | (175) | (176) | |||||||
Financial liabilities at end of period | 287 | 464 | 639 | |||||||
Financial liabilities | 287 | 464 | 639 | |||||||
Lease liabilities – Vehicles | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 53 | 21 | 37 | |||||||
Proceeds from borrowings | 0 | 0 | 0 | |||||||
Proceeds from lease liabilities and other non cash effects | 12 | 62 | 0 | |||||||
Repayments of borrowings and lease liabilities | (32) | (30) | (16) | |||||||
Financial liabilities at end of period | 33 | 53 | 21 | |||||||
Financial liabilities | 33 | 53 | 21 | |||||||
Lease liabilities - Printers | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 35 | 41 | 0 | |||||||
Proceeds from borrowings | 0 | 0 | ||||||||
Proceeds from lease liabilities and other non cash effects | 0 | 0 | 41 | |||||||
Repayments of borrowings and lease liabilities | (8) | (6) | 0 | |||||||
Financial liabilities at end of period | 27 | 35 | 41 | |||||||
Financial liabilities | 27 | 35 | 41 | |||||||
Loans – Equipment | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 209 | 262 | 319 | |||||||
Proceeds from borrowings | 0 | 0 | 0 | |||||||
Proceeds from lease liabilities and other non cash effects | 0 | 0 | 0 | |||||||
Repayments of borrowings and lease liabilities | (55) | (53) | (57) | |||||||
Financial liabilities at end of period | 154 | 209 | 262 | |||||||
Financial liabilities | 154 | 209 | 262 | |||||||
Loans - Building | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | 12,525 | 13,687 | 14,826 | |||||||
Proceeds from borrowings | 0 | 0 | ||||||||
Proceeds from lease liabilities and other non cash effects | 0 | 0 | 0 | |||||||
Repayments of borrowings and lease liabilities | (1,187) | (1,162) | (1,139) | |||||||
Financial liabilities at end of period | 12,525 | 13,687 | ||||||||
Financial liabilities | € 12,525 | 13,687 | ||||||||
Loan agreement with Société Générale | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities at beginning of period | € 1,300 | |||||||||
Proceeds from borrowings | € 13,900 | |||||||||
Financial liabilities at end of period | 11,338 | |||||||||
Financial liabilities | € 11,338 | € 1,300 | ||||||||
Loan agreement, maximum borrowing capacity | € 15,200 | |||||||||
Interest-free loan for innovation | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Financial liabilities | € 1,500 | |||||||||
PGE loan agreement, Societe Generale and BNP Paribas | ||||||||||
Disclosure of financial liabilities [Line Items] | ||||||||||
Notional amount | € 28,700 | |||||||||
Borrowing, number of loan agreement | loan_agreement | 2 | |||||||||
Borrowing, maturity | 1 year | |||||||||
Borrowing, maturity, extension period option | 5 years | |||||||||
Borrowing, percentage of state-guaranteed loan | 90% |
Financial liabilities - Additio
Financial liabilities - Additional Information (Details) - EUR (€) € in Thousands | 12 Months Ended | ||||||
Aug. 30, 2019 | Jul. 03, 2017 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Disclosure of financial liabilities [Line Items] | |||||||
Proceeds from borrowings | € 0 | € 28,700 | € 1,360 | ||||
Financial liabilities | 42,251 | € 44,251 | € 19,087 | € 18,723 | |||
Loan agreement with Société Générale | |||||||
Disclosure of financial liabilities [Line Items] | |||||||
Loan agreement, collateral | € 15,200 | ||||||
Proceeds from borrowings | € 13,900 | ||||||
Borrowings, maturity period | 12 years | ||||||
Financial liabilities | € 11,338 | € 1,300 | € 1,300 | ||||
Security interest on pledge of financial instruments will be released in 2024 | 4,200 | ||||||
Security interest on pledge of financial instruments will be released in 2027 | 5,000 | ||||||
Security interest on pledge of financial instruments will be released in 2031 | € 6,000 | ||||||
Loan agreement with Société Générale | Fixed interest rate | |||||||
Disclosure of financial liabilities [Line Items] | |||||||
Borrowings, interest rate | 2.01% |
Financial liabilities - Discl_2
Financial liabilities - Disclosure of Schedule for the Contractual Flows of Financial Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | € 2,102 | € 30,748 | € 2,142 |
Financial liabilities – non-current portion | 40,149 | 13,503 | 16,945 |
BPI PTZI IPH41 | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 0 | 0 | 150 |
Financial liabilities – non-current portion | 0 | 0 | 0 |
BPI Refundable advance - FORCE | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 0 | 0 | 0 |
Financial liabilities – non-current portion | 0 | 0 | 1,454 |
State guaranteed loan Société Générale | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 0 | 20,000 | 0 |
Financial liabilities – non-current portion | 20,000 | 0 | 0 |
State guaranteed loan BNP Paribas | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 0 | 8,700 | 0 |
Financial liabilities – non-current portion | 8,700 | 0 | 0 |
State guaranteed loans - accrued interest | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 15 | 0 | 0 |
Financial liabilities – non-current portion | 0 | 0 | 0 |
Lease finance obligations – Rent Le Virage | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 532 | 522 | 511 |
Financial liabilities – non-current portion | 820 | 1,352 | 1,876 |
Lease liabilities – Premises Innate Inc | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 90 | 74 | 72 |
Financial liabilities – non-current portion | 255 | 317 | 375 |
Lease finance obligations – Laboratory equipment | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 177 | 177 | 175 |
Financial liabilities – non-current portion | 110 | 287 | 463 |
Lease liabilities – Vehicles | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 16 | 23 | 13 |
Financial liabilities – non-current portion | 17 | 30 | 8 |
Lease liabilities - Printers | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 9 | 8 | 6 |
Financial liabilities – non-current portion | 18 | 26 | 35 |
Loans – Equipment | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 55 | 55 | 55 |
Financial liabilities – non-current portion | 99 | 154 | 208 |
Loans - Building | |||
Disclosure of financial liabilities [Line Items] | |||
Financial liabilities – current portion | 1,210 | 1,187 | 1,161 |
Financial liabilities – non-current portion | € 10,128 | € 11,338 | € 12,526 |
Financial liabilities - Discl_3
Financial liabilities - Disclosure of Maturity Analysis for Non-Derivative Financial Liabilities (Details) € in Thousands | Dec. 31, 2022 EUR (€) |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | € 44,528 |
≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 2,758 |
2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 36,658 |
≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 5,112 |
State guaranteed loan Société Générale | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 20,982 |
State guaranteed loan Société Générale | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 312 |
State guaranteed loan Société Générale | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 20,670 |
State guaranteed loan Société Générale | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
State guaranteed loan BNP Paribas | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 8,970 |
State guaranteed loan BNP Paribas | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 86 |
State guaranteed loan BNP Paribas | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 8,884 |
State guaranteed loan BNP Paribas | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
State guaranteed loans - accrued interest | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 15 |
State guaranteed loans - accrued interest | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 15 |
State guaranteed loans - accrued interest | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
State guaranteed loans - accrued interest | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
Lease finance obligations – Rent Le Virage | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 1,396 |
Lease finance obligations – Rent Le Virage | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 558 |
Lease finance obligations – Rent Le Virage | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 838 |
Lease finance obligations – Rent Le Virage | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
Lease liabilities – Premises Innate Inc | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 408 |
Lease liabilities – Premises Innate Inc | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 96 |
Lease liabilities – Premises Innate Inc | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 312 |
Lease liabilities – Premises Innate Inc | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
Lease liabilities – Laboratory equipment | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 289 |
Lease liabilities – Laboratory equipment | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 179 |
Lease liabilities – Laboratory equipment | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 110 |
Lease liabilities – Laboratory equipment | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
Lease liabilities – Vehicles | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 39 |
Lease liabilities – Vehicles | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 19 |
Lease liabilities – Vehicles | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 20 |
Lease liabilities – Vehicles | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
Lease liabilities - Printers | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 27 |
Lease liabilities - Printers | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 9 |
Lease liabilities - Printers | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 18 |
Lease liabilities - Printers | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
Loans – Equipment | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 157 |
Loans – Equipment | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 57 |
Loans – Equipment | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 100 |
Loans – Equipment | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 0 |
Loans - Building | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 12,245 |
Loans - Building | ≤ 1 year | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 1,427 |
Loans - Building | 2 to 5 years included | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | 5,706 |
Loans - Building | ≥ 5 years | |
Disclosure of financial liabilities [Line Items] | |
Undiscounted cash flows | € 5,112 |
Employee benefits - Disclosure
Employee benefits - Disclosure of Defined Benefit Plans (Details) - EUR (€) € in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of defined benefit plans [line items] | |||
Defined benefit obligations | € 2,550 | € 2,975 | € 4,177 |
Allowance for retirement defined benefit | |||
Disclosure of defined benefit plans [line items] | |||
Defined benefit obligations | 2,184 | 2,544 | 3,713 |
Allowance for seniority awards | |||
Disclosure of defined benefit plans [line items] | |||
Defined benefit obligations | € 366 | € 432 | € 463 |
Employee benefits - Additional
Employee benefits - Additional Information (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Mar. 24, 2016 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of defined benefit plans [line items] | ||||
Other long term benefits, years of service, threshold two | 15 years | 15 years | ||
Other long term benefits, years of service, threshold three | 20 years | 20 years | ||
Other long term benefits, years of service, threshold one | 10 years | 10 years | ||
Defined benefit obligation, at present value | € 2,550 | € 2,975 | € 4,177 | |
Increase (decrease) in employee benefit obligation per 50 basis point changes in discount rate | 174 | |||
Post-employment benefit expense, defined contribution plans | 1,432 | 1,434 | 1,420 | |
Allowance for seniority awards | ||||
Disclosure of defined benefit plans [line items] | ||||
Defined benefit obligation, at present value | € 366 | € 432 | € 463 |
Employee benefits - Disclosur_2
Employee benefits - Disclosure of Actuarial Assumptions for Defined Benefit Plans (Details) - Allowance for retirement defined benefit | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of defined benefit plans [line items] | |||
Discount rate (iBoxx Corporate AA) for retirement | 3.75% | 0.95% | 0.50% |
Annual rate of increase in wages | 4% | 3% | 3% |
Annual mobility rate | 4.30% | 4.20% | 2.60% |
Rate of contributions | 47.07% | 48.39% | 45.17% |
Rate of wages costs | 23.46% | 24.18% | 22.06% |
16-24 years | 12% | 12% | 6% |
25-29 years | 10% | 9% | 5% |
30-34 years | 7% | 7% | 3.70% |
35-39 years | 5% | 4.50% | 3% |
40-44 years | 3% | 3% | 2% |
45-49 years | 1.50% | 1.50% | 1% |
+50 years | 0% | 0% | 0% |
Executives | |||
Disclosure of defined benefit plans [line items] | |||
Age at retirement | 64 years | 64 years | 64 years |
Non-executives | |||
Disclosure of defined benefit plans [line items] | |||
Age at retirement | 62 years | 62 years | 62 years |
Employee benefits - Disclosur_3
Employee benefits - Disclosure of Net Defined Benefit Liability (Asset) (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of defined benefit plans [line items] | |||
Net defined benefit liability (asset) at beginning of period | € 2,976 | € 4,177 | € 3,760 |
Service cost | 427 | 484 | 252 |
Interest costs | (62) | (47) | (35) |
Actuarial (loss) gain | (790) | (584) | 200 |
Net defined benefit liability (asset) at end of period | 2,550 | 2,976 | 4,177 |
Decrease in net defined benefit liability | 2,550 | 2,976 | 4,177 |
Increase (decrease) due to changes in accounting policy required by IFRSs | |||
Disclosure of defined benefit plans [line items] | |||
Net defined benefit liability (asset) at beginning of period | € (1,054) | ||
Net defined benefit liability (asset) at end of period | (1,054) | (1,054) | |
Decrease in net defined benefit liability | € (1,054) | € (1,054) |
Share capital and share based_3
Share capital and share based payments - Additional Information (Details) | 12 Months Ended | |||||||||||||||||||||
Nov. 07, 2022 shares € / shares | Jul. 27, 2022 shares € / shares | Jul. 13, 2022 shares € / shares | Apr. 22, 2022 shares € / shares | Feb. 14, 2022 shares | Jan. 03, 2022 shares | Dec. 31, 2022 EUR (€) shares € / shares | Dec. 31, 2021 EUR (€) shares € / shares | Dec. 31, 2020 EUR (€) shares € / shares | Dec. 16, 2022 € / shares | Aug. 06, 2021 € / shares | Jul. 22, 2021 € / shares | Jul. 19, 2021 € / shares | Jul. 07, 2021 € / shares | Jun. 04, 2021 € / shares | Sep. 24, 2020 € / shares | Sep. 11, 2020 € / shares | Jul. 13, 2020 € / shares | Jul. 07, 2020 € / shares | Jan. 27, 2020 € / shares | Jan. 15, 2020 € / shares | Dec. 31, 2019 € / shares shares | |
Disclosure of changes in the share capital | ||||||||||||||||||||||
Share capital | € | € 4,011,308 | € 3,978,000 | € 3,950,000 | |||||||||||||||||||
Number of shares outstanding | 79,542,627 | |||||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | ||
Total number of shares issued (in shares) | 80,226,164 | 79,556,722 | 79,000,952 | 78,825,621 | ||||||||||||||||||
Number of own shares | 18,575 | |||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 4,249,000 | € 2,617,000 | € 2,475,000 | |||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 185,280 | |||||||||||||||||||||
AGA Employee 2017 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 110,500 | 110,500 | 110,500 | |||||||||||||||||||
AGA Perf Management 2018 / AGA Perf Employees 2018 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 0 | € (232,000) | € 618,000 | |||||||||||||||||||
Performance conditions threshold | 55% | |||||||||||||||||||||
AGA Perf Employees 2018-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 103,125 | |||||||||||||||||||||
AGA Perf Management 2018-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 110,000 | |||||||||||||||||||||
AGA 2018-1 Employees | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | 0 | 0 | 23,000 | |||||||||||||||||||
AGAP Management 2017-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 0 | € 71,000 | € 43,000 | |||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||
AGAP Employee 2019 / AGAP Management 2019 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € (181,000) | € 649,000 | € 867,000 | |||||||||||||||||||
AGA Bonus 2019-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 0 | € 0 | € 0 | |||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 57,376 | 57,376 | 57,376 | |||||||||||||||||||
AGA Perf Employees 2020-1 / AGA Perf Management 2020 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Revenue from collaboration and licensing agreements, minimum accrual between attribution and definitive acquisition date | € | € 100,000,000 | |||||||||||||||||||||
AGAP Employee 2020 / AGAP Management 2020 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | 1,738,000 | € 1,253,000 | € 502,000 | |||||||||||||||||||
AGA Bonus 2020-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 0 | € 0 | € 394,000 | |||||||||||||||||||
Percentage of premium increased | 30% | |||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 61,976 | 48,362 | 0 | |||||||||||||||||||
AGAP Employee 2021 / AGAP Management 2021 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 1,577,000 | € 473,000 | € 0 | |||||||||||||||||||
AGA Bonus 2021-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 0 | € 432,000 | € 0 | |||||||||||||||||||
Percentge of annual variable compensation | 50% | |||||||||||||||||||||
Percentage of premium increased | 50% | |||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 125,748 | 125,748 | 0 | |||||||||||||||||||
BSAAR | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 750 | 230,000 | 1,500 | |||||||||||||||||||
Share-based payment transactions with employees, awards, expected term (year) | 10 years | |||||||||||||||||||||
AGA Perf Management 2019-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Performance conditions threshold | 50% | |||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 171,550 | |||||||||||||||||||||
AGA Bonus 2022-1 | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Expense from share-based payment transactions with employees | € | € 499,000 | € 0 | € 0 | |||||||||||||||||||
Percentge of annual variable compensation | 50% | |||||||||||||||||||||
Percentage of premium increased | 50% | |||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | |||||||||||||||||||||
Common shares | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Number of shares outstanding | 80,212,069 | 79,542,627 | 78,986,490 | 78,811,114 | ||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0.05 | |||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 319,050 | 125,748 | 13,614 | 25,000 | 46,320 | |||||||||||||||||
2016 free preferred shares | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0.05 | |||||||||||||||||||||
Total number of shares issued (in shares) | 6,881 | |||||||||||||||||||||
2017 free preferred shares | ||||||||||||||||||||||
Disclosure of changes in the share capital | ||||||||||||||||||||||
Par value per share (in EUR per share) | € / shares | € 0.05 | |||||||||||||||||||||
Total number of shares issued (in shares) | 7,581 |
Share capital and share based_4
Share capital and share based payments - Disclosure of Changes in Share Capital (Details) - EUR (€) | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2022 | Dec. 16, 2022 | Nov. 07, 2022 | Jul. 27, 2022 | Jul. 25, 2022 | Jul. 13, 2022 | Apr. 22, 2022 | Feb. 14, 2022 | Dec. 31, 2021 | Aug. 06, 2021 | Jul. 22, 2021 | Jul. 19, 2021 | Jul. 07, 2021 | Jun. 04, 2021 | Dec. 31, 2020 | Sep. 24, 2020 | Sep. 11, 2020 | Jul. 13, 2020 | Jul. 07, 2020 | Jan. 27, 2020 | Jan. 15, 2020 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Balance at beginning of period | € 107,440,000 | € 155,976,000 | € 217,416,000 | ||||||||||||||||||||||
Nominal value (in EUR per share) | € 0.05 | € 0 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | € 0.05 | ||
Exercise and subscription of equity instruments | € 202,000 | € 499,000 | € 47,000 | ||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 669,442 | 555,770 | 175,331 | ||||||||||||||||||||||
Increase (decrease) through share-based payment transactions, equity | € 4,249,000 | € 2,617,000 | € 2,476,000 | ||||||||||||||||||||||
Balance at end of period | € 54,151,000 | € 107,440,000 | € 155,976,000 | € 54,151,000 | € 107,440,000 | 155,976,000 | |||||||||||||||||||
Balance at end of period (in shares) | 79,542,627 | 79,542,627 | |||||||||||||||||||||||
Proceeds from issuing shares | 621,000 | ||||||||||||||||||||||||
Payments for the issuing of shares | € 2,150,000 | ||||||||||||||||||||||||
Exercise of share warrants | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Nominal value (in EUR per share) | € 0.05 | ||||||||||||||||||||||||
Definitive Acquisition Of Free Shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Nominal value (in EUR per share) | 0.05 | ||||||||||||||||||||||||
Common shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Nominal value (in EUR per share) | € 0.05 | ||||||||||||||||||||||||
Common shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Balance at beginning of period (in shares) | 79,542,627 | 78,986,490 | 78,811,114 | ||||||||||||||||||||||
Nominal value (in EUR per share) | € 0.05 | € 0.05 | |||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 0 | 125,748 | 13,614 | 25,000 | 213,125 | 200,000 | 4,440 | 30,000 | 57,376 | 25,000 | 85,650 | 1,500 | |||||||||||||
Exercise and subscription of equity instruments through conversion (in shares) | 319,050 | 36,660 | 11,050 | 650 | 4,550 | 650 | |||||||||||||||||||
Balance at end of period (in shares) | 80,212,069 | 79,542,627 | 78,986,490 | 80,212,069 | 79,542,627 | 78,986,490 | |||||||||||||||||||
Common shares | Exercise of share warrants | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 750 | ||||||||||||||||||||||||
Common shares | Definitive Acquisition Of Free Shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 138,960 | ||||||||||||||||||||||||
Common shares | Common shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 46,320 | ||||||||||||||||||||||||
Common shares | AGA Bonus Management 2020-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 48,362 | ||||||||||||||||||||||||
Common shares | AGA Bonus Management 2021-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 12,500 | ||||||||||||||||||||||||
Preferred shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Balance at beginning of period (in shares) | 14,095 | 14,462 | 14,507 | ||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||
Exercise and subscription of equity instruments through conversion (in shares) | 0 | (282) | (85) | (5) | (35) | (5) | |||||||||||||||||||
Balance at end of period (in shares) | 14,095 | 14,095 | 14,462 | 14,095 | 14,095 | 14,462 | |||||||||||||||||||
Preferred shares | Exercise of share warrants | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 0 | ||||||||||||||||||||||||
Preferred shares | Definitive Acquisition Of Free Shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 0 | ||||||||||||||||||||||||
Preferred shares | Common shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 0 | ||||||||||||||||||||||||
Preferred shares | AGA Bonus Management 2020-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 0 | ||||||||||||||||||||||||
Preferred shares | AGA Bonus Management 2021-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments (in shares) | 0 | ||||||||||||||||||||||||
Share capital | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Balance at beginning of period | € 3,977,836 | € 3,950,048 | € 3,941,281 | ||||||||||||||||||||||
Exercise and subscription of equity instruments | € 0 | € 6,287.7 | € 6,287 | € 680.70 | € 1,250 | € 9,301.5 | € 10,656 | € 10,000 | € 222 | € 1,500 | € 2,869 | € 1,250 | € 4,283 | € 75 | 34,000 | 28,000 | 9,000 | ||||||||
Exercise and subscription of equity instruments through conversion | € 15,953 | 1,819 | € 548 | € 32 | € 226 | € 32 | |||||||||||||||||||
Increase (decrease) through share-based payment transactions, equity | € 0 | 0 | 0 | ||||||||||||||||||||||
Balance at end of period | 4,011,308 | 3,977,836 | 3,950,048 | 4,011,308 | 3,977,836 | 3,950,048 | |||||||||||||||||||
Share capital | Exercise of share warrants | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | 38 | ||||||||||||||||||||||||
Share capital | Definitive Acquisition Of Free Shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | 6,948 | ||||||||||||||||||||||||
Share capital | Common shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | 2,316 | ||||||||||||||||||||||||
Share capital | AGA Bonus Management 2020-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 2,418 | ||||||||||||||||||||||||
Share capital | AGA Bonus Management 2021-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | 625 | ||||||||||||||||||||||||
Share premium | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Balance at beginning of period | 375,219,667 | 372,130,982 | 369,617,017 | ||||||||||||||||||||||
Exercise and subscription of equity instruments | € 9,995 | € (6,287) | € (681) | € (1,250) | 182,141 | (10,656) | € 398,000 | € 7,637 | € 59,700 | € (2,869) | € 43,000 | € (4,283) | € 2,985 | 168,000 | 471,000 | 38,000 | |||||||||
Exercise and subscription of equity instruments through conversion | € (15,953) | (1,819) | € (548) | (32) | € (226) | € (32) | |||||||||||||||||||
Increase (decrease) through share-based payment transactions, equity | 4,249,113 | 2,617,289 | 2,475,422 | 4,249,000 | 2,617,000 | 2,476,000 | |||||||||||||||||||
Balance at end of period | € 379,636,744 | € 375,219,667 | € 372,130,982 | € 379,636,744 | € 375,219,667 | € 372,130,982 | |||||||||||||||||||
Share premium | Exercise of share warrants | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | 1,493 | ||||||||||||||||||||||||
Share premium | Definitive Acquisition Of Free Shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | (6,948) | ||||||||||||||||||||||||
Share premium | Common shares | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | 187,596 | ||||||||||||||||||||||||
Share premium | AGA Bonus Management 2020-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | (2,418) | ||||||||||||||||||||||||
Share premium | AGA Bonus Management 2021-1 | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 21,500 | ||||||||||||||||||||||||
Share premium | Common shares | Exercise of share warrants | |||||||||||||||||||||||||
Disclosure of changes in the share capital | |||||||||||||||||||||||||
Exercise and subscription of equity instruments | € 1,492.5 |
Share capital and share based_5
Share capital and share based payments - Disclosure of Number and Weighted Average Exercise Prices of Other Equity Instruments (Details) | 1 Months Ended | 12 Months Ended | ||||||||||||||||||||||||
Dec. 16, 2022 shares | Dec. 12, 2022 shares | Oct. 03, 2022 shares | Jul. 27, 2022 shares | Apr. 22, 2022 shares | Feb. 14, 2022 shares | Feb. 12, 2022 shares | Oct. 01, 2021 shares | Jul. 22, 2021 shares | Aug. 05, 2020 shares | Jul. 13, 2020 shares | Jul. 03, 2019 shares | Apr. 29, 2019 shares | Jan. 14, 2019 shares | Apr. 03, 2018 shares | Sep. 20, 2017 shares | Dec. 30, 2016 shares | Oct. 21, 2016 shares | Jul. 01, 2015 shares | Apr. 27, 2015 shares | Jul. 16, 2014 shares | Jul. 17, 2013 shares | Dec. 31, 2022 shares € / shares | Dec. 31, 2022 shares € / shares | Dec. 31, 2021 shares € / shares | Dec. 31, 2020 shares € / shares | |
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 185,280 | |||||||||||||||||||||||||
Warrant | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 10,428,877 | 8,200,356 | 6,398,008 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 1,711,671 | 1,112,601 | 418,263 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 2,684,141 | 2,061,019 | 1,552,225 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 6,033,065 | 6,033,065 | 5,026,736 | 4,427,520 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 6,784,637 | 6,784,637 | 5,778,308 | 5,869,143 | ||||||||||||||||||||||
BSAAR 2011 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 650,000 | 650,000 | 650,000 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 25,000 | 25,000 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 625,000 | 625,000 | 395,000 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 255,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 255,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 2.04 | € 2.04 | € 2.04 | € 2.04 | ||||||||||||||||||||||
BSAAR 2012 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 146,050 | 146,050 | 146,050 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 86,700 | 85,950 | 85,950 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 59,350 | 59,350 | 60,100 | 60,100 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 59,350 | 59,350 | 60,100 | 60,100 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 2.04 | € 2.04 | € 2.04 | € 2.04 | ||||||||||||||||||||||
BSAAR 2015 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 1,050,382 | 1,050,382 | 1,050,382 | 1,050,382 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 2,720 | 2,720 | 2,720 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 1,940 | 1,940 | 1,940 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 1,045,722 | 1,045,722 | 1,045,722 | 1,045,722 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 1,045,722 | 1,045,722 | 1,045,722 | 1,045,722 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 7.20 | € 7.20 | € 7.20 | € 7.20 | ||||||||||||||||||||||
AGAP Management 2016-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 2,000 | 2,000 | 2,000 | 2,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 550 | 550 | 550 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 250 | 250 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 1,200 | 1,200 | 1,200 | 1,450 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 156,000 | 156,000 | 156,000 | 188,500 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP Employees 2016-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 2,486 | 2,486 | 2,486 | 2,486 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 251 | 251 | 251 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 167 | 167 | 50 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 2,068 | 2,068 | 2,068 | 2,185 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 268,840 | 268,840 | 268,840 | 284,050 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Management 2016-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 50,000 | 50,000 | 50,000 | 50,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP Management 2016-2 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 3,000 | 3,000 | 3,000 | 3,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 3,000 | 3,000 | 3,000 | 3,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 333,000 | 333,000 | 333,000 | 333,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Management 2016-2 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 250,000 | 250,000 | 250,000 | 250,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 250,000 | 250,000 | 250,000 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP Employees 2017-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 5,725 | 5,725 | 5,725 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 5,725 | 5,725 | 833 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 4,892 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 489,200 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP Management 2017-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 2,400 | 2,400 | 2,400 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 2,400 | 2,400 | 800 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 1,600 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 160,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Employee 2017 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 28,556 | 114,500 | 114,500 | 114,500 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 4,000 | 4,000 | 4,000 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 110,500 | 110,500 | 110,500 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Employees 2018 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 90,650 | 67,028 | 67,028 | 67,028 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 469 | 469 | 469 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 66,559 | 66,559 | 66,559 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP Perf Employees 2018-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 327,500 | 327,500 | 327,500 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 224,375 | 224,375 | 85,000 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 103,125 | 103,125 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 242,500 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 242,500 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP Perf Management 2018-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 260,000 | 260,000 | 260,000 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 150,000 | 150,000 | 60,000 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 110,000 | 110,000 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 200,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 200,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Employees 2018 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 90,650 | 90,650 | 90,650 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 5,000 | 5,000 | 5,000 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 85,650 | 85,650 | 85,650 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA New Members 2017-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 25,000 | 25,000 | 25,000 | 25,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 25,000 | 25,000 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 25,000 | 25,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 25,000 | 25,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Bonus 2019-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 57,376 | 57,376 | 57,376 | 57,376 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 57,376 | 57,376 | 57,376 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP 2019 Employees 2019 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 546,700 | 546,700 | 546,700 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 375,150 | 189,900 | 86,100 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 171,550 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 356,800 | 460,600 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 356,800 | 460,600 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGAP 2019 Management 2019 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 355,000 | 355,000 | 355,000 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 207,500 | 30,000 | 30,000 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 147,500 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 325,000 | 325,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 325,000 | 325,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Bonus 2020-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 79,861 | 79,861 | 79,861 | 79,861 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 17,885 | 17,885 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 61,976 | 48,362 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 13,614 | 79,861 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 13,614 | 79,861 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Perf Employees 2020-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 769,202 | 766,650 | 766,650 | 766,650 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 286,306 | 249,826 | 70,540 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 480,344 | 480,344 | 516,824 | 696,110 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 480,344 | 480,344 | 516,824 | 696,110 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Perf Management 2020-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 710,000 | 710,000 | 710,000 | 710,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 60,000 | 30,000 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 650,000 | 650,000 | 680,000 | 710,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 650,000 | 650,000 | 680,000 | 710,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
AGA Bonus 2021-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 125,748 | 125,748 | 125,748 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | ||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 125,748 | 125,748 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 125,748 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 125,748 | |||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | |||||||||||||||||||||||
AGA Perf Employees 2021-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 1,066,600 | 1,066,600 | 1,066,600 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 95,600 | 17,500 | ||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | ||||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 971,000 | 971,000 | 1,049,100 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 971,000 | 971,000 | 1,049,100 | |||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | |||||||||||||||||||||||
AGA Perf Management 2021-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 610,000 | 610,000 | 610,000 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 90,000 | 30,000 | ||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | ||||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 520,000 | 520,000 | 580,000 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 520,000 | 520,000 | 580,000 | |||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | |||||||||||||||||||||||
AGA "Plan Epargne Entreprise" 2022 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 138,960 | 138,960 | ||||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | |||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 138,960 | |||||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | ||||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | ||||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | ||||||||||||||||||||||||
AGA Bonus 2022-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 128,061 | 128,061 | ||||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | |||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | |||||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 128,061 | 128,061 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 128,061 | 128,061 | ||||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | ||||||||||||||||||||||||
AGA Perf Employees 2022-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 1,371,500 | 1,371,500 | ||||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | |||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 1,371,500 | 0 | ||||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 1,371,500 | 1,371,500 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 1,371,500 | 1,371,500 | ||||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | ||||||||||||||||||||||||
AGA Perf Management 2022-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 550,000 | 550,000 | ||||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | |||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 550,000 | 0 | ||||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 550,000 | 550,000 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 550,000 | 550,000 | ||||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | ||||||||||||||||||||||||
Stock Options 2020-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 102,000 | 102,000 | 102,000 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 102,000 | 102,000 | 72,000 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 30,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 30,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 0 | € 0 | € 0 | € 0 | ||||||||||||||||||||||
BSA 2011-2 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 225,000 | 225,000 | 225,000 | |||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 25,000 | 25,000 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 200,000 | 200,000 | 183,060 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 0 | 0 | 0 | 41,940 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 0 | 0 | 0 | 41,940 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 1.77 | € 1.77 | € 1.77 | € 1.77 | ||||||||||||||||||||||
BSA 2013 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 237,500 | 237,500 | 237,500 | 237,500 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 191,140 | 191,140 | 191,140 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 46,360 | 46,360 | 46,360 | 46,360 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 46,360 | 46,360 | 46,360 | 46,360 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 2.36 | € 2.36 | € 2.36 | € 2.36 | ||||||||||||||||||||||
BSA 2014 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 150,000 | 150,000 | 150,000 | 150,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 75,000 | 75,000 | 75,000 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 75,000 | 75,000 | 75,000 | 75,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 75,000 | 75,000 | 75,000 | 75,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 8.65 | € 8.65 | € 8.65 | € 8.65 | ||||||||||||||||||||||
BSA 2015-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 70,000 | 70,000 | 70,000 | 70,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 70,000 | 70,000 | 70,000 | 70,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 70,000 | 70,000 | 70,000 | 70,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 9.59 | € 9.59 | € 9.59 | € 9.59 | ||||||||||||||||||||||
BSA 2015-2 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 14,200 | 14,200 | 14,200 | 14,200 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 14,200 | 14,200 | 14,200 | 14,200 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 14,200 | 14,200 | 14,200 | 14,200 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 14.05 | € 14.05 | € 14.05 | € 14.05 | ||||||||||||||||||||||
BSA 2017 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 37,000 | 37,000 | 37,000 | 37,000 | ||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 37,000 | 37,000 | 37,000 | 37,000 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 37,000 | 37,000 | 37,000 | 37,000 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 11 | € 11 | € 11 | € 11 | ||||||||||||||||||||||
BSA 2022-1 | ||||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||||||||
Number of free shares granted (in shares) | 40,000 | 40,000 | ||||||||||||||||||||||||
Number of other equity instruments forfeited in share-based payment arrangement (in shares) | 31,740 | |||||||||||||||||||||||||
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | 0 | |||||||||||||||||||||||||
Number of other equity instruments outstanding in share-based payment arrangement (in shares) | 8,260 | 8,260 | 0 | 0 | ||||||||||||||||||||||
Number of other equity instruments exercisable in share-based payment arrangement (in shares) | 8,260 | 8,260 | 0 | 0 | ||||||||||||||||||||||
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares | € 2.31 | € 2.31 |
Share capital and share based_6
Share capital and share based payments - Disclosure of Terms and Conditions of Other Equity Instruments (Details) | 12 Months Ended | |||||||||||||||||||
Dec. 12, 2022 EUR (€) shares € / shares | Oct. 03, 2022 EUR (€) shares € / shares | Feb. 12, 2022 EUR (€) shares € / shares | Oct. 01, 2021 EUR (€) shares € / shares | Jul. 22, 2021 EUR (€) shares € / shares | Aug. 05, 2020 EUR (€) shares € / shares | Jul. 13, 2020 EUR (€) shares € / shares | Nov. 04, 2019 EUR (€) shares € / shares | Jul. 03, 2019 EUR (€) shares € / shares | Apr. 29, 2019 EUR (€) shares € / shares | Jan. 14, 2019 EUR (€) shares € / shares | Nov. 20, 2018 EUR (€) shares € / shares | Jul. 03, 2018 EUR (€) shares € / shares | Apr. 03, 2018 EUR (€) shares € / shares | Sep. 20, 2017 EUR (€) shares € / shares | Dec. 30, 2016 EUR (€) shares € / shares | Oct. 21, 2016 EUR (€) shares € / shares | Dec. 31, 2022 shares | Dec. 31, 2021 shares | Dec. 31, 2020 shares | |
AGAP Management 2016-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 2,000 | 2,000 | 2,000 | 2,000 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 130 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 10.87 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 5% | |||||||||||||||||||
Volatility | 40% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 911 | |||||||||||||||||||
AGAP Employees 2016-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 2,486 | 2,486 | 2,486 | 2,486 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 130 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 10.87 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 5% | |||||||||||||||||||
Volatility | 40% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 911 | |||||||||||||||||||
AGA Management 2016-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 50,000 | 50,000 | 50,000 | 50,000 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 10.87 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 10.55 | |||||||||||||||||||
AGA Employees 2016-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 99,932 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 10.87 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 5% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 10.55 | |||||||||||||||||||
AGAP Management 2016-2 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 3,000 | 3,000 | 3,000 | 3,000 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 111 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 12.73 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 9% | |||||||||||||||||||
Volatility | 40% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 956 | |||||||||||||||||||
AGA Management 2016-2 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 250,000 | 250,000 | 250,000 | 250,000 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 12.73 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 14.61 | |||||||||||||||||||
AGA Employees 2016-2 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 149,943 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 12.73 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 5% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 10.55 | |||||||||||||||||||
AGA Bonus 2017 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 114,500 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 5.52 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 4% | |||||||||||||||||||
Volatility | 55% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 5.83 | |||||||||||||||||||
AGA Employee 2017 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 28,556 | 114,500 | 114,500 | 114,500 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 10.90 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 10.30 | |||||||||||||||||||
AGAP Employees 2017-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 5,725 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 100 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 5.52 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 5% | |||||||||||||||||||
Volatility | 55% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 90 | |||||||||||||||||||
AGAP Management 2017 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 2,400 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 100 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 5.52 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 11% | |||||||||||||||||||
Volatility | 55% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 90 | |||||||||||||||||||
AGA Bonus 2018 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 67,028 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 5.06 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 4.69 | |||||||||||||||||||
AGA Perf Employees 2018 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 327,500 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 8 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 4% | |||||||||||||||||||
Volatility | 45% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 3.81 | |||||||||||||||||||
AGA Perf Management 2018 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 260,000 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 8 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10% | |||||||||||||||||||
Volatility | 45% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 3.81 | |||||||||||||||||||
AGA New Members 2017-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 25,000 | 25,000 | 25,000 | 25,000 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 5.74 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 5.74 | |||||||||||||||||||
AGA Employees 2018 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 90,650 | 67,028 | 67,028 | 67,028 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 7.31 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 4.03% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 7.31 | |||||||||||||||||||
AGA Bonus 2019-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 57,376 | 57,376 | 57,376 | 57,376 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 5.90 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 5.72 | |||||||||||||||||||
AGA Perf Employees 2019-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 546,700 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 3.13 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10% | |||||||||||||||||||
Volatility | 45% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 3.13 | |||||||||||||||||||
AGA Perf Management 2019-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 355,000 | |||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 3.13 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10% | |||||||||||||||||||
Volatility | 45% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 3.13 | |||||||||||||||||||
AGA Bonus 2020-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 79,861 | 79,861 | 79,861 | 79,861 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 6.40 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 6.40 | |||||||||||||||||||
AGA Perf Employees 2020-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 769,202 | 766,650 | 766,650 | 766,650 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 2.94 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10% | |||||||||||||||||||
Volatility | 45% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 2.94 | |||||||||||||||||||
AGA Perf Management 2020-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 710,000 | 710,000 | 710,000 | 710,000 | ||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 2.94 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10% | |||||||||||||||||||
Volatility | 45% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 2.94 | |||||||||||||||||||
AGA Bonus 2021-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Non transferability period (in years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 125,748 | 125,748 | 125,748 | |||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 3.43 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 3.43 | |||||||||||||||||||
AGA Perf Employees 2021-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 1,066,600 | 1,066,600 | 1,066,600 | |||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 1.76 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 13.32% | |||||||||||||||||||
Volatility | 50% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 1.76 | |||||||||||||||||||
AGA Perf Management 2021-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 610,000 | 610,000 | 610,000 | |||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 1.76 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 13.32% | |||||||||||||||||||
Volatility | 50% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 1.76 | |||||||||||||||||||
AGA "Plan Epargne Entreprise" 2022 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Number of free shares granted (in shares) | shares | 138,960 | 138,960 | ||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 4.10 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 4.10 | |||||||||||||||||||
AGA Bonus 2022-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 128,061 | 128,061 | ||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 3.89 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 0% | |||||||||||||||||||
Volatility | 0% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 3.89 | |||||||||||||||||||
AGA Perf Employees 2022-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years 1 month 6 days | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 1,371,500 | 1,371,500 | ||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 1.39 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10.50% | |||||||||||||||||||
Volatility | 50% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 1.39 | |||||||||||||||||||
AGA Perf Management 2022-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Vesting period (years) | 3 years 1 month 6 days | |||||||||||||||||||
Number of free shares granted (in shares) | shares | 550,000 | 550,000 | ||||||||||||||||||
Share entitlement per free share (in shares) | shares | 1 | |||||||||||||||||||
Grant date share fair value (in EUR per share) | € / shares | € 1.39 | |||||||||||||||||||
Expected dividends | € | € 0 | |||||||||||||||||||
Expected turnover (yearly basis) | 10.50% | |||||||||||||||||||
Volatility | 50% | |||||||||||||||||||
Fair value per AGA (in EUR per share) | € / shares | € 1.39 |
Share capital and share based_7
Share capital and share based payments - Disclosure of Changes in Number of Other Equity Instruments Outstanding (Details) - shares | 12 Months Ended | |||
Feb. 14, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||
Exercised during the period | (185,280) | |||
AGA | ||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||
Balance at beginning of period | 3,678,354 | 2,752,198 | 1,607,345 | |
Granted during the period | 2,188,521 | 1,802,348 | 1,556,511 | |
Forfeited during the period | (567,330) | (614,338) | (268,587) | |
Exercised during the period | (622,372) | (261,854) | (143,071) | |
Expired during the period | 0 | 0 | 0 | |
Balance at end of period | 4,677,173 | 3,678,354 | 2,752,198 | |
BSA | ||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||
Balance at beginning of period | 242,560 | 284,500 | 309,500 | |
Granted during the period | 40,000 | 0 | 0 | |
Forfeited during the period | (31,740) | 0 | 0 | |
Exercised during the period | 0 | (16,940) | (25,000) | |
Expired during the period | 0 | (25,000) | 0 | |
Balance at end of period | 250,820 | 242,560 | 284,500 | |
BSAAR | ||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||
Balance at beginning of period | 1,105,822 | 1,360,822 | 1,362,322 | |
Granted during the period | 0 | 0 | 0 | |
Forfeited during the period | 0 | 0 | 0 | |
Exercised during the period | (750) | (230,000) | (1,500) | |
Expired during the period | 0 | (25,000) | 0 | |
Balance at end of period | 1,105,072 | 1,105,822 | 1,360,822 |
Share capital and share based_8
Share capital and share based payments - Disclosure of Closing Balance of Share-Based Payment Arrangements (Details) | 12 Months Ended | |||||||||||||||||||
Dec. 16, 2022 EUR (€) shares € / shares | Dec. 12, 2022 EUR (€) shares € / shares | Oct. 03, 2022 EUR (€) shares € / shares | Oct. 01, 2021 EUR (€) shares € / shares | Jul. 22, 2021 EUR (€) shares € / shares | Aug. 05, 2020 EUR (€) shares € / shares | Jul. 13, 2020 EUR (€) shares € / shares | Apr. 29, 2019 EUR (€) shares € / shares | Nov. 20, 2018 EUR (€) shares € / shares | Apr. 03, 2018 EUR (€) shares € / shares | Sep. 20, 2017 EUR (€) shares € / shares | Oct. 21, 2016 EUR (€) shares € / shares | Jul. 01, 2015 EUR (€) shares € / shares | Apr. 27, 2015 EUR (€) shares € / shares | Jul. 16, 2014 EUR (€) shares € / shares | Jul. 17, 2013 EUR (€) shares € / shares | Dec. 31, 2022 shares | Dec. 31, 2021 shares | Dec. 31, 2020 shares | Dec. 31, 2019 shares | |
AGA | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 4,677,173 | 3,678,354 | 2,752,198 | 1,607,345 | ||||||||||||||||
Number of free shares granted (in shares) | 2,188,521 | 1,802,348 | 1,556,511 | |||||||||||||||||
AGAP Management 2016-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 1,200 | 1,200 | 1,450 | |||||||||||||||||
Closing Balance, Exercisable | 156,000 | 156,000 | 188,500 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | 2,000 | 2,000 | 2,000 | 2,000 | ||||||||||||||||
Share entitlement per free share (in shares) | 130 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 10.87 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 40% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 911 | |||||||||||||||||||
AGAP Employees 2016-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 2,068 | 2,068 | 2,185 | |||||||||||||||||
Closing Balance, Exercisable | 268,840 | 268,840 | 284,050 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | 2,486 | 2,486 | 2,486 | 2,486 | ||||||||||||||||
Share entitlement per free share (in shares) | 130 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 10.87 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 40% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 911 | |||||||||||||||||||
AGAP 2016-2 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 3,000 | 3,000 | ||||||||||||||||||
AGAP Management 2017 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 1,600 | ||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | 2,400 | |||||||||||||||||||
Share entitlement per free share (in shares) | 100 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 5.52 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 55% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 90 | |||||||||||||||||||
AGA Perf Employees 2018 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 242,500 | ||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | 327,500 | |||||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 8 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 45% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 3.81 | |||||||||||||||||||
AGA Perf Management 2018 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 200,000 | ||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | 260,000 | |||||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 8 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 45% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 3.81 | |||||||||||||||||||
AGA New Members 2017-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 25,000 | 25,000 | |||||||||||||||||
Closing Balance, Exercisable | 0 | 25,000 | 25,000 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years | |||||||||||||||||||
Number of free shares granted (in shares) | 25,000 | 25,000 | 25,000 | 25,000 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 5.74 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 0% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 5.74 | |||||||||||||||||||
AGA Perf Employees 2019-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 356,800 | 460,600 | ||||||||||||||||||
AGA Perf Management 2019-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 325,000 | 325,000 | ||||||||||||||||||
AGA Bonus 2020-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 13,614 | 79,861 | |||||||||||||||||
Closing Balance, Exercisable | 0 | 13,614 | 79,861 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | 79,861 | 79,861 | 79,861 | 79,861 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 6.40 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 0% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 6.40 | |||||||||||||||||||
AGA Perf Employees 2020-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 480,344 | 516,824 | 696,110 | |||||||||||||||||
Closing Balance, Exercisable | 480,344 | 516,824 | 696,110 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | 769,202 | 766,650 | 766,650 | 766,650 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 2.94 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 45% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 2.94 | |||||||||||||||||||
AGA Perf Management 2020-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 650,000 | 680,000 | 710,000 | |||||||||||||||||
Closing Balance, Exercisable | 650,000 | 680,000 | 710,000 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | 710,000 | 710,000 | 710,000 | 710,000 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 2.94 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 45% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 2.94 | |||||||||||||||||||
AGA Bonus 2021-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 125,748 | 0 | |||||||||||||||||
Closing Balance, Exercisable | 0 | 125,748 | ||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | 125,748 | 125,748 | 125,748 | |||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 3.43 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 0% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 3.43 | |||||||||||||||||||
AGA Perf Employees 2021-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 971,000 | 1,049,100 | 0 | |||||||||||||||||
Closing Balance, Exercisable | 971,000 | 1,049,100 | ||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | 1,066,600 | 1,066,600 | 1,066,600 | |||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 1.76 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 50% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 1.76 | |||||||||||||||||||
AGA Perf Management 2021-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 520,000 | 580,000 | 0 | |||||||||||||||||
Closing Balance, Exercisable | 520,000 | 580,000 | ||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years 6 months | |||||||||||||||||||
Number of free shares granted (in shares) | 610,000 | 610,000 | 610,000 | |||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 1.76 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 50% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 1.76 | |||||||||||||||||||
AGA Bonus 2022-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 128,061 | 0 | 0 | |||||||||||||||||
Closing Balance, Exercisable | 128,061 | |||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 1 year | |||||||||||||||||||
Number of free shares granted (in shares) | 128,061 | 128,061 | ||||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 3.89 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 0% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 3.89 | |||||||||||||||||||
AGA Perf Employees 2022-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 1,371,500 | 0 | 0 | |||||||||||||||||
Closing Balance, Exercisable | 1,371,500 | |||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years 1 month 6 days | |||||||||||||||||||
Number of free shares granted (in shares) | 1,371,500 | 1,371,500 | ||||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 1.39 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 50% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 1.39 | |||||||||||||||||||
AGA Perf Management 2022-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 550,000 | 0 | 0 | |||||||||||||||||
Closing Balance, Exercisable | 550,000 | |||||||||||||||||||
Vesting Period Other Equity Instruments Granted | 3 years 1 month 6 days | |||||||||||||||||||
Number of free shares granted (in shares) | 550,000 | 550,000 | ||||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 1.39 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 50% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 1.39 | |||||||||||||||||||
BSA | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 250,820 | 242,560 | 284,500 | 309,500 | ||||||||||||||||
Closing Balance, Exercisable | 250,820 | 242,560 | 284,500 | |||||||||||||||||
Number of free shares granted (in shares) | 40,000 | 0 | 0 | |||||||||||||||||
BSA 2011-2 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 0 | 41,940 | |||||||||||||||||
Closing Balance, Exercisable | 0 | 0 | 41,940 | |||||||||||||||||
Number of free shares granted (in shares) | 225,000 | 225,000 | 225,000 | |||||||||||||||||
BSA 2013 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 46,360 | 46,360 | 46,360 | |||||||||||||||||
Closing Balance, Exercisable | 46,360 | 46,360 | 46,360 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | 237,500 | 237,500 | 237,500 | 237,500 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Exercise Price Other Equity Instruments Granted | € / shares | € 2.36 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 2.45 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 31.83% | |||||||||||||||||||
Average Life Other Equity Instruments Granted | 5 years 6 months | |||||||||||||||||||
Risk Free Interest Rate Other Equity Instruments Granted | 2.42% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 0.87 | |||||||||||||||||||
BSA 2014 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 75,000 | 75,000 | 75,000 | |||||||||||||||||
Closing Balance, Exercisable | 75,000 | 75,000 | 75,000 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | 150,000 | 150,000 | 150,000 | 150,000 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Exercise Price Other Equity Instruments Granted | € / shares | € 8.65 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 6.85 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 46.72% | |||||||||||||||||||
Average Life Other Equity Instruments Granted | 5 years 6 months | |||||||||||||||||||
Risk Free Interest Rate Other Equity Instruments Granted | 1% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 2.51 | |||||||||||||||||||
BSA 2015-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 70,000 | 70,000 | 70,000 | |||||||||||||||||
Closing Balance, Exercisable | 70,000 | 70,000 | 70,000 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | 70,000 | 70,000 | 70,000 | 70,000 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Exercise Price Other Equity Instruments Granted | € / shares | € 9.59 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 13.65 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 54.08% | |||||||||||||||||||
Average Life Other Equity Instruments Granted | 5 years 6 months | |||||||||||||||||||
Risk Free Interest Rate Other Equity Instruments Granted | 0.25% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 6.59 | |||||||||||||||||||
BSA 2015-2 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 14,200 | 14,200 | 14,200 | |||||||||||||||||
Closing Balance, Exercisable | 14,200 | 14,200 | 14,200 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | 14,200 | 14,200 | 14,200 | 14,200 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Exercise Price Other Equity Instruments Granted | € / shares | € 14.05 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 13.64 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 47.83% | |||||||||||||||||||
Average Life Other Equity Instruments Granted | 5 years 6 months | |||||||||||||||||||
Risk Free Interest Rate Other Equity Instruments Granted | 0.25% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 4.73 | |||||||||||||||||||
BSA 2017 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 37,000 | 37,000 | 37,000 | |||||||||||||||||
Closing Balance, Exercisable | 37,000 | 37,000 | 37,000 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | 37,000 | 37,000 | 37,000 | 37,000 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Exercise Price Other Equity Instruments Granted | € / shares | € 11 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 10.41 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 61.74% | |||||||||||||||||||
Average Life Other Equity Instruments Granted | 6 years | |||||||||||||||||||
Risk Free Interest Rate Other Equity Instruments Granted | 0.20% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 0.57 | |||||||||||||||||||
BSA 2022-1 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 8,260 | 0 | 0 | |||||||||||||||||
Closing Balance, Exercisable | 8,260 | 0 | 0 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | 40,000 | 40,000 | ||||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Exercise Price Other Equity Instruments Granted | € / shares | € 2.31 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 1.31 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 50% | |||||||||||||||||||
Average Life Other Equity Instruments Granted | 5 years 6 months | |||||||||||||||||||
Risk Free Interest Rate Other Equity Instruments Granted | 2.40% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 1.21 | |||||||||||||||||||
BSAAR | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 1,105,072 | 1,105,822 | 1,360,822 | 1,362,322 | ||||||||||||||||
Closing Balance, Exercisable | 1,105,072 | 1,105,822 | 1,360,822 | |||||||||||||||||
Number of free shares granted (in shares) | 0 | 0 | 0 | |||||||||||||||||
BSAAR 2011 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 0 | 0 | 255,000 | |||||||||||||||||
Closing Balance, Exercisable | 0 | 0 | 255,000 | |||||||||||||||||
Number of free shares granted (in shares) | 650,000 | 650,000 | 650,000 | |||||||||||||||||
BSAAR 2012 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 59,350 | 60,100 | 60,100 | |||||||||||||||||
Closing Balance, Exercisable | 59,350 | 60,100 | 60,100 | |||||||||||||||||
Number of free shares granted (in shares) | 146,050 | 146,050 | 146,050 | |||||||||||||||||
BSAAR 2015 | ||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | ||||||||||||||||||||
Closing Balance | 1,045,722 | 1,045,722 | 1,045,722 | |||||||||||||||||
Closing Balance, Exercisable | 1,045,722 | 1,045,722 | 1,045,722 | |||||||||||||||||
Vesting Period Other Equity Instruments Granted | 2 years | |||||||||||||||||||
Number of free shares granted (in shares) | 1,050,382 | 1,050,382 | 1,050,382 | 1,050,382 | ||||||||||||||||
Share entitlement per free share (in shares) | 1 | |||||||||||||||||||
Exercise Price Other Equity Instruments Granted | € / shares | € 7.20 | |||||||||||||||||||
Grant Date Share Fair Value Other Equity Instruments Granted | € / shares | € 13.77 | |||||||||||||||||||
Expected Volatility Other Equity Instruments Granted | 41% | |||||||||||||||||||
Average Life Other Equity Instruments Granted | 10 years | |||||||||||||||||||
Risk Free Interest Rate Other Equity Instruments Granted | 1.22% | |||||||||||||||||||
Expected Dividend Other Equity Instruments Granted | € | € 0 | |||||||||||||||||||
Fair Value Per Share At Grant Date Other Equity Instruments Granted | € / shares | € 1.15 |
Share capital and share based_9
Share capital and share based payments - Disclosure of Breakdown of Expenses per Financial Year (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | € 4,249 | € 2,617 | € 2,475 |
AGA Perf Management 2018 / AGA Perf Employees 2018 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 0 | (232) | 618 |
AGA 2018-1 Employees | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 0 | 0 | 23 |
AGAP Management 2017-1 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 0 | 71 | 43 |
AGAP Employee 2019 / AGAP Management 2019 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | (181) | 649 | 867 |
AGA Bonus 2019-1 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 0 | 0 | 0 |
AGA Bonus 2020-1 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 0 | 0 | 394 |
AGAP Employee 2020 / AGAP Management 2020 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 1,738 | 1,253 | 502 |
Stock Options 2020-1 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 0 | (28) | 28 |
AGA Bonus 2021-1 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 0 | 432 | 0 |
AGAP Employee 2021 / AGAP Management 2021 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 1,577 | 473 | 0 |
AGA "Plan Epargne Entreprise" 2022 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 570 | 0 | 0 |
AGA Bonus 2022-1 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | 499 | 0 | 0 |
AGAP Employee 2022 / AGAP Management 2022 | |||
Disclosure of terms and conditions of share-based payment arrangement [Line Items] | |||
Share-based compensation | € 46 | € 0 | € 0 |
Financial instruments recogni_3
Financial instruments recognized in the statement of financial position and related effect on the income statement (Details) - EUR (€) € in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | € 189,049 | € 207,955 | € 242,206 |
Financial assets, fair value | 189,049 | 207,955 | 242,206 |
Financial liabilities | 63,162 | 72,824 | 48,624 |
Financial liabilities, fair value | 63,162 | 72,822 | 48,624 |
Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 0 | 0 | 0 |
Debt at amortized cost | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 63,162 | 72,822 | 48,624 |
Financial liabilities—non-current portion | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 40,149 | 13,503 | 16,945 |
Financial liabilities, fair value | 40,149 | 13,503 | 16,945 |
Financial liabilities—non-current portion | Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 0 | 0 | 0 |
Financial liabilities—non-current portion | Debt at amortized cost | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 40,149 | 13,503 | 16,945 |
Financial liabilities—current portion | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 2,102 | 30,748 | 2,142 |
Financial liabilities, fair value | 2,102 | 30,748 | 2,142 |
Financial liabilities—current portion | Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 0 | 0 | 0 |
Financial liabilities—current portion | Debt at amortized cost | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 2,102 | 30,748 | 2,142 |
Trade payables and others | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 20,911 | 28,573 | 29,539 |
Financial liabilities, fair value | 20,911 | 28,573 | 29,539 |
Trade payables and others | Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 0 | 0 | 0 |
Trade payables and others | Debt at amortized cost | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial liabilities | 20,911 | 28,573 | 29,539 |
Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 136,604 | 159,714 | 190,571 |
Receivables | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 52,445 | 48,241 | 51,635 |
Non-current financial assets | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 35,119 | 39,878 | 38,934 |
Financial assets, fair value | 35,119 | 39,878 | 38,934 |
Non-current financial assets | Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 35,119 | 39,878 | 38,934 |
Non-current financial assets | Receivables | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 0 | 0 | |
Trade receivables and others | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 52,445 | 48,241 | 51,635 |
Financial assets, fair value | 52,445 | 48,241 | 51,635 |
Trade receivables and others | Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 0 | 0 | 0 |
Trade receivables and others | Receivables | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 52,445 | 48,241 | 51,635 |
Short-term investments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 17,260 | 16,080 | 14,845 |
Financial assets, fair value | 17,260 | 16,080 | 14,845 |
Short-term investments | Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 17,260 | 16,080 | 14,845 |
Short-term investments | Receivables | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 0 | 0 | 0 |
Cash and cash equivalents | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 84,225 | 103,756 | 136,792 |
Financial assets, fair value | 84,225 | 103,756 | 136,792 |
Cash and cash equivalents | Fair value through profit or loss | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | 84,225 | 103,756 | 136,792 |
Cash and cash equivalents | Receivables | |||
Disclosure of detailed information about financial instruments [line items] | |||
Financial assets | € 0 | € 0 | € 0 |
Revenue and government financ_3
Revenue and government financing for research expenditures - Additional Information (Details) € in Thousands, $ in Thousands | 1 Months Ended | 4 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||||
Sep. 09, 2022 EUR (€) | Aug. 02, 2022 EUR (€) | Aug. 02, 2022 USD ($) | Jun. 30, 2022 EUR (€) program | Jun. 30, 2022 USD ($) program | Jun. 17, 2022 EUR (€) | Jun. 17, 2022 USD ($) | Jun. 01, 2022 USD ($) | Jan. 05, 2021 USD ($) | Dec. 07, 2020 EUR (€) | Dec. 07, 2020 USD ($) | Dec. 31, 2021 USD ($) | Jun. 30, 2020 USD ($) | Jan. 31, 2019 USD ($) | Oct. 31, 2018 EUR (€) | Oct. 31, 2018 USD ($) | Jun. 30, 2015 USD ($) | Jan. 31, 2019 USD ($) | Jun. 30, 2022 EUR (€) program | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2017 USD ($) | Dec. 31, 2019 EUR (€) | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||
Revenue from collaboration and licensing agreements | € | € 49,580 | € 12,112 | € 56,155 | [1] | ||||||||||||||||||||||
2015 monalizumab agreement, with AstraZeneca | ||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||
Revenue from collaboration and licensing agreements | € 13,400 | $ 14,000 | ||||||||||||||||||||||||
Initial payment | $ | $ 250,000 | |||||||||||||||||||||||||
Exercise of option | $ | $ 100,000 | |||||||||||||||||||||||||
Revenue from favorable cumulative adjustment | € | € 38,321 | |||||||||||||||||||||||||
Milestone payment received | 47,700 | 50,000 | € 47,700 | $ 50,000 | € 41,227 | $ 50,000 | $ 50,000 | |||||||||||||||||||
Receipts from co-development agreement and option agreement | $ | $ 250,000 | |||||||||||||||||||||||||
IPH5201 agreement, with AstraZeneca | ||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||
Revenue from collaboration and licensing agreements | € | 4,677 | € 0 | € 13,418 | |||||||||||||||||||||||
Milestone payment received | € 4,900 | $ 5,000 | $ 5,000 | $ 5,000 | 4,700 | $ 5,000 | ||||||||||||||||||||
Receipts from co-development agreement and option agreement | $ | $ 24,000 | $ 26,000 | $ 50,000 | |||||||||||||||||||||||
Agreement related to additional preclinical molecules with AstraZeneca | ||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||
Revenue from collaboration and licensing agreements | € 17,400 | $ 20,000 | ||||||||||||||||||||||||
Milestone payment received | € 17,400 | $ 20,000 | ||||||||||||||||||||||||
Number of preclinical programs | program | 4 | 4 | 4 | |||||||||||||||||||||||
Agreements with Sanofi for NK Cell engages | ||||||||||||||||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||||||||||||||||
Revenue from collaboration and licensing agreements | € | € 3,000 | |||||||||||||||||||||||||
Milestone payment received | € 3,000 | $ 7,000 | $ 3,000 | € 3,000 | ||||||||||||||||||||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Revenue and government financ_4
Revenue and government financing for research expenditures - Disclosure of Revenue from Collaboration and Licensing Agreements (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | € 49,580 | € 12,112 | € 56,155 | [1] |
Proceeds from collaboration and licensing agreements | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | 48,806 | 10,497 | 54,038 | |
of which monalizumab agreement - AstraZeneca | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | 22,376 | 7,497 | 33,620 | |
of which IPH5201 agreement - AstraZeneca | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | 4,677 | 0 | 13,418 | |
of which preclinical molecules agreement - AstraZeneca | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | 17,400 | 0 | 0 | |
of which Sanofi agreement | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | 4,000 | 3,000 | 7,000 | |
of which other agreements | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | 353 | 0 | 0 | |
Invoicing of research and development costs (IPH5201) | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | 1,391 | 1,613 | 2,531 | |
Exchange gains (loss) on collaboration agreements | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | (627) | 0 | (602) | |
Others | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Revenue from collaboration and licensing agreements | € 10 | € 0 | € 188 | |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Revenue and government financ_5
Revenue and government financing for research expenditures - Disclosure of Changes in Deferred Revenue and Collaboration Liabilities (Details) € in Thousands, $ in Thousands | 1 Months Ended | 12 Months Ended | |||||||||||||||
Aug. 02, 2022 EUR (€) | Aug. 02, 2022 USD ($) | Jun. 30, 2022 EUR (€) | Jun. 30, 2022 USD ($) | Jun. 17, 2022 EUR (€) | Jun. 17, 2022 USD ($) | Jun. 01, 2022 USD ($) | Dec. 07, 2020 EUR (€) | Dec. 07, 2020 USD ($) | Jun. 30, 2020 USD ($) | Oct. 31, 2018 EUR (€) | Oct. 31, 2018 USD ($) | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2022 USD ($) | |
Deferred income including contract liabilities [abstract] | |||||||||||||||||
Deferred income | € 14,481 | € 37,913 | € 43,973 | ||||||||||||||
Collaboration liabilities – current portion | 10,223 | 7,418 | 1,832 | ||||||||||||||
Collaboration liabilities – non-current portion | 52,988 | 32,997 | 44,854 | ||||||||||||||
2015 monalizumab agreement, with AstraZeneca | |||||||||||||||||
Deferred Revenue, Roll Forward [Abstract] | |||||||||||||||||
Milestone payment received | € 47,700 | $ 50,000 | € 47,700 | $ 50,000 | € 41,227 | $ 50,000 | $ 50,000 | ||||||||||
Deferred income including contract liabilities [abstract] | |||||||||||||||||
Collaboration liabilities – current portion | 1,832 | 21,304 | |||||||||||||||
Collaboration liabilities – non-current portion | 52,988 | 44,854 | |||||||||||||||
IPH5201 agreement, with AstraZeneca | |||||||||||||||||
Deferred Revenue, Roll Forward [Abstract] | |||||||||||||||||
Milestone payment received | € 4,900 | $ 5,000 | $ 5,000 | $ 5,000 | 4,700 | 5,000 | |||||||||||
Agreement related to additional preclinical molecules with AstraZeneca | |||||||||||||||||
Deferred Revenue, Roll Forward [Abstract] | |||||||||||||||||
Milestone payment received | € 17,400 | $ 20,000 | |||||||||||||||
Deferred income including contract liabilities [abstract] | |||||||||||||||||
Deferred income | 0 | 17,400 | |||||||||||||||
Increase in deferred income including contract liabilities | 0 | ||||||||||||||||
Decrease in deferred income including contract liabilities | (17,400) | ||||||||||||||||
Deferred revenue | |||||||||||||||||
Deferred Revenue, Roll Forward [Abstract] | |||||||||||||||||
Contract liabilities at beginning of period | 37,913 | 43,973 | 89,112 | ||||||||||||||
Revenue for the current financial year | (39,776) | (7,497) | (47,038) | ||||||||||||||
Transfer from collaboration liabilities | 30,989 | (1,084) | 2,465 | ||||||||||||||
Contract liabilities at end of period | 14,481 | 37,913 | 43,973 | ||||||||||||||
Collaboration Liabilities, Roll Forward [Abstract] | |||||||||||||||||
Contract liabilities at beginning of period | 37,913 | 43,973 | 89,112 | ||||||||||||||
Contract liabilities at end of period | 14,481 | 37,913 | 43,973 | ||||||||||||||
Deferred revenue | 2015 monalizumab agreement, with AstraZeneca | |||||||||||||||||
Deferred Revenue, Roll Forward [Abstract] | |||||||||||||||||
Contract liabilities at beginning of period | 20,159 | 26,572 | 62,657 | ||||||||||||||
Revenue for the current financial year | (22,376) | (7,497) | (33,620) | ||||||||||||||
Transfer from collaboration liabilities | (30,989) | 1,084 | (2,465) | ||||||||||||||
Increase through milestone payments, contract liabilities | 47,687 | ||||||||||||||||
Contract liabilities at end of period | 14,481 | 20,159 | 26,572 | ||||||||||||||
Collaboration Liabilities, Roll Forward [Abstract] | |||||||||||||||||
Contract liabilities at beginning of period | 20,159 | 26,572 | 62,657 | ||||||||||||||
Contract liabilities at end of period | 14,481 | 20,159 | 26,572 | ||||||||||||||
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca | |||||||||||||||||
Deferred Revenue, Roll Forward [Abstract] | |||||||||||||||||
Contract liabilities at beginning of period | 40,415 | 46,686 | 21,304 | ||||||||||||||
Contract liabilities at end of period | 63,211 | 40,415 | 46,686 | ||||||||||||||
Collaboration Liabilities, Roll Forward [Abstract] | |||||||||||||||||
Contract liabilities at beginning of period | 40,415 | 46,686 | 21,304 | ||||||||||||||
Additions | € 34,300 | $ 36,000 | 37,564 | 4,262 | 46,320 | ||||||||||||
Deductions | (14,768) | (10,534) | (20,938) | ||||||||||||||
Contract liabilities at end of period | 63,211 | € 40,415 | € 46,686 | ||||||||||||||
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca | PACIFIC-9 | |||||||||||||||||
Collaboration Liabilities, Roll Forward [Abstract] | |||||||||||||||||
Additions | 34,335 | 36,000 | |||||||||||||||
Deferred income including contract liabilities [abstract] | |||||||||||||||||
Collaboration liabilities – non-current portion | € 34,335 | $ 36,000 | |||||||||||||||
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca | Exchange Rate Fluctuations | |||||||||||||||||
Collaboration Liabilities, Roll Forward [Abstract] | |||||||||||||||||
Additions | $ | $ 2,145 |
Revenue and government financ_6
Revenue and government financing for research expenditures - Disclosure of Variance of Deferred Revenue (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Deferred revenue – current portion | € 6,560 | € 12,500 | € 11,299 |
Deferred revenue – non-current portion | 7,921 | 25,413 | 32,674 |
Deferred revenue | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Contract liabilities at beginning of period | 37,913 | 43,973 | 89,112 |
Recognition in P&L | (39,776) | (7,497) | (47,038) |
Proceeds | 47,687 | 353 | (4,365) |
Transfer from collaboration liabilities | (30,989) | 1,084 | (2,465) |
Contract liabilities at end of period | 14,481 | 37,913 | 43,973 |
Deferred revenue | Monalizumab | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Contract liabilities at beginning of period | 20,159 | 26,572 | 62,657 |
Recognition in P&L | (22,376) | (7,497) | (33,620) |
Proceeds | 47,687 | 0 | 0 |
Transfer from collaboration liabilities | (30,989) | 1,084 | (2,465) |
Contract liabilities at end of period | 14,481 | 20,159 | 26,572 |
Deferred revenue | IPH5201 | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Contract liabilities at beginning of period | 0 | 0 | 9,054 |
Recognition in P&L | 0 | (13,418) | |
Proceeds | 0 | 4,365 | |
Transfer from collaboration liabilities | 0 | 0 | |
Contract liabilities at end of period | 0 | 0 | |
Deferred revenue | Preclinical molecules | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Contract liabilities at beginning of period | 17,400 | 17,400 | 17,400 |
Recognition in P&L | (17,400) | 0 | 0 |
Proceeds | 0 | 0 | 0 |
Transfer from collaboration liabilities | 0 | 0 | 0 |
Contract liabilities at end of period | 0 | 17,400 | 17,400 |
Deferred revenue | Others | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Contract liabilities at beginning of period | 353 | 0 | |
Recognition in P&L | (353) | 0 | |
Proceeds | 0 | 353 | |
Transfer from collaboration liabilities | 0 | 0 | |
Contract liabilities at end of period | € 0 | € 353 | € 0 |
Revenue and government financ_7
Revenue and government financing for research expenditures - Disclosure of Government Financing for Research Expenditures (Details) - EUR (€) € in Thousands | 12 Months Ended | ||||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Aug. 31, 2020 | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||
Research Tax Credit(1) | € 7,925 | € 10,310 | € 13,084 | ||
Grant | 110 | 2,281 | 534 | ||
Government financing for research expenditures | 8,035 | 12,591 | 13,618 | [1] | |
Research tax credit, receivable, current | 25,904 | 10,310 | € 0 | ||
Gross carrying amount [member] | |||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||
Research Tax Credit(1) | 9,167 | ||||
Accumulated impairment [member] | |||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||
Research Tax Credit(1) | € 1,270 | ||||
BPI France, Covid-19 program, non-refundable | |||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||
Grant | 1,988 | ||||
Research tax credit, initial payment | € 1,360 | ||||
Research tax credit, receivable, current | € 628 | ||||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Operating expenses - Disclosure
Operating expenses - Disclosure of Expenses by Nature (Details) - EUR (€) | 12 Months Ended | 53 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2022 | ||
Statement Line Items [Line Items] | |||||
Subcontracting costs | € (24,432,000) | € (24,290,000) | € (19,862,000) | ||
Cost of supplies and consumable materials | (3,582,000) | (3,065,000) | (3,558,000) | ||
Personnel expenses other than share-based compensation | (22,354,000) | (23,475,000) | (20,436,000) | ||
Share-based compensation | (4,249,000) | (2,617,000) | (2,475,000) | ||
Personnel expenses | (26,603,000) | (26,092,000) | (22,911,000) | ||
Non-scientific advisory and consulting | (5,685,000) | (5,269,000) | (4,783,000) | ||
Leasing and maintenance | (1,998,000) | (2,014,000) | (2,164,000) | ||
Travel expenses and meeting attendance | (718,000) | (273,000) | (284,000) | ||
Marketing, communication and public relations | (660,000) | (472,000) | (504,000) | ||
Scientific advisory and consulting | (1,263,000) | (288,000) | (962,000) | ||
Other purchases and external expenses | (2,648,000) | (2,425,000) | (2,053,000) | ||
Depreciation and amortization | (4,424,000) | (4,569,000) | (9,385,000) | ||
Intellectual property expenses | (1,292,000) | (1,584,000) | (1,270,000) | ||
Other income and (expenses), net | (795,000) | (2,188,000) | (958,000) | ||
Impairment of intangible assets | (41,000,000) | 0 | 0 | [1] | |
Total operating expenses | (115,099,000) | (72,528,000) | (68,694,000) | [1] | |
R&D | |||||
Statement Line Items [Line Items] | |||||
Subcontracting costs | (24,432,000) | (24,189,000) | (19,866,000) | ||
Cost of supplies and consumable materials | (3,051,000) | (2,533,000) | (3,590,000) | ||
Personnel expenses other than share-based compensation | (14,329,000) | (14,859,000) | (13,825,000) | ||
Share-based compensation | (2,044,000) | (349,000) | (836,000) | ||
Personnel expenses | (16,373,000) | (15,208,000) | (14,661,000) | ||
Non-scientific advisory and consulting | (1,441,000) | (161,000) | (342,000) | ||
Leasing and maintenance | (200,000) | (260,000) | (559,000) | ||
Travel expenses and meeting attendance | (466,000) | (103,000) | (146,000) | ||
Marketing, communication and public relations | (130,000) | (79,000) | (96,000) | ||
Scientific advisory and consulting | (1,263,000) | (288,000) | (962,000) | ||
Other purchases and external expenses | (91,000) | (30,000) | (46,000) | ||
Depreciation and amortization | (2,928,000) | (3,153,000) | (8,231,000) | ||
Intellectual property expenses | (996,000) | (1,279,000) | (877,000) | ||
Other income and (expenses), net | (292,000) | 279,000 | (332,000) | ||
Impairment of intangible assets | 0 | 0 | 0 | ||
Total operating expenses | (51,663,000) | (47,004,000) | (49,708,000) | ||
G&A | |||||
Statement Line Items [Line Items] | |||||
Subcontracting costs | 0 | (101,000) | 4,000 | ||
Cost of supplies and consumable materials | (531,000) | (532,000) | 32,000 | ||
Personnel expenses other than share-based compensation | (8,025,000) | (8,616,000) | (6,611,000) | ||
Share-based compensation | (2,204,000) | (2,267,000) | (1,639,000) | ||
Personnel expenses | (10,229,000) | (10,883,000) | (8,250,000) | ||
Non-scientific advisory and consulting | (4,244,000) | (5,108,000) | (4,441,000) | ||
Leasing and maintenance | (1,798,000) | (1,754,000) | (1,605,000) | ||
Travel expenses and meeting attendance | (252,000) | (170,000) | (138,000) | ||
Marketing, communication and public relations | (530,000) | (393,000) | (408,000) | ||
Scientific advisory and consulting | 0 | 0 | 0 | ||
Other purchases and external expenses | (2,557,000) | (2,395,000) | (2,007,000) | ||
Depreciation and amortization | (1,496,000) | (1,416,000) | (1,154,000) | ||
Intellectual property expenses | (296,000) | (305,000) | (393,000) | ||
Other income and (expenses), net | (503,000) | (2,467,000) | (626,000) | ||
Impairment of intangible assets | 0 | 0 | 0 | ||
Total operating expenses | (22,436,000) | € (25,524,000) | € (18,986,000) | ||
Impairment Loss | |||||
Statement Line Items [Line Items] | |||||
Subcontracting costs | 0 | ||||
Cost of supplies and consumable materials | 0 | ||||
Personnel expenses other than share-based compensation | 0 | ||||
Share-based compensation | 0 | ||||
Personnel expenses | 0 | ||||
Non-scientific advisory and consulting | 0 | ||||
Leasing and maintenance | 0 | ||||
Travel expenses and meeting attendance | 0 | ||||
Marketing, communication and public relations | 0 | ||||
Scientific advisory and consulting | 0 | ||||
Other purchases and external expenses | 0 | ||||
Depreciation and amortization | 0 | ||||
Intellectual property expenses | 0 | ||||
Other income and (expenses), net | 0 | ||||
Impairment of intangible assets | (41,000,000) | ||||
Total operating expenses | (41,000,000) | ||||
PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S | |||||
Statement Line Items [Line Items] | |||||
Impairment of intangible assets | € (41,000,000) | € 0 | |||
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Operating expenses - Disclosu_2
Operating expenses - Disclosure of Audit and Non-Audit Fees (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Analysis of income and expense [abstract] | |||
Audit fees | € 855 | € 702 | € 684 |
Non-audit fees | 248 | 78 | 115 |
Total | € 1,103 | € 780 | € 799 |
Operating expenses - Additional
Operating expenses - Additional Information (Details) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 EUR (€) employee | Dec. 31, 2021 EUR (€) employee | Dec. 31, 2020 EUR (€) | |
Analysis of income and expense [abstract] | |||
Short-term employee benefits expense | € 22,354 | ||
Personnel expenses other than share-based compensation | € (22,354) | € (23,475) | € (20,436) |
Number of employees | employee | 208 | 214 | |
Raw materials and consumables used | € 3,582 | € 3,065 | € 3,558 |
Net financial loss (Details)
Net financial loss (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Analysis of income and expense [abstract] | ||||
Interests and gains on financial assets | € 546 | € 327 | € 564 | |
Unrealized gains on financials assets | 418 | 1,177 | 313 | |
Foreign exchange gains | 3,810 | 4,839 | 3,978 | |
Other financial income | 0 | 0 | 0 | |
Financial income | 4,775 | 6,344 | 4,855 | [1] |
Foreign exchange losses | (2,983) | (3,591) | (5,557) | |
Unrealized losses on financial assets | (2,050) | (95) | (865) | |
Interest on financial liabilities | (288) | (312) | (341) | |
Other financial expenses | 0 | 0 | 0 | |
Financial expenses | (5,321) | (3,997) | (6,763) | [1] |
Net financial income (loss) | € (546) | € 2,347 | € (1,908) | [1] |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Income Tax - Additional Informa
Income Tax - Additional Information (Details) € in Thousands, $ in Thousands | 12 Months Ended | |||||
Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 EUR (€) | Dec. 31, 2020 USD ($) | |
Income Tax [Abstract] | ||||||
Unused tax losses with no expiration date | € 466,153 | € 392,633 | € 339,274 | |||
Unused tax losses subject to expiration | € 15,419 | $ 16,446 | € 14,198 | $ 16,081 | € 11,955 | $ 14,670 |
Expiration period | 20 years |
Income Tax - Disclosure of Tax
Income Tax - Disclosure of Tax Rate Reconciliation (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Income Tax [Abstract] | ||||
Net income (loss) before tax | € (58,103) | € (52,809) | € (63,984) | |
Statutory tax rate | 25% | 26.50% | 28% | |
Income tax benefit / (expense) calculated at statutory tax rate | € 14,526 | € 13,994 | € 17,916 | |
Differences in tax rates | 0 | 62 | 128 | |
Research tax credit | 1,971 | 3,091 | 3,961 | |
Provision for defined benefit obligations | 106 | 39 | (117) | |
Share-based compensation | (1,062) | (694) | (693) | |
Revenue from collaboration agreements | 2,210 | (3,313) | 8,824 | |
Non-recognition of deferred tax assets related to tax losses and temporary differences | (18,290) | (14,433) | (15,746) | |
Carry-back | 0 | 0 | 0 | |
Impact linked to intra-group merger operations | 0 | 0 | (16,288) | |
Impact linked to the exercise of a real estate leasing option | 0 | 0 | (1,103) | |
Others differences | 539 | 1,254 | 3,118 | |
Income tax benefit / (expense) | € 0 | € 0 | € 0 | |
Effective tax rate | 0% | 0% | 0% | |
Deferred tax income / (loss) | € 0 | € 0 | € 0 | |
Income tax benefit / (expense) | € 0 | € 0 | € 0 | [1] |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Discontinued Operations - Addit
Discontinued Operations - Additional Information (Details) - Lumoxiti, with AstraZeneca € in Millions, $ in Millions | 1 Months Ended | |||
Apr. 30, 2022 USD ($) | Apr. 30, 2022 USD ($) | Apr. 30, 2022 EUR (€) | Dec. 31, 2020 USD ($) | |
Disclosure of analysis of single amount of discontinued operations [line items] | ||||
Payments for manufacturing costs | $ 6.2 | $ 6.2 | € 5.9 | |
Manufacturing costs split | ||||
Disclosure of analysis of single amount of discontinued operations [line items] | ||||
Estimated financial effect of contingent liabilities | $ 12.8 |
Discontinued Operations - Discl
Discontinued Operations - Disclosure of Analysis of Financial Performance of Discontinued Operations (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Revenue and other income | ||||
Revenue from collaboration and licensing agreements | € 49,580 | € 12,112 | € 56,155 | [1] |
Total revenue and other income | 57,674 | 24,703 | 69,773 | [1] |
Operating expenses | ||||
Research and development expenses | (51,663) | (47,004) | (49,708) | [1] |
General and administrative expenses | (22,436) | (25,524) | (18,986) | [1] |
Impairment of intangible assets | (41,000) | 0 | 0 | [1] |
Total operating expenses | (115,099) | (72,528) | (68,694) | [1] |
Net income (loss) from distribution agreements | 0 | 0 | 0 | [1] |
Operating income (loss) | (57,425) | (47,825) | 1,079 | [1] |
Financial income | 4,775 | 6,344 | 4,855 | [1] |
Financial expenses | (5,321) | (3,997) | (6,763) | [1] |
Net financial income (loss) | (546) | 2,347 | (1,908) | [1] |
Net income (loss) before tax | (57,972) | (45,478) | (829) | [1] |
Income tax expense | 0 | 0 | 0 | |
Net income (loss) from discontinued operations | (131) | (7,331) | (63,155) | [1] |
Discontinued operations | ||||
Revenue and other income | ||||
Revenue from collaboration and licensing agreements | 194 | 926 | 0 | |
Other income | 22 | 874 | 678 | |
Total revenue and other income | 216 | 1,800 | 678 | |
Operating expenses | ||||
Research and development expenses | 0 | (624) | (8,905) | |
General and administrative expenses | (346) | (8,507) | (12,260) | |
Impairment of intangible assets | 0 | 0 | (43,529) | |
Total operating expenses | (346) | (9,131) | (21,165) | |
Net income (loss) from distribution agreements | 0 | 0 | 861 | |
Operating income (loss) | (131) | (7,331) | (63,155) | |
Financial income | 0 | 0 | 0 | |
Financial expenses | 0 | 0 | 0 | |
Net financial income (loss) | 0 | 0 | 0 | |
Net income (loss) before tax | € (131) | € (7,331) | € (63,155) | |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Discontinued Operations - Dis_2
Discontinued Operations - Disclosure of Analysis of Cash-Flows from Discontinued Operations (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Discontinued Operations [Abstract] | |||
Net cash generated from / (used in) operating activities | € (5,097) | € (3,552) | € (22,391) |
Net cash generated from / (used in) investing activities | 0 | 0 | (6,620) |
Net cash generated from / (used in) financing activities | 0 | 0 | 0 |
Net cash flows from discontinued operations | € (5,097) | € (3,552) | € (29,011) |
Commitments, contingencies an_2
Commitments, contingencies and litigations (Details) - EUR (€) € in Thousands | Jul. 03, 2017 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of contingent liabilities [table] | ||||||
Non-cancellable off-balance sheet purchase commitments | € 8,774 | |||||
Total financial liabilities | 42,251 | € 44,251 | € 19,087 | € 18,723 | ||
Provisions | 1,740 | € 900 | € 897 | |||
Loan agreement with Société Générale | ||||||
Disclosure of contingent liabilities [table] | ||||||
Loan agreement, collateral | € 15,200 | |||||
Security interest on pledge of financial instruments will be released in 2024 | 4,200 | |||||
Security interest on pledge of financial instruments will be released in 2027 | 5,000 | |||||
Security interest on pledge of financial instruments will be released in 2031 | € 6,000 | |||||
Total financial liabilities | 11,338 | € 1,300 | € 1,300 | |||
Provision for taxes other than income tax [member] | ||||||
Disclosure of contingent liabilities [table] | ||||||
Provisions | 1,270 | |||||
Preclinical Services | ||||||
Disclosure of contingent liabilities [table] | ||||||
Non-cancellable off-balance sheet purchase commitments | 7,421 | |||||
Clinical Services | ||||||
Disclosure of contingent liabilities [table] | ||||||
Non-cancellable off-balance sheet purchase commitments | € 1,353 |
Related party transactions - Di
Related party transactions - Disclosure of Key Management Personnel Compensation (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Related party transactions [abstract] | |||
Personnel expenses and other short-term employee benefits | € 2,176 | € 3,456 | € 3,131 |
Extra pension benefits | 43 | 11 | 0 |
Share-based compensation | 1,989 | 2,067 | 1,363 |
Advisory fees | 661 | 0 | 0 |
Executive Committee members compensation | € 4,869 | € 5,534 | € 4,494 |
Related party transactions - Ad
Related party transactions - Additional Information (Details) € in Thousands | Dec. 31, 2022 EUR (€) director | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Sep. 30, 2016 EUR (€) |
Disclosure of transactions between related parties [Line Items] | ||||
Number of members of the Executive Committee also members of the Executive Board | director | 2 | |||
Provision for attendance fees | € 348 | € 338 | € 274 | |
BPI France | ||||
Disclosure of transactions between related parties [Line Items] | ||||
Total borrowings | € 1,500 |
Related party transactions - _2
Related party transactions - Disclosure of Transactions Between Related Parties (Details) € in Thousands | 12 Months Ended |
Dec. 31, 2022 EUR (€) | |
Related party transactions [abstract] | |
Collection | € 54,774 |
Receivables | 3,078 |
Payments | (17,745) |
Liabilities | (7,298) |
Net collection (payments) | 37,029 |
Net receivables (liabilities) | € (4,220) |
Income (loss) per share - Summa
Income (loss) per share - Summary of Income (Loss) per Share (Details) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||
Income (Loss) Per Share [Abstract] | ||||
Net income (loss) | € (58,103) | € (52,809) | € (63,984) | [1] |
Weighted average number of ordinary shares in circulation (in shares) | 79,639,826 | 79,542,627 | 78,934,960 | |
Basic income (loss) per share (in EUR per share) | € (0.73) | € (0.66) | € (0.81) | [1] |
Adjustment for share instruments (in shares) | 0 | 0 | 0 | |
Diluted income (loss) per share (in EUR per share) | € (0.73) | € (0.66) | € (0.81) | [1] |
[1]The 2020 comparatives has been restated to consider the impact of classifying the Lumoxiti business as discontinued operations in 2021. See note 2.v and 17 of our consolidated financial statements appearing elsewhere in this Annual Report. |
Income (loss) per share - Addit
Income (loss) per share - Additional Information (Details) - shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income (Loss) Per Share [Abstract] | |||
Number of instruments with potential future dilutive effect not included in calculation of diluted earnings per share (in shares) | 2,265,301 | 2,166,829 | 1,564,662 |
Events after the reporting da_2
Events after the reporting date (Details) - Agreements with Genzyme for NK Cell engages € in Millions | 1 Months Ended |
Mar. 31, 2023 EUR (€) | |
Disclosure of non-adjusting events after reporting period [table] | |
Milestone payment received | € 25 |
Agreements with Genzyme for NK Cell engages | |
Disclosure of non-adjusting events after reporting period [table] | |
Milestone payment received | € 25 |